glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic B
acid I
decarboxylase I
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 O
by O
production O
of O
3H-GABA O
from O
3H-glutamate O
, O
enzyme O
kinetics O
, O
binding O
to O
the O
enzyme O
cofactor O
pyridoxal O
phosphate O
(PLP) O
, O
stability O
according O
to O
differences O
in O
pH O
, O
temperature O
and O
duration O
of O
storage O
, O
and O
antigenic O
reactivity O
with O
various O
GAD-specific O
antisera O
. O
RESULTS O
: O
The O
properties O
of O
rGAD67/65 O
were O
compared O
with O
published O
data O
for O
mammalian O
brain O
GAD O
(brackets) O
. O
These O
included O
a O
specific O
enzyme O
activity O
of O
22.7 O
(16.7) O
nKat O
, O
optimal O
pH O
for O
enzymatic O
activity O
7.4 O
(6.8) O
, O
K(m) O
of O
1.3 O
(1.3) O
mM O
, O
efficient O
non-covalent O
binding O
to O
the O
cofactor O
PLP O
, O
and O
high O
autoantigenic O
potency O
. O
The O
stability O
of O
rGAD67/65 O
was O
optimal O
over O
3 O
months O
at O
-80 O
degrees O
C O
, O
or O
in O
lyophilized O
form O
at O
-20 O
degrees O
C O
. O
CONCLUSIONS O
: O
Hybrid O
rGAD67/65 O
has O
enzymatic O
and O
other O
properties O
similar O
to O
those O
of O
the O
mixed O
isoforms O
of O
GAD O
in O
preparations O
from O
mammalian O
brain O
as O
described O
elsewhere O
, O
in O
addition O
to O
its O
previously O
described O
similar O
immunoreactivity O
. O

Na(+) O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Underexpression O
of O
the O
Na+-dependent O
neutral O
amino O
acid O
transporter O
ASCT2 O
in O
the O
spontaneously O
hypertensive O
rat O
kidney.This O
study O
examined O
the O
inward O
transport O
of O
l-[(14)C]alanine O
, O
an O
ASCT2 O
preferential O
substrate O
, O
in O
monolayers O
of O
immortalized O
renal O
proximal O
tubular O
epithelial O
(PTE) O
cells O
from O
Wistar-Kyoto O
(WKY) O
and O
spontaneously O
hypertensive O
(SHR) O
rats O
. O
The O
expression O
of O
ASCT2 O
in O
WKY O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 O
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 B
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 O
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

Pro O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
of O
the O
mammalian O
type O
I O
and O
type O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
determine O
differential O
ligand O
selectivity O
to O
GnRH-I O
and O
GnRH-II.Mammalian O
type O
I O
and O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
(GnRHRs) O
show O
differential O
ligand O
preference O
for O
GnRH-I O
and O
GnRH-II O
, O
respectively O
. O
Using O
a O
variety O
of O
chimeric O
receptors O
based O
on O
green O
monkey O
GnRHR-2 O
(gmGnRHR-2) O
, O
a O
representative O
type O
II O
GnRHR O
, O
and O
rat O
GnRHR O
, O
a O
representative O
type O
I O
GnRHR O
, O
this O
study O
elucidated O
specific O
domains O
responsible O
for O
this O
ligand O
selectivity O
. O
A O
chimeric O
gmGnRHR-2 O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 B
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat O
GnRHR) O
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O
[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O
than O
native O
GnRH-I O
, O
indicating O
that O
amino O
acids O
at O
positions O
7 O
and O
8 O
of O
GnRHs O
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type O
I O
and O
type O
II O
GnRHRs O
. O
As O
a O
whole O
, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O
the O
molecular O
interaction O
between O
GnRHs O
and O
their O
cognate O
receptors O
. O

milrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Modulation O
of O
TNF O
and O
GM-CSF O
release O
from O
dispersed O
human O
nasal O
polyp O
cells O
and O
human O
whole O
blood O
by O
inhibitors O
of O
different O
PDE O
isoenzymes O
and O
glucocorticoids.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
role O
of O
the O
inhibitors O
of O
different O
PDE O
isoenzymes O
(PDE O
1-5) O
on O
the O
production O
of O
two O
pro-inflammatory O
cytokines O
- O
tumor O
necrosis O
factor O
alpha O
(TNF) O
and O
granulocyte-macrophage O
colony-stimulating O
factor O
(GM-CSF) O
. O
Two O
in O
vitro O
models O
were O
used O
to O
compare O
the O
antiinflammatory O
properties O
of O
PDE O
inhibitors O
with O
that O
of O
glucocorticoids O
. O
The O
effect O
on O
TNF O
release O
from O
diluted O
human O
blood O
following O
lipopolysaccharide O
(LPS O
from O
Salmonella O
abortus O
equi) O
stimulation O
as O
well O
as O
the O
GM-CSF O
and O
TNF O
release O
from O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE B
4 I
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

resveratrol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
SIRT1 O
inhibits O
NADPH O
oxidase O
activation O
and O
protects O
endothelial O
function O
in O
the O
rat O
aorta O
: O
Implications O
for O
vascular O
aging.Vascular O
aging O
is O
characterized O
by O
up-regulation O
of O
NADPH O
oxidase O
, O
oxidative O
stress O
and O
endothelial O
dysfunction O
. O
Previous O
studies O
demonstrate O
that O
the O
activity O
of O
the O
evolutionarily O
conserved O
NAD(+)-dependent O
deacetylase O
SIRT1 O
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
(nicotinamide O
, O
sirtinol O
, O
EX527) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) B
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O
up-regulates O
NADPH O
oxidase-derived O
ROS O
production O
in O
the O
vascular O
wall O
, O
mimicking O
the O
vascular O
aging O
phenotype O
. O
Moreover O
, O
a O
new O
mechanism O
for O
controlling O
endothelial O
function O
after O
SIRT1 O
activation O
involves O
a O
decreased O
PGC-1α O
acetylation O
and O
the O
subsequent O
PPARα O
activation O
, O
resulting O
in O
both O
decreased O
NADPH O
oxidase-driven O
ROS O
production O
and O
NO O
inactivation O
. O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mitochondrial O
arginase O
II O
modulates O
nitric-oxide O
synthesis O
through O
nonfreely O
exchangeable O
L-arginine O
pools O
in O
human O
endothelial O
cells.Reduced O
synthesis O
of O
nitric O
oxide O
(NO) O
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine O
, O
the O
common O
substrate O
of O
constitutive O
nitric-oxide O
synthase O
(NOS) O
and O
cytosolic O
arginase O
I O
and O
mitochondrial O
arginase O
II O
. O
To O
determine O
whether O
arginases B
modulate O
the O
endothelial O
NO O
synthesis O
, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase O
inhibitor O
N(omega)-hydroxy-nor-L-arginine O
(Nor-NOHA) O
on O
the O
activity O
of O
NOS O
, O
arginases O
, O
and O
L-arginine O
transporter O
and O
on O
NO O
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
. O
In O
unstimulated O
cells O
, O
Nor-NOHA O
dose-dependently O
reduced O
the O
arginase O
activity O
with O
maximal O
inhibition O
at O
20 O
microM O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
without O
extracellular O
L-arginine O
, O
Nor-NOHA O
dose-dependently O
increased O
the O
NOS O
activity O
and O
the O
NO O
release O
with O
maximal O
effects O
at O
20 O
microM O
. O
Extracellular O
L-arginine O
also O
dose-dependently O
increased O
NO O
release O
and O
arginase O
activity O
. O
When O
HUVECs O
were O
stimulated O
by O
thrombin O
in O
the O
presence O
of O
100 O
microM O
L-arginine O
, O
NOS O
activity O
and O
NO O
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated O
cells O
. O
However O
, O
despite O
activation O
of O
L-arginine O
uptake O
, O
the O
inhibition O
of O
arginase O
activity O
by O
Nor-NOHA O
was O
still O
significant O
. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine O
pools O
with O
extracellular O
L-lysine O
did O
not O
prevent O
Nor-NOHA O
from O
increasing O
the O
NO O
release O
. O
This O
indicates O
the O
presence O
of O
pools O
, O
which O
are O
accessible O
to O
NOS O
and O
arginase O
, O
but O
not O
exchangeable O
. O
Interestingly O
, O
the O
mitochondrial O
arginase O
II O
was O
constitutively O
expressed O
, O
whereas O
the O
cytosolic O
arginase O
I O
was O
barely O
detectable O
in O
HUVECs O
. O
These O
data O
suggest O
that O
endothelial O
NO O
synthesis O
depends O
on O
the O
activity O
of O
arginase O
II O
in O
mitochondria O
and O
l-arginine O
carriers O
in O
cell O
membrane O
. O

17-HDHA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Impaired O
local O
production O
of O
pro-resolving O
lipid O
mediators O
in O
obesity O
and O
17-HDHA O
as O
a O
potential O
treatment O
for O
obesity-associated O
inflammation.Obesity-induced O
chronic O
low-grade O
inflammation O
originates O
from O
adipose O
tissue O
and O
is O
crucial O
for O
obesity-driven O
metabolic O
deterioration O
including O
insulin O
resistance O
and O
type O
2 O
diabetes.Chronic O
inflammation O
may O
be O
a O
consequence O
of O
a O
failure O
to O
actively O
resolve O
inflammation,and O
could O
result O
from O
a O
lack O
of O
local O
specialized O
pro-resolving O
lipid O
mediators O
(SPM) O
such O
as O
resolvins O
and O
protectins O
, O
which O
derive O
from O
the O
n-3 O
polyunsaturated O
fatty O
acids O
eicosapentaenoic O
acid O
(EPA) O
and O
docosahexaenoic O
acid O
(DHA) O
. O
We O
assessed O
obesity-induced O
changes O
of O
n-3-derived O
SPM O
in O
adipose O
tissue O
and O
effects O
of O
dietary O
EPA/DHA O
thereon.Moreover O
, O
we O
treated O
obese O
mice O
with O
SPM O
precursors O
and O
investigated O
effects O
on O
inflammation O
and O
metabolic O
dysregulation O
. O
Obesity O
significantly O
decreased O
DHA-derived O
17-hydroxydocosahexaenoic O
acid O
(17-HDHA O
, O
resolvin O
D1 O
precursor) O
and O
protectin O
D1 O
levels O
in O
murine O
adipose O
tissue O
. O
Dietary O
EPA/DHA O
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin O
sensitivity O
. O
Notably O
, O
17-HDHA O
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines O
, O
increased O
adiponectin B
expression O
and O
improved O
glucose O
tolerance O
parallel O
to O
insulin O
sensitivity O
in O
obese O
mice O
. O
These O
findings O
indicate O
that O
impaired O
biosynthesis O
of O
certain O
SPM O
and O
SPM O
precursors O
including O
17-HDHA O
and O
protectin O
D1 O
contributes O
to O
adipose O
tissue O
inflammation O
in O
obesity O
and O
suggest O
17-HDHA O
as O
a O
novel O
treatment O
option O
for O
obesity-associated O
complications O
. O

DHP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 B
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

Ifenprodil O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating.Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1 B
/ O
GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O
interface O
of O
the O
GluN1/GluN2B O
amino O
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism O
. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B O
receptor O
gating O
, O
we O
recorded O
steady-state O
currents O
from O
cell-attached O
and O
outside-out O
patches O
. O
At O
pH O
7.9 O
in O
cell-attached O
patches O
, O
ifenprodil O
increased O
the O
occupancy O
of O
the O
long-lived O
shut O
conformations O
, O
thereby O
reducing O
the O
open O
probability O
of O
the O
receptor O
with O
no O
change O
in O
the O
mean O
open O
time O
. O
In O
addition O
, O
ifenprodil O
selectively O
affected O
the O
area O
of O
shut O
time O
constants O
, O
but O
not O
the O
time O
constants O
themselves O
. O
Kinetic O
analyses O
suggested O
that O
ifenprodil O
prevents O
the O
transition O
of O
the O
receptor O
to O
an O
open O
state O
and O
increases O
its O
dwell O
time O
in O
an O
intrinsically O
occurring O
closed O
conformation O
or O
desensitized O
state O
. O
We O
found O
distinct O
differences O
in O
the O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O
mean O
open O
time O
of O
GluN1/GluN2B O
receptors O
, O
which O
may O
be O
responsible O
for O
its O
usefulness O
as O
a O
context-dependent O
inhibitor O
in O
conditions O
like O
ischemia O
and O
stroke O
, O
when O
the O
pH O
of O
the O
extracellular O
milieu O
becomes O
acidic O
. O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Lifelong O
exposure O
to O
bisphenol O
a O
alters O
cardiac O
structure/function O
, O
protein O
expression O
, O
and O
DNA O
methylation O
in O
adult O
mice.Bisphenol O
A O
(BPA) O
is O
an O
estrogenizing O
endocrine O
disruptor O
compound O
of O
concern O
. O
Our O
objective O
was O
to O
test O
whether O
lifelong O
BPA O
would O
impact O
cardiac O
structure/function O
, O
calcium O
homeostasis O
protein O
expression O
, O
and O
the O
DNA O
methylation O
of O
cardiac O
genes O
. O
We O
delivered O
0.5 O
and O
5.0 O
µg/kg/day O
BPA O
lifelong O
from O
gestation O
day O
11 O
or O
200 O
µg/kg/day O
from O
gestation O
day O
11 O
to O
postnatal O
day O
21 O
via O
the O
drinking O
water O
to O
C57bl/6n O
mice O
. O
BPA O
5.0 O
males O
and O
females O
had O
increased O
body O
weight O
, O
body O
mass O
index O
, O
body O
surface O
area O
, O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB B
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O
in O
all O
BPA O
males O
and O
BPA O
0.5 O
females O
and O
reduced O
in O
BPA O
200 O
females O
. O
Global O
DNA O
methylation O
was O
increased O
in O
BPA O
0.5 O
males O
and O
reduced O
in O
BPA O
0.5 O
females O
. O
BPA O
induced O
sex-specific O
altered O
DNA O
methylation O
in O
specific O
CpG O
pairs O
in O
the O
calsequestrin O
2 O
CpG O
island O
. O
These O
results O
suggest O
that O
continual O
exposure O
to O
BPA O
impacts O
cardiac O
structure/function O
, O
protein O
expression O
, O
and O
epigenetic O
DNA O
methylation O
marks O
in O
males O
and O
females O
. O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Anti-diabetic O
property O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
is O
mediated O
through O
the O
expression O
of O
Glut-4 O
in O
L6 O
myotubes.Tinospora O
cordifolia O
is O
a O
well O
reported O
plant O
possessing O
numerous O
medicinal O
values O
including O
anti-diabetic O
property O
. O
Aim O
of O
the O
present O
study O
is O
to O
study O
the O
mechanism O
of O
action O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin B
dependent I
glucose I
transporter-4 I
(Glut-4) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
, O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Carvedilol O
modulates O
the O
expression O
of O
hypoxia-inducible O
factor-1alpha O
and O
vascular O
endothelial O
growth O
factor O
in O
a O
rat O
model O
of O
volume-overload O
heart O
failure.BACKGROUND O
: O
The O
use O
of O
beta-blockers O
has O
emerged O
as O
a O
beneficial O
treatment O
for O
congestive O
heart O
failure O
. O
Hypoxia-inducible O
factor-1alpha O
(HIF-1alpha) O
is O
tightly O
regulated O
in O
the O
ventricular O
myocardium O
. O
However O
, O
the O
expression O
of O
HIF-1alpha O
in O
chronic O
heart O
failure O
resulting O
from O
volume O
overload O
and O
after O
treatment O
with O
beta-blocker O
is O
little O
known O
. O
METHODS O
AND O
RESULTS O
: O
To O
test O
the O
hypothesis O
that O
HIF-1alpha O
plays O
a O
role O
in O
the O
failing O
myocardium O
because O
of O
volume O
overload O
, O
an O
aorta-caval O
shunt O
was O
created O
for O
4 O
weeks O
in O
adult O
Sprague-Dawley O
rats O
to O
induce O
volume-overload O
heart O
failure O
. O
Carvedilol O
at O
50 O
mg/kg O
body O
weight O
per O
day O
after O
surgery O
was O
given O
. O
The O
heart O
weight O
and O
body O
weight O
ratio O
increased O
from O
2.6 O
+/- O
0.3 O
in O
the O
sham O
group O
to O
3.9 O
+/- O
0.7 O
(P O
< O
.001) O
in O
the O
shunt O
group O
. O
Left O
ventricular O
end-diastolic O
dimension O
increased O
from O
6.5 O
+/- O
0.5 O
mm O
to O
8.7 O
+/- O
0.6 O
mm O
(P O
< O
.001) O
. O
Treatment O
with O
carvedilol O
in O
the O
shunt O
group O
reversed O
the O
heart O
weight O
and O
ventricular O
dimension O
to O
the O
baseline O
values O
. O
Western O
blot O
showed O
that O
HIF-1alpha O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
brain O
natriuretic O
peptide O
(BNP) O
proteins O
were O
upregulated O
and O
nerve O
growth O
factor-beta O
(NGF-beta) O
downregulated O
in O
the O
shunt O
group O
. O
Real-time O
polymerase O
chain O
reaction O
showed O
that O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
and O
BNP O
increased O
and O
mRNA O
of O
NGF-beta O
decreased O
in O
the O
shunt O
group O
. O
Treatment O
with O
carvedilol O
reversed O
both O
protein O
and O
mRNA O
of O
HIF-1alpha O
, O
VEGF O
, O
BNP O
, O
and O
NGF-beta O
to O
the O
baseline O
values O
. O
Increased O
immunohistochemical O
labeling O
of O
HIF-1alpha B
, O
VEGF O
, O
and O
BNP O
in O
the O
ventricular O
myocardium O
was O
observed O
in O
the O
shunt O
group O
and O
carvedilol O
again O
normalized O
the O
labeling O
. O
CONCLUSION O
: O
HIF-1alpha O
and O
VEGF O
mRNA O
and O
protein O
expression O
were O
upregulated O
in O
the O
rat O
model O
of O
volume-overload O
heart O
failure O
. O
Treatment O
with O
carvedilol O
is O
associated O
with O
a O
reversal O
of O
abnormal O
regulation O
of O
HIF-1alpha O
and O
VEGF O
in O
the O
failing O
ventricular O
myocardium O
. O

pyrano[2,3-b]quinolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase O
( O
BuChE) B
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

buspirone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
exposure O
of O
highly O
toxic O
aconitine O
does O
not O
significantly O
impact O
the O
activity O
and O
expression O
of O
cytochrome O
P450 O
3A O
in O
rats O
determined O
by O
a O
novel O
ultra O
performance O
liquid O
chromatography-tandem O
mass O
spectrometric O
method O
of O
a O
specific O
probe O
buspirone.Aconitum O
species O
are O
widely O
used O
to O
treat O
rheumatism O
, O
cardiovascular O
diseases O
, O
and O
tumors O
in O
China O
and O
other O
Asian O
countries O
. O
The O
herbs O
are O
always O
used O
with O
drugs O
such O
as O
paclitaxel O
. O
Aconitine O
(AC) O
is O
one O
of O
the O
main O
bioactive/high-toxic O
alkaloids O
of O
Aconitum O
roots O
. O
AC O
is O
metabolized O
by O
cytochrome O
P450 O
(CYP) O
3A O
. O
However O
, O
whether O
AC O
inhibits/induces O
CYP3A O
, O
which O
causes O
drug-drug O
interaction O
(DDI) O
is O
unclear O
. O
Our O
study O
aims O
to O
explore O
the O
potent O
effects O
of O
AC O
, O
as O
a O
marker O
component O
of O
Aconitum O
, O
on O
CYP3A B
using O
the O
probe O
buspirone O
in O
rats O
. O
The O
effects O
of O
oral O
AC O
on O
pharmacokinetics O
of O
buspirone O
were O
evaluated O
. O
CYP3A O
activity O
and O
protein O
levels O
in O
rat O
liver O
microsomes O
pretreated O
with O
oral O
AC O
were O
also O
measured O
using O
in O
vitro O
buspirone O
metabolism O
and O
Western O
blot O
. O
Buspirone O
and O
its O
major O
metabolites O
1-(2-pyrimidinyl)piperazine O
and O
6'-hydroxybuspirone O
were O
determined O
using O
a O
newly O
validated O
UPLC-MS/MS O
method O
. O
Single O
dose O
and O
7-day O
AC O
administration O
at O
0.125mg/kg O
had O
no O
effect O
on O
CYP3A O
activity O
since O
no O
change O
in O
the O
formation O
of O
1-(2-pyrimidinyl)piperazine O
and O
6'-hydroxybuspirone O
. O
CYP3A O
activity O
and O
protein O
levels O
in O
liver O
microsomes O
were O
also O
not O
affected O
by O
7-day O
AC O
pretreatment O
at O
0.125mg/kg O
. O
Therefore O
, O
AC O
neither O
inhibits O
nor O
induces O
CYP3A O
in O
rats O
, O
indicating O
AC O
does O
not O
cause O
CYP3A-related O
DDI O
in O
the O
liver O
. O

Sildenafil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Long-term O
use O
of O
sildenafil.The O
treatment O
of O
erectile O
dysfunction O
(ED) O
has O
been O
revolutionised O
by O
new O
agents O
to O
inhibit O
the O
enzyme O
PDE5 O
. O
The O
scientific O
basis O
of O
this O
treatment O
of O
ED O
includes O
relaxation O
of O
the O
corpus O
cavernosum O
smooth O
muscle O
tissue O
by O
inhibition O
of O
PDE5 O
that O
breaks O
down O
cGMP O
, O
the O
key O
pathway O
for O
the O
production O
of O
erectile O
function O
in O
humans O
. O
Many O
clinical O
studies O
, O
both O
pre- O
and O
post-marketing O
, O
have O
demonstrated O
the O
clinical O
efficacy O
and O
safety O
of O
sildenafil O
(Viagra O
, O
Pfizer) O
- O
the O
first O
approved O
selective O
PDE O
inhibitor O
for O
the O
treatment O
of O
ED O
. O
Sildenafil O
is O
inhibitory O
of O
PDE5 O
at O
a O
rate O
tenfold O
higher O
than O
for O
the O
next O
PDE O
( O
PDE6) B
 O
, O
which O
produces O
visual O
changes O
through O
the O
retinal O
rods O
. O
Its O
clinical O
effectiveness O
has O
been O
well O
documented O
in O
the O
majority O
of O
men O
with O
ED O
irrespective O
of O
aetiology O
. O
The O
aetiology O
of O
ED O
, O
also O
, O
does O
not O
appear O
to O
effect O
the O
function O
of O
sildenafil O
in O
relaxing O
corpus O
cavernosum O
smooth O
muscle O
tissue O
. O
Adverse O
events O
are O
usually O
associated O
with O
the O
vascular O
changes O
from O
PDE5 O
inhibition O
. O
These O
include O
headache O
and O
flushing O
. O
Each O
of O
these O
adverse O
events O
, O
however O
, O
declines O
with O
medication O
use O
. O
With O
the O
use O
of O
sildenafil O
, O
it O
has O
been O
clearly O
, O
clinically O
demonstrated O
that O
the O
selective O
inhibition O
of O
PDE5 O
is O
an O
appropriate O
, O
effective O
, O
safe O
method O
for O
the O
treatment O
of O
ED O
of O
all O
aetiologies O
and O
severities O
. O

cysteine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 O
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O
CB1 O
implicated O
in O
the O
recognition O
of O
SR O
141716A O
. O
Receptors O
were O
transiently O
expressed O
in O
COS-3 O
cells O
, O
and O
their O
binding O
characteristics O
were O
studied O
with O
SR O
141716A O
and O
with O
CP O
55,940 O
, O
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors O
. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 O
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 B
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices O
. O

heterocyclic O
amine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
by O
human O
NADH O
cytochrome O
b5 O
reductase O
and O
cytochrome O
b5.Heterocyclic O
and O
aromatic O
amine O
carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts O
, O
and O
bioactivation O
to O
arylhydroxylamine O
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA O
. O
Carcinogenic O
arylhydroxylamine O
metabolites O
are O
cleared O
by O
a O
microsomal O
, O
NADH-dependent O
, O
oxygen-insensitive O
reduction O
pathway O
in O
humans O
, O
which O
may O
be O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic O
amine O
carcinogens O
. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver O
. O
On O
the O
basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine O
metabolites O
of O
therapeutic O
drugs O
, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine O
carcinogens O
was O
catalyzed O
by O
NADH O
cytochrome O
b5 O
reductase O
(b5R) O
and O
cytochrome O
b5 O
(cyt O
b5) O
. O
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines O
of O
the O
aromatic O
amine O
4-aminobiphenyl O
(4-ABP; O
found O
in O
cigarette O
smoke) O
and O
the O
heterocyclic O
amine O
2-amino-1-methyl-6-phenylimidazo O
[4,5-b] O
pyridine O
(PhIP; O
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human O
b5R O
and O
cyt B
b5 I
. O
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM) O
, O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems O
. O
The O
stoichiometry O
for O
b5R O
and O
cyt O
b5 O
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10) O
. O
Polyclonal O
antisera O
to O
either O
b5R O
or O
cyt O
b5 O
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl O
(NHOH-4-ABP) O
reduction O
by O
95 O
and O
89% O
, O
respectively O
, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP O
and O
N-hydroxy-PhIP O
(NHOH-PhIP) O
. O
Finally O
, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt O
b5 O
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity O
. O
We O
conclude O
that O
b5R O
and O
cyt O
b5 O
are O
together O
solely O
capable O
of O
the O
reduction O
of O
arylhydroxylamine O
carcinogens O
, O
and O
we O
further O
hypothesize O
that O
this O
pathway O
may O
be O
a O
source O
of O
individual O
variability O
with O
respect O
to O
cancer O
susceptibility O
following O
4-ABP O
or O
PhIP O
exposure O
. O

tert-butylhydroquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Identification O
of O
aldo-keto O
reductases O
as O
NRF2-target O
marker O
genes O
in O
human O
cells.Transcription O
factor O
NF-E2-related O
factor O
2 O
(NRF2) O
plays O
a O
crucial O
role O
in O
the O
cellular O
defense O
against O
oxidative/electrophilic O
stress O
by O
up-regulating O
multiple O
antioxidant O
genes O
. O
Numerous O
studies O
with O
genetically O
modified O
animals O
have O
demonstrated O
that O
Nrf2 O
is O
a O
sensitivity O
determining O
factor O
upon O
the O
exposure O
to O
environmental O
chemicals O
including O
carcinogens O
. O
Moreover O
, O
recent O
studies O
have O
demonstrated O
that O
polymorphism O
in O
the O
human O
NRF2 O
promoter O
is O
associated O
with O
higher O
risks O
for O
developing O
acute O
lung O
injury O
, O
gastric O
mucosal O
inflammation O
, O
and O
nephritis O
. O
Therefore O
, O
the O
identification O
of O
reliable O
and O
effective O
human O
target O
genes O
of O
NRF2 O
may O
allow O
the O
monitoring O
of O
NRF2 O
activity O
and O
to O
predict O
individual O
sensitivity O
to O
environmental O
stress-induced O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 B
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Secondly O
, O
the O
linkage O
between O
NRF2 O
and O
the O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane-inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O
cell O
line O
THP-1 O
as O
well O
as O
in O
human O
primary O
blood O
CD14(+) O
monocytes O
. O
In O
conclusion O
, O
together O
with O
the O
high O
inducibility O
and O
NRF2 O
dependency O
shown O
in O
renal O
epithelial O
cells O
as O
well O
as O
in O
peripherally O
available O
blood O
cells O
, O
current O
findings O
suggest O
that O
AKRs O
can O
be O
utilized O
as O
a O
marker O
of O
NRF2 O
activity O
in O
human O
cells O
. O

Nle O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Modulation O
of O
the O
JAK/ERK/STAT O
signaling O
in O
melanocortin-induced O
inhibition O
of O
local O
and O
systemic O
responses O
to O
myocardial O
ischemia/reperfusion.The O
janus O
kinases O
(JAK) O
, O
extracellular O
signal-regulated O
kinases O
(ERK) O
and O
signal O
transducers O
and O
activators O
of O
transcription O
(STAT) O
pathways O
have O
been O
shown O
to O
play O
a O
cardioprotective O
role O
. O
We O
previously O
gave O
evidence O
that O
melanocortins O
afford O
cardioprotection O
in O
conditions O
of O
myocardial O
ischemia/reperfusion O
. O
Here O
we O
aimed O
to O
investigate O
the O
influence O
of O
melanocortins O
on O
the O
JAK/ERK/STAT O
signaling O
in O
cardiac O
and O
systemic O
responses O
to O
prolonged O
myocardial O
ischemia/reperfusion O
. O
Ischemia O
was O
produced O
in O
rats O
by O
ligature O
of O
the O
left O
anterior O
descending O
coronary O
artery O
for O
30min O
. O
At O
the O
end O
of O
the O
2-h O
reperfusion O
, O
western O
blot O
analysis O
of O
the O
cardioprotective O
transcription O
factors O
pJAK2 O
, O
pERK1/2 O
, O
pTyr-STAT3 O
and O
pSer-STAT3 O
, O
the O
inflammatory O
mediator O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
the O
pro-apoptotic O
factors O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
[Nle(4) O
, O
D-Phe(7)]α-melanocyte-stimulating O
hormone O
(NDP- O
α-MSH) B
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 O
and O
Bcl-XL O
, O
and O
marked O
decrease O
of O
the O
myocardial O
infarct O
size O
. O
Melanocortin O
treatment O
did O
not O
affect O
left O
ventricle O
pSer-STAT3 O
(ERK1/2-dependent) O
and O
BAX O
levels O
. O
In O
the O
spleen O
, O
NDP-α-MSH O
and O
ACTH-(1-24) O
induced O
similar O
effects O
on O
the O
expression O
of O
the O
above O
transcription O
factors/proteins O
, O
except O
for O
pERK1/2 O
(down-regulated) O
and O
HO-1 O
(unaffected) O
. O
Blockade O
of O
JAK O
and O
ERK O
pathways O
with O
AG490 O
and O
U0126 O
, O
respectively O
, O
abrogated O
the O
myocardial O
infarct O
size O
reduction O
by O
NDP-α-MSH O
. O
These O
results O
indicate O
that O
melanocortins O
inhibit O
local O
and O
systemic O
inflammatory O
and O
apoptotic O
cascades O
triggered O
by O
prolonged O
myocardial O
ischemia/reperfusion O
, O
with O
consequent O
reduction O
in O
myocardium O
infarct O
size O
, O
seemingly O
via O
activation O
of O
the O
JAK/STAT O
signaling O
and O
with O
modulation O
of O
an O
ERK O
(STAT O
unrelated) O
signaling O
pathway O
. O

sulfamates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA B
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O
in O
mammals O
, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O
medicinally O
relevant O
CAs O
. O

paraoxon O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adverse O
outcome O
pathways O
during O
zebrafish O
embryogenesis O
: O
a O
case O
study O
with O
paraoxon.Using O
paraoxon O
as O
a O
reference O
acetylcholinesterase O
( O
AChE) B
inhibitor O
, O
the O
objective O
of O
this O
study O
was O
to O
develop O
an O
adverse O
outcome O
pathway O
(AOP) O
that O
provided O
quantitative O
linkages O
across O
levels O
of O
biological O
organization O
during O
zebrafish O
embryogenesis O
. O
Within O
normal O
zebrafish O
embryos O
, O
we O
first O
demonstrated O
that O
ache O
transcripts O
and O
AChE O
activity O
increased O
in O
a O
stage-dependent O
manner O
following O
segmentation O
. O
We O
then O
showed O
that O
static O
exposure O
of O
embryos O
to O
paraoxon O
(31.2-500 O
nM) O
from O
5 O
to O
96 O
hpf O
resulted O
in O
significant O
stage- O
and O
concentration-dependent O
AChE O
inhibition O
, O
albeit O
these O
effects O
were O
fully O
reversible O
within O
48 O
h O
following O
transfer O
to O
clean O
water O
. O
However O
, O
even O
in O
the O
presence O
of O
significant O
AChE O
inhibition O
, O
exposure O
to O
non-teratogenic O
paraoxon O
concentrations O
(≤250 O
nM) O
did O
not O
adversely O
impact O
secondary O
motoneuron O
development O
at O
96 O
hpf O
. O
Therefore O
, O
we O
investigated O
the O
potential O
effects O
of O
paraoxon O
exposure O
on O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
an O
early O
locomotor O
behavior O
that O
results O
from O
innervation O
of O
primary O
(not O
secondary) O
motoneuron O
axons O
to O
target O
axial O
muscles O
. O
Based O
on O
these O
studies O
, O
the O
frequency O
of O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
a O
developmental O
stage O
with O
minimal O
AChE O
expression O
and O
activity O
- O
was O
significantly O
higher O
following O
exposure O
to O
paraoxon O
concentrations O
as O
low O
as O
31.2 O
nM O
. O
Overall O
, O
our O
data O
suggest O
that O
(1) O
normal O
AChE O
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
(2) O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
are O
sensitive O
to O
paraoxon O
exposure O
, O
an O
effect O
that O
may O
be O
independent O
of O
AChE O
inhibition O
. O
Using O
a O
well-studied O
reference O
chemical O
, O
this O
study O
highlights O
the O
potential O
challenges O
in O
developing O
quantitative O
AOPs O
to O
support O
chemical O
screening O
and O
prioritization O
strategies O
. O

linoleic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
four O
new O
mouse O
cytochrome O
P450 O
enzymes O
of O
the O
CYP2J O
subfamily.The O
cytochrome O
P450 O
superfamily O
encompasses O
a O
diverse O
group O
of O
enzymes O
that O
catalyze O
the O
oxidation O
of O
various O
substrates O
. O
The O
mouse O
CYP2J B
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic O
acid O
(AA) O
, O
linoleic O
acid O
(LA) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O
The O
mouse O
Cyp2j O
locus O
contains O
seven O
genes O
and O
three O
pseudogenes O
located O
in O
a O
contiguous O
0.62 O
megabase O
cluster O
on O
chromosome O
4 O
. O
We O
describe O
four O
new O
mouse O
CYP2J O
isoforms O
(designated O
CYP2J8 O
, O
CYP2J11 O
, O
CYP2J12 O
, O
and O
CYP2J13) O
. O
The O
four O
cDNAs O
contain O
open O
reading O
frames O
that O
encode O
polypeptides O
with O
62-84% O
identity O
with O
the O
three O
previously O
identified O
mouse O
CYP2Js O
. O
All O
four O
new O
CYP2J O
proteins O
were O
expressed O
in O
Sf21 O
insect O
cells O
. O
Each O
recombinant O
protein O
metabolized O
AA O
and O
LA O
to O
epoxides O
and O
hydroxy O
derivatives O
. O
Specific O
antibodies O
, O
mRNA O
probes O
, O
and O
polymerase O
chain O
reaction O
primer O
sets O
were O
developed O
for O
each O
mouse O
CYP2J O
to O
examine O
their O
tissue O
distribution O
. O
CYP2J8 O
transcripts O
were O
found O
in O
the O
kidney O
, O
liver O
, O
and O
brain O
, O
and O
protein O
expression O
was O
confirmed O
in O
the O
kidney O
and O
brain O
(neuropil) O
. O
CYP2J11 O
transcripts O
were O
most O
abundant O
in O
the O
kidney O
and O
heart O
, O
with O
protein O
detected O
primarily O
in O
the O
kidney O
(proximal O
convoluted O
tubules) O
, O
liver O
, O
and O
heart O
(cardiomyocytes) O
. O
CYP2J12 O
transcripts O
were O
prominently O
present O
in O
the O
brain O
, O
and O
CYP2J13 O
transcripts O
were O
detected O
in O
multiple O
tissues O
, O
with O
the O
highest O
expression O
in O
the O
kidney O
. O
CYP2J12 O
and O
CYP2J13 O
protein O
expression O
could O
not O
be O
determined O
because O
the O
antibodies O
developed O
were O
not O
immunospecific O
. O
We O
conclude O
that O
the O
four O
new O
CYP2J O
isoforms O
might O
be O
involved O
in O
the O
metabolism O
of O
AA O
and O
LA O
to O
bioactive O
lipids O
in O
mouse O
hepatic O
and O
extrahepatic O
tissues O
. O

CDCA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Bile O
acids O
induce O
cdx2 O
expression O
through O
the O
farnesoid O
x O
receptor O
in O
gastric O
epithelial O
cells.Clinical O
and O
experimental O
studies O
showed O
that O
the O
reflux O
of O
bile O
into O
the O
stomach O
contributes O
to O
the O
induction O
of O
intestinal O
metaplasia O
of O
the O
stomach O
and O
gastric O
carcinogenesis O
. O
Caudal-type O
homeobox O
2 O
(Cdx2) O
plays O
a O
key O
role O
in O
the O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin O
2 O
(MUC2) O
. O
We O
investigated O
the O
involvement O
of O
the O
farnesoid O
X O
receptor O
(FXR) O
, O
a O
nuclear O
receptor O
for O
bile O
acids O
, O
in O
the O
chenodeoxycholic O
acid O
(CDCA)-induced O
expression O
of O
Cdx2 B
and O
MUC2 O
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells) O
. O
RGM-1 O
cells O
were O
treated O
with O
CDCA O
or O
GW4064 O
, O
an O
FXR O
agonist O
, O
in O
the O
presence O
or O
absence O
of O
guggulsterone O
, O
an O
FXR O
antagonist O
. O
CDCA O
induced O
dose-dependent O
expression O
of O
Cdx2 O
and O
MUC2 O
at O
both O
the O
mRNA O
and O
protein O
levels O
. O
The O
maximum O
stimulation O
of O
Cdx2 O
and O
MUC2 O
mRNA O
induced O
by O
CDCA O
was O
observed O
at O
3 O
h O
and O
by O
6 O
h O
, O
respectively O
. O
GW4064 O
also O
induced O
expression O
of O
these O
molecules O
. O
The O
effects O
of O
CDCA O
and O
GW4064 O
on O
expression O
of O
Cdx2 O
and O
MUC2 O
were O
abolished O
by O
guggulsterone O
. O
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR O
. O

LY117018 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
the O
uterotropic O
activity O
of O
estrogens O
and O
antiestrogens O
by O
the O
short O
acting O
antiestrogen O
LY117018.The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
the O
dihydroxylated O
antiestrogen O
LY117018 O
, O
with O
a O
high O
affinity O
for O
the O
estrogen B
receptor I
and O
low O
intrinsic O
estrogenic O
activity O
, O
could O
inhibit O
the O
uterotropic O
actions O
of O
steroidal O
[estradiol-17 O
beta O
(E2)] O
and O
nonsteroidal O
[ICI O
3188 O
and O
trianisylchloroethylene O
(TACE)] O
estrogens O
in O
immature O
rats O
and O
also O
the O
uterotropic O
actions O
of O
tamoxifen O
and O
monohydroxytamoxifen O
in O
the O
ovariectomized O
mouse O
and O
immature O
rat O
. O
In O
the O
first O
series O
of O
experiments O
, O
LY117018 O
was O
compared O
with O
monohydroxytamoxifen O
. O
Both O
antiestrogens O
inhibited O
the O
uterotropic O
actions O
of O
E2 O
(0.32 O
micrograms O
daily) O
, O
ICI O
3188 O
(5 O
micrograms O
daily) O
, O
and O
TACE O
(40 O
and O
160 O
micrograms O
daily) O
in O
a O
dose-related O
manner O
(0.32-82 O
micrograms O
daily) O
. O
The O
potency O
of O
the O
antiestrogens O
against O
E2 O
and O
ICI O
3188 O
was O
similar O
, O
however O
, O
at O
higher O
doses O
(20.48 O
and O
82 O
micrograms O
daily) O
LY117018 O
reduced O
uterine O
weights O
to O
below O
the O
lowest O
level O
achieved O
by O
monohydroxytamoxifen O
. O
In O
contrast O
, O
LY117018 O
was O
less O
effective O
against O
the O
long O
acting O
estrogen O
TACE O
. O
The O
competitive O
interaction O
of O
LY117018 O
with O
tamoxifen O
and O
monohydroxytamoxifen O
was O
compared O
in O
3-day O
ovariectomized O
mouse O
and O
immature O
rat O
uterine O
weight O
tests O
. O
Tamoxifen O
and O
monohydroxytamoxifen O
were O
fully O
estrogenic O
in O
the O
mouse O
(5 O
micrograms O
daily) O
and O
partially O
estrogenic O
in O
the O
rat O
(1.5-20 O
micrograms O
daily) O
. O
LY117018 O
was O
a O
partial O
estrogen O
in O
the O
mouse O
and O
a O
weekly O
active O
partial O
estrogen O
in O
the O
rat O
(2.5-120 O
micrograms O
daily) O
. O
LY117018 O
produced O
dose-related O
decreases O
in O
the O
uterine O
weight O
increases O
induced O
by O
tamoxifen O
and O
monohydroxytamoxifen O
in O
both O
species O
. O
However O
, O
in O
the O
rat O
, O
LY117018 O
was O
more O
effective O
against O
the O
less O
potent O
compound O
tamoxifen O
, O
at O
a O
6:1 O
dosage O
ratio O
compared O
with O
a O
24:1 O
dosage O
ratio O
required O
for O
the O
potent O
compound O
monohydroxytamoxifen O
. O
LY117018 O
had O
a O
short O
duration O
of O
action O
as O
an O
antiestrogen O
when O
compared O
with O
monohydroxytamoxifen O
. O
LY117018 O
(120 O
micrograms) O
was O
only O
completely O
effective O
as O
an O
antiestrogen O
if O
administered O
repeatedly O
with O
E2 O
whereas O
a O
single O
injection O
of O
monohydroxytamoxifen O
(120 O
micrograms) O
was O
sufficient O
to O
inhibit O
fully O
E2 O
action O
in O
the O
uterus O
for O
up O
to O
4 O
days O
. O
Because O
LY117018 O
has O
a O
shorter O
duration O
of O
action O
than O
monohydroxytamoxifen O
, O
a O
high O
dosage O
ratio O
of O
LY117018 O
over O
monohydroxytamoxifen O
is O
required O
to O
maintain O
effective O
competitive O
antagonism O
in O
the O
uterus O
. O
Overall O
, O
these O
findings O
suggest O
that O
monohydroxytamoxifen O
and O
LY117018 O
probably O
act O
through O
the O
same O
mechanism O
of O
action O
via O
the O
estrogen O
receptor O
. O

MEG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
In O
vivo O
genotoxicity O
of O
methyleugenol O
in O
gpt O
delta O
transgenic O
rats O
following O
medium-term O
exposure.Methyleugenol O
(MEG) O
, O
which O
is O
commonly O
used O
as O
a O
fragrance O
and O
flavoring O
agent O
, O
has O
been O
shown O
to O
induce O
hepatocellular O
tumors O
in O
rodents O
. O
However O
, O
the O
role O
of O
genotoxicity O
as O
a O
possible O
mechanism O
of O
action O
is O
not O
fully O
understood O
even O
though O
the O
DNA-reactive O
metabolite O
of O
MEG O
has O
been O
identified O
. O
In O
this O
study O
, O
a O
gpt O
delta O
transgenic O
rat O
model O
was O
used O
to O
clarify O
whether O
genotoxic O
mechanisms O
are O
involved O
in O
MEG-induced O
hepatocarcinogenesis O
following O
medium-term O
exposure O
. O
F344 O
gpt O
delta O
rats O
were O
subjected O
to O
repeated O
oral O
administration O
of O
MEG O
at O
dosages O
of O
0 O
, O
10 O
, O
30 O
, O
or O
100mg/kg O
(a O
carcinogenic O
dose) O
for O
13 O
weeks O
. O
The O
relative O
weight O
of O
the O
liver O
of O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
and O
the O
absolute O
weight O
of O
the O
liver O
of O
the O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG O
were O
significantly O
increased O
. O
In O
addition O
, O
the O
number O
and O
area O
of O
glutathione O
S-transferase O
placental O
form O
( O
GST-P) B
positive O
foci O
and O
proliferating O
cell O
nuclear O
antigen O
(PCNA) O
positive O
cell O
ratios O
in O
the O
hepatocytes O
were O
significantly O
increased O
in O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
compared O
with O
the O
control O
animals O
. O
In O
the O
in O
vivo O
mutation O
assays O
, O
a O
significant O
increase O
in O
the O
gpt O
and O
Spi(-) O
mutant O
frequencies O
was O
observed O
in O
both O
sexes O
at O
the O
carcinogenic O
dose O
. O
These O
results O
suggest O
the O
possible O
participation O
of O
genotoxic O
mechanisms O
in O
MEG-induced O
hepatocarcinogenesis O
. O

jaspamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
jaspamide O
on O
human O
cardiomyocyte O
function O
and O
cardiac B
ion I
channel I
activity.Jaspamide O
(jasplakinolide; O
NSC-613009) O
is O
a O
cyclodepsipeptide O
that O
has O
antitumor O
activity O
. O
A O
narrow O
margin O
of O
safety O
was O
observed O
between O
doses O
required O
for O
efficacy O
in O
mouse O
tumor O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O
amplitude O
, O
putative O
measurements O
of O
cell O
viability O
and O
cardiac O
contractility O
, O
respectively O
. O
Concentration-dependent O
increases O
in O
rhythmic O
beating O
rate O
were O
noted O
at O
≤ O
6 O
h O
of O
treatment O
, O
followed O
by O
dose-dependent O
decreases O
after O
6 O
and O
72 O
h O
exposure O
. O
The O
toxic O
effects O
of O
jaspamide O
were O
compared O
with O
that O
of O
the O
known O
cardiotoxicant O
mitoxantrone O
, O
and O
confirmed O
by O
multiparameter O
fluorescence O
imaging O
analysis O
. O
These O
results O
support O
the O
hypothesis O
that O
the O
toxicity O
observed O
in O
rats O
and O
dogs O
is O
due O
to O
toxic O
effects O
of O
jaspamide O
on O
cardiomyocytes O
. O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Artemisinic O
acid O
inhibits O
melanogenesis O
through O
downregulation O
of O
C/EBP O
α-dependent O
expression O
of O
HMG-CoA O
reductase O
gene.Cholesterol O
is O
associated O
with O
the O
regulation O
of O
melanogenesis O
which O
is O
the O
major O
physiological O
defense O
against O
solar O
irradiation O
. O
The O
present O
study O
was O
designed O
to O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
( O
MITF) B
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG O
CoA O
reductase O
gene O
, O
which O
is O
mediated O
by O
C/EBP O
α O
inhibition O
and O
suggest O
that O
artemisinic O
acid O
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibitor O
. O

Beta-glucogallin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG-mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK O
and O
p38 O
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation O
. O
In O
this O
study O
, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG O
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O
the O
ocular O
media O
of O
mice O
with O
experimental O
uveitis O
. O
Accordingly O
, O
these O
results O
suggest O
BGG O
is O
a O
potential O
therapy O
for O
inflammatory O
diseases O
. O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Juglone O
, O
isolated O
from O
Juglans O
mandshurica O
Maxim O
, O
induces O
apoptosis O
via O
down-regulation O
of O
AR O
expression O
in O
human O
prostate O
cancer O
LNCaP O
cells.Juglone O
is O
a O
natural O
compound O
which O
has O
been O
isolated O
from O
Juglans O
mandshurica O
Maxim O
. O
Recent O
studies O
have O
shown O
that O
juglone O
had O
various O
pharmacological O
effects O
such O
as O
anti-viral O
, O
anti-bacterial O
and O
anti-cancer O
. O
However O
, O
its O
anti-cancer O
activity O
on O
human O
prostate O
cancer O
LNCaP O
cell O
has O
not O
been O
examined O
. O
Thus O
, O
the O
current O
study O
was O
designed O
to O
elucidate O
the O
molecular O
mechanism O
of O
apoptosis O
induced O
by O
juglone O
in O
androgen-sensitive O
prostate O
cancer O
LNCaP O
cells O
. O
MTT O
assay O
was O
performed O
to O
examine O
the O
anti-proliferative O
effect O
of O
juglone O
. O
Occurrence O
of O
apoptosis O
was O
detected O
by O
Hoechst O
33342 O
staining O
and O
flow O
cytometry O
in O
LNCaP O
cells O
treated O
with O
juglone O
for O
24h O
. O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific O
antigen O
( O
PSA) B
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR O
and O
PSA O
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O
AR O
expression O
. O
Therefore O
, O
our O
results O
indicated O
that O
juglone O
may O
be O
a O
potential O
candidate O
of O
drug O
for O
androgen-sensitive O
prostate O
cancer O
. O

vardenafil O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Conformational O
variations O
of O
both O
phosphodiesterase-5 B
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil O
and O
sildenafil.Vardenafil O
has O
higher O
affinity O
to O
phosphodiesterase-5 O
(PDE5) O
than O
sildenafil O
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O
However O
, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures O
. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 O
catalytic O
domain O
in O
complex O
with O
vardenafil O
. O
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil O
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 O
and O
its O
complexes O
with O
the O
inhibitors O
. O
In O
addition O
, O
the O
molecular O
configuration O
of O
vardenafil O
differs O
from O
that O
of O
sildenafil O
when O
bound O
to O
PDE5 O
. O
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil O
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE O
structures O
. O
The O
conformational O
variation O
of O
both O
PDE5 O
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs O
. O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Indomethacin O
activates O
carbonic O
anhydrase O
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase O
inhibitor O
acetazolamide O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O
concentrations O
between O
10(-8)-10(-4) O
M O
on O
purified O
human O
red O
cell O
CA O
I O
and O
II O
as O
well O
as O
on O
human O
gastric O
mucosa O
CA O
IV O
using O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA B
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX O
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

isatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine B
oxidase I
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO O
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O
the O
nineteen O
homologues O
evaluated O
, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O
MAO-A O
and O
-B O
were O
0.096 O
and O
0.0014 O
μM O
, O
respectively O
. O
In O
most O
instances O
, O
C6-substituted O
phthalides O
exhibit O
MAO-B O
specific O
inhibition O
. O
Among O
a O
series O
of O
6-benzyloxyphthalides O
bearing O
substituents O
on O
the O
para O
position O
of O
the O
phenyl O
ring O
the O
general O
order O
of O
potency O
was O
CF(3) O
> O
I O
> O
Br O
> O
Cl O
> O
F O
> O
CH(3) O
> O
H O
. O
The O
results O
also O
show O
that O
the O
binding O
modes O
of O
representative O
phthalides O
are O
reversible O
and O
competitive O
at O
both O
MAO O
isoforms O
. O
Based O
on O
these O
data O
, O
C6-substituted O
phthalides O
may O
serve O
as O
leads O
for O
the O
development O
of O
therapies O
for O
neurodegenerative O
disorders O
such O
as O
Parkinson's O
disease O
. O

dasatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib O
(BMS-354825) O
: O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR B
-ABL.PURPOSE O
: O
Dasatinib O
(BMS-354825) O
, O
a O
potent O
oral O
multi-targeted O
kinase O
inhibitor O
against O
SRC O
and O
BCR-ABL O
, O
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired O
resistance O
and O
intolerance O
. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib O
in O
mouse O
, O
rat O
, O
dog O
, O
and O
monkey O
. O
Possible O
mechanisms O
contributing O
to O
the O
incomplete O
oral O
bioavailability O
of O
dasatinib O
in O
animals O
were O
investigated O
. O
METHODS O
: O
Metabolic O
stability O
of O
dasatinib O
was O
measured O
after O
incubation O
with O
liver O
microsomes O
(either O
NADPH- O
or O
UDPGA-fortified) O
and O
isolated O
hepatocytes O
obtained O
from O
mouse O
, O
rat O
, O
dog O
, O
monkey O
, O
and O
human O
. O
In O
all O
cases O
, O
substrate O
depletion O
over O
time O
was O
measured O
, O
and O
appropriate O
scaling O
factors O
were O
used O
to O
predict O
in O
vivo O
clearance O
. O
Pharmacokinetics O
of O
dasatinib O
were O
determined O
in O
mice O
, O
rats O
, O
dogs O
, O
and O
monkeys O
after O
administration O
of O
single O
intravenous O
or O
oral O
doses O
. O
In O
addition O
, O
the O
routes O
of O
excretion O
were O
investigated O
after O
administration O
of O
dasatinib O
to O
bile O
duct O
cannulated O
(BDC) O
rats O
. O
Absorption O
and O
first-pass O
metabolism O
were O
evaluated O
as O
possible O
reasons O
for O
the O
incomplete O
oral O
bioavailability O
using O
various O
in O
vitro O
and O
in O
vivo O
models O
like O
Caco-2 O
cells O
, O
P-glycoprotein O
(P-gp) O
knockout O
mice O
, O
and O
intra-portal O
dosing O
in O
rats O
. O
RESULTS O
: O
In O
vivo O
systemic O
plasma O
clearance O
values O
of O
dasatinib O
were O
62 O
, O
26 O
, O
25 O
, O
and O
34 O
ml/min/kg O
in O
mouse O
, O
rat O
, O
dog O
, O
and O
monkey O
, O
respectively O
. O
Scaling O
of O
in O
vitro O
hepatocyte O
and O
liver O
microsomal O
data O
gave O
reasonably O
good O
predictions O
of O
in O
vivo O
clearances O
across O
all O
species O
. O
Percent O
distribution O
in O
blood O
cells O
ranged O
from O
43% O
in O
mouse O
to O
57% O
in O
dog O
. O
Dasatinib O
showed O
high O
volumes O
of O
distribution O
(>3 O
l/kg) O
and O
high O
serum O
protein O
binding O
values O
(>90%) O
in O
all O
four O
species O
tested O
. O
Oral O
bioavailability O
of O
dasatinib O
ranged O
from O
14% O
in O
the O
mouse O
to O
34% O
in O
the O
dog O
. O
In O
rats O
, O
bioavailability O
after O
an O
intraportal O
dose O
was O
comparable O
to O
that O
after O
intra-arterial O
administration O
. O
In O
BDC O
rats O
, O
less O
than O
15% O
of O
an O
intravenous O
dose O
was O
excreted O
unchanged O
in O
urine O
, O
bile O
, O
and O
the O
gastrointestinal O
tract O
, O
suggesting O
that O
dasatinib O
is O
cleared O
primarily O
via O
metabolism O
. O
Dasatinib O
has O
high O
intrinsic O
permeability O
in O
Caco-2 O
cells O
, O
however O
, O
the O
efflux O
ratio O
was O
approximately O
two-fold O
indicating O
that O
it O
may O
be O
a O
substrate O
for O
an O
intestinal O
efflux O
transporter O
. O
However O
, O
in O
vivo O
studies O
in O
P-gp O
knockout O
mice O
versus O
wild-type O
mice O
showed O
no O
difference O
in O
the O
amount O
of O
dasatinib O
remaining O
unabsorbed O
in O
the O
gastrointestinal O
tract O
, O
suggesting O
that O
P-gp O
may O
not O
be O
responsible O
for O
the O
incomplete O
bioavailability O
. O
CONCLUSIONS O
: O
Dasatinib O
shows O
intermediate O
clearance O
in O
mouse O
, O
rat O
, O
dog O
, O
and O
monkey O
, O
and O
distributes O
extensively O
in O
those O
species O
. O
Oxidative O
metabolism O
appears O
to O
be O
the O
predominant O
clearance O
pathway O
. O
The O
incomplete O
oral O
bioavailability O
may O
be O
due O
to O
both O
incomplete O
absorption O
and O
high O
first-pass O
metabolism O
. O
However O
, O
the O
efflux O
transporter O
, O
P-glycoprotein O
does O
not O
appear O
to O
be O
limiting O
oral O
absorption O
. O

OMT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Neuroprotective O
effects O
of O
oxymatrine O
against O
excitotoxicity O
partially O
through O
down-regulation O
of O
NR2B-containing O
NMDA O
receptors.Oxymatrine O
(OMT) O
is O
a O
major O
bioactive O
component O
derived O
from O
Sophora O
flavescens O
Ait O
(kushen) O
, O
which O
is O
widely O
used O
in O
Chinese O
medicine O
. O
Recent O
studies O
have O
shown O
that O
it O
has O
neuroprotective O
effects; O
however O
, O
its O
underlying O
mechanisms O
remain O
unclear O
. O
We O
focus O
on O
the O
mechanisms O
of O
pharmacologic O
action O
in O
OMT O
by O
detecting O
its O
pharmacological O
properties O
against O
focal O
cerebral O
ischemia O
in O
vivo O
and O
NMDA-induced O
neurotoxicity O
in O
vitro O
. O
OMT O
prevented O
cerebral O
ischemic O
injury O
in O
mice O
induced O
via O
a O
2 O
h O
middle O
cerebral O
artery O
occlusion O
and O
a O
24 O
h O
reperfusion O
, O
in O
vivo O
. O
In O
vitro O
cultured O
neurons O
challenged O
with O
N-methyl-D-aspartate O
(NMDA O
, O
200 O
μM) O
for O
30 O
min O
showed O
significant O
decrease O
in O
the O
viability O
of O
neurons; O
however O
, O
OMT O
was O
able O
to O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 B
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia O
. O

artemisinic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Artemisinic O
acid O
inhibits O
melanogenesis O
through O
downregulation O
of O
C/EBP O
α-dependent O
expression O
of O
HMG-CoA O
reductase O
gene.Cholesterol O
is O
associated O
with O
the O
regulation O
of O
melanogenesis O
which O
is O
the O
major O
physiological O
defense O
against O
solar O
irradiation O
. O
The O
present O
study O
was O
designed O
to O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG O
CoA O
reductase O
gene O
, O
which O
is O
mediated O
by O
C/EBP B
α I
inhibition O
and O
suggest O
that O
artemisinic O
acid O
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibitor O
. O

fenofibrate O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Effects O
of O
fenofibrate O
, O
a O
PPAR-α O
ligand O
, O
on O
the O
haemodynamics O
of O
glycerol-induced O
renal O
failure O
in O
rats.The O
modulating O
effect O
of O
peroxisome O
proliferator-activated O
receptor O
α O
ligand O
on O
haemodynamic O
effects O
of O
phenylepherine O
(PE) O
, O
angiotensin O
II O
(AII) O
, O
endothelin O
1 O
(ET1) O
, O
acetylcholine O
(Ach) O
, O
sodium O
nitroprusside O
(SNP) O
and O
isoproterenol O
(ISO) O
were O
evaluated O
in O
glycerol-induced O
acute O
kidney O
injury O
in O
rats O
. O
The O
effect O
of O
PE O
on O
fenofibrate-treated O
animals O
was O
a O
dose-dependent O
increase O
in O
mean O
arterial O
blood O
pressure O
(MAP) O
. O
For O
AII O
and O
ET1 B
, O
MAP O
was O
also O
increased O
for O
the O
fenofibrate O
group O
but O
not O
in O
a O
dose-dependent O
fashion O
. O
On O
the O
medullary O
blood O
flow O
(MBF) O
, O
while O
the O
lower O
doses O
of O
PE O
and O
AII O
increased O
the O
perfusion O
unit O
on O
the O
fenofibrate-treated O
group O
, O
the O
higher O
doses O
decreased O
the O
perfusion O
unit O
. O
The O
ET1 O
increased O
the O
perfusion O
unit O
on O
this O
group O
but O
not O
in O
dose-dependent O
fashion O
. O
The O
effects O
of O
PE O
and O
AII O
on O
the O
cortical O
blood O
flow O
(CBF) O
of O
fenofibrate-treated O
group O
is O
similar O
to O
that O
of O
MBF O
for O
the O
same O
group O
but O
not O
for O
ET1 O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
in O
all O
the O
groups O
was O
the O
decrease O
in O
MAP O
. O
ISO O
caused O
dose-dependent O
increase O
in O
MBF O
of O
fenofibrate-treated O
group O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
on O
the O
CBF O
perfusion O
unit O
was O
that O
of O
the O
increase O
for O
the O
fenofibrate-treated O
group O
. O
The O
study O
showed O
that O
fenofibrate O
did O
not O
attenuate O
increased O
blood O
pressure O
induced O
by O
PE O
, O
AII O
and O
ET1 O
but O
caused O
enhanced O
vasodilation O
by O
Ach O
, O
SNP O
and O
ISO O
. O

LY O
344864 O
acts O
as O
NOT O
for O
what O
entity O
? O
Both O
5-HT1B O
and O
5-HT1F O
receptors O
modulate O
c-fos O
expression O
within O
rat O
trigeminal O
nucleus O
caudalis.A O
possible O
mechanism O
of O
action O
of O
antimigraine O
drugs O
such O
as O
sumatriptan O
is O
inhibition O
of O
the O
trigeminovascular O
pathway O
. O
Sumatriptan's O
effects O
might O
be O
mediated O
by O
5-HT1B O
, O
5-HT1D O
or O
5-HT1F O
receptors O
. O
To O
establish O
the O
relative O
importance O
of O
these O
subtypes O
, O
we O
compared O
the O
effects O
of O
sumatriptan O
with O
those O
of O
a O
selective O
5-HT1F O
receptor O
agonist O
(LY O
344864) O
on O
c-fos O
protein O
expression O
in O
the O
trigeminal O
nucleus O
caudalis O
. O
c-fos O
expression O
was O
induced O
in O
urethane-anaesthetized O
rats O
by O
intracisternal O
capsaicin O
administration O
. O
Sumatriptan O
and O
LY O
344864 O
decreased O
the O
number O
of O
capsaicin-induced O
c-fos-like O
immunoreactive O
cells O
within O
trigeminal O
nucleus O
caudalis O
(ID50 O
= O
0.04 O
and O
0.6 O
mg O
kg(-1)) O
. O
The O
effect O
of O
sumatriptan O
, O
but O
not O
of O
LY O
344864 O
, O
was O
prevented O
by O
pretreatment O
with O
the O
antagonist O
SDZ O
21-009 O
, O
which O
displays O
high O
affinity O
for O
rat B
5-HT1B I
receptors O
. O
LY O
344864 O
appears O
to O
attenuate O
c-fos-like O
immunoreactivity O
via O
5-HT1F O
receptors O
, O
while O
sumatriptan O
acts O
via O
5-HT1B O
receptors O
. O
The O
fact O
that O
activation O
of O
5-HT1F O
receptors O
is O
sufficient O
to O
modulate O
the O
activity O
of O
the O
trigeminal O
system O
suggests O
that O
this O
receptor O
may O
be O
a O
target O
for O
antimigraine O
drugs O
with O
improved O
safety O
profile O
. O

glyburide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cross-inhibition O
of O
SR-BI- O
and O
ABCA1-mediated O
cholesterol O
transport O
by O
the O
small O
molecules O
BLT-4 O
and O
glyburide.Scavenger O
receptor O
class O
B O
type O
I O
(SR-BI) O
and O
ABCA1 O
are O
structurally O
dissimilar O
cell O
surface O
proteins O
that O
play O
key O
roles O
in O
HDL O
metabolism O
. O
SR-BI O
is O
a O
receptor O
that O
binds O
HDL O
with O
high O
affinity O
and O
mediates O
both O
the O
selective O
lipid O
uptake O
of O
cholesteryl O
esters O
from O
lipid-rich O
HDL O
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol O
from O
cells O
to O
HDL O
. O
ABCA1 O
mediates O
the O
efflux O
of O
unesterified O
cholesterol O
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1-mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 B
(IC(50) O
approximately O
275-300 O
microM) O
. O
As O
is O
the O
case O
with O
BLTs O
, O
glyburide O
increased O
the O
apparent O
affinity O
of O
HDL O
binding O
to O
SR-BI O
. O
The O
reciprocal O
inhibition O
of O
SR-BI O
and O
ABCA1 O
by O
BLT-4 O
and O
glyburide O
raises O
the O
possibility O
that O
these O
proteins O
may O
share O
similar O
or O
common O
steps O
in O
their O
mechanisms O
of O
lipid O
transport O
. O

verapamil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Verapamil O
prevents O
torsade O
de O
pointes O
by O
reduction O
of O
transmural O
dispersion O
of O
repolarization O
and O
suppression O
of O
early O
afterdepolarizations O
in O
an O
intact O
heart O
model O
of O
LQT3.BACKGROUND O
: O
In O
long O
QT O
syndrome O
(LQTS) O
, O
prolongation O
of O
the O
QT-interval O
is O
associated O
with O
sudden O
cardiac O
death O
resulting O
from O
potentially O
life-threatening O
polymorphic O
tachycardia O
of O
the O
torsade O
de O
pointes O
(TdP) O
type O
. O
Experimental O
as O
well O
as O
clinical O
reports O
support O
the O
hypothesis O
that O
calcium B
channel I
blockers O
such O
as O
verapamil O
may O
be O
an O
appropriate O
therapeutic O
approach O
in O
LQTS O
. O
We O
investigated O
the O
electrophysiologic O
mechanism O
by O
which O
verapamil O
suppresses O
TdP O
, O
in O
a O
recently O
developed O
intact O
heart O
model O
of O
LQT3 O
. O
METHODS O
AND O
RESULTS O
: O
In O
8 O
Langendorff-perfused O
rabbit O
hearts O
, O
veratridine O
(0.1 O
microM) O
, O
an O
inhibitor O
of O
sodium O
channel O
inactivation O
, O
led O
to O
a O
marked O
increase O
in O
QT-interval O
and O
simultaneously O
recorded O
monophasic O
ventricular O
action O
potentials O
(MAPs) O
(p O
< O
0.05) O
thereby O
mimicking O
LQT3 O
. O
In O
bradycardic O
(AV-blocked) O
hearts O
, O
simultaneous O
recording O
of O
up O
to O
eight O
epi- O
and O
endocardial O
MAPs O
demonstrated O
a O
significant O
increase O
in O
total O
dispersion O
of O
repolarization O
(56% O
, O
p O
< O
0.05) O
and O
reverse O
frequency-dependence O
. O
After O
lowering O
potassium O
concentration O
, O
veratridine O
reproducibly O
led O
to O
early O
afterdepolarizations O
(EADs) O
and O
TdP O
in O
6 O
of O
8 O
(75%) O
hearts O
. O
Additional O
infusion O
of O
verapamil O
(0.75 O
microM) O
suppressed O
EADs O
and O
consecutively O
TdP O
in O
all O
hearts O
. O
Verapamil O
significantly O
shortened O
endocardial O
but O
not O
epicardial O
MAPs O
which O
resulted O
in O
significant O
reduction O
of O
ventricular O
transmural O
dispersion O
of O
repolarization O
. O
CONCLUSIONS O
: O
Verapamil O
is O
highly O
effective O
in O
preventing O
TdP O
via O
shortening O
of O
endocardial O
MAPs O
, O
reduction O
of O
left O
ventricular O
transmural O
dispersion O
of O
repolarization O
and O
suppression O
of O
EADs O
in O
an O
intact O
heart O
model O
of O
LQT3 O
. O
These O
data O
suggest O
a O
possible O
therapeutic O
role O
of O
verapamil O
in O
the O
treatment O
of O
LQT3 O
patients O
. O

Meclofenamic O
acid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Meclofenamic O
acid O
and O
diclofenac O
, O
novel O
templates O
of O
KCNQ2/Q3 O
potassium B
channel I
openers O
, O
depress O
cortical O
neuron O
activity O
and O
exhibit O
anticonvulsant O
properties.The O
voltage-dependent O
M-type O
potassium O
current O
(M-current) O
plays O
a O
major O
role O
in O
controlling O
brain O
excitability O
by O
stabilizing O
the O
membrane O
potential O
and O
acting O
as O
a O
brake O
for O
neuronal O
firing O
. O
The O
KCNQ2/Q3 O
heteromeric O
channel O
complex O
was O
identified O
as O
the O
molecular O
correlate O
of O
the O
M-current O
. O
Furthermore O
, O
the O
KCNQ2 O
and O
KCNQ3 O
channel O
alpha O
subunits O
are O
mutated O
in O
families O
with O
benign O
familial O
neonatal O
convulsions O
, O
a O
neonatal O
form O
of O
epilepsy O
. O
Enhancement O
of O
KCNQ2/Q3 O
potassium O
currents O
may O
provide O
an O
important O
target O
for O
antiepileptic O
drug O
development O
. O
Here O
, O
we O
show O
that O
meclofenamic O
acid O
(meclofenamate) O
and O
diclofenac O
, O
two O
related O
molecules O
previously O
used O
as O
anti-inflammatory O
drugs O
, O
act O
as O
novel O
KCNQ2/Q3 O
channel O
openers O
. O
Extracellular O
application O
of O
meclofenamate O
(EC(50) O
= O
25 O
microM) O
and O
diclofenac O
(EC(50) O
= O
2.6 O
microM) O
resulted O
in O
the O
activation O
of O
KCNQ2/Q3 O
K(+) O
currents O
, O
heterologously O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
. O
Both O
openers O
activated O
KCNQ2/Q3 O
channels O
by O
causing O
a O
hyperpolarizing O
shift O
of O
the O
voltage O
activation O
curve O
(-23 O
and O
-15 O
mV O
, O
respectively) O
and O
by O
markedly O
slowing O
the O
deactivation O
kinetics O
. O
The O
effects O
of O
the O
drugs O
were O
stronger O
on O
KCNQ2 O
than O
on O
KCNQ3 O
channel O
alpha O
subunits O
. O
In O
contrast O
, O
they O
did O
not O
enhance O
KCNQ1 O
K(+) O
currents O
. O
Both O
openers O
increased O
KCNQ2/Q3 O
current O
amplitude O
at O
physiologically O
relevant O
potentials O
and O
led O
to O
hyperpolarization O
of O
the O
resting O
membrane O
potential O
. O
In O
cultured O
cortical O
neurons O
, O
meclofenamate O
and O
diclofenac O
enhanced O
the O
M-current O
and O
reduced O
evoked O
and O
spontaneous O
action O
potentials O
, O
whereas O
in O
vivo O
diclofenac O
exhibited O
an O
anticonvulsant O
activity O
(ED(50) O
= O
43 O
mg/kg) O
. O
These O
compounds O
potentially O
constitute O
novel O
drug O
templates O
for O
the O
treatment O
of O
neuronal O
hyperexcitability O
including O
epilepsy O
, O
migraine O
, O
or O
neuropathic O
pain O
. O

trichostatin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Creb1-Mecp2-(m)CpG O
complex O
transactivates O
postnatal O
murine O
neuronal O
glucose O
transporter O
isoform O
3 O
expression.The O
murine O
neuronal O
facilitative O
glucose O
transporter O
isoform O
3 O
(Glut3) O
is O
developmentally O
regulated O
, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA O
methyl O
transferase O
3a O
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O
biological O
function O
, O
glut3 O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3-(m)CpGs O
. O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 B
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3-(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O
escape O
from O
(m)CpG-induced O
gene O
suppression O
, O
and O
thereby O
promoting O
developmental O
neuronal O
glut3 O
gene O
transcription O
and O
expression O
. O

phthalides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO O
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O
the O
nineteen O
homologues O
evaluated O
, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O
MAO-A O
and O
-B O
were O
0.096 O
and O
0.0014 O
μM O
, O
respectively O
. O
In O
most O
instances O
, O
C6-substituted O
phthalides O
exhibit O
MAO-B O
specific O
inhibition O
. O
Among O
a O
series O
of O
6-benzyloxyphthalides O
bearing O
substituents O
on O
the O
para O
position O
of O
the O
phenyl O
ring O
the O
general O
order O
of O
potency O
was O
CF(3) O
> O
I O
> O
Br O
> O
Cl O
> O
F O
> O
CH(3) O
> O
H O
. O
The O
results O
also O
show O
that O
the O
binding O
modes O
of O
representative O
phthalides O
are O
reversible O
and O
competitive O
at O
both O
MAO B
isoforms O
. O
Based O
on O
these O
data O
, O
C6-substituted O
phthalides O
may O
serve O
as O
leads O
for O
the O
development O
of O
therapies O
for O
neurodegenerative O
disorders O
such O
as O
Parkinson's O
disease O
. O

Sulindac O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Sulindac O
independently O
modulates O
extracellular O
signal-regulated O
kinase O
1/2 O
and O
cyclic B
GMP-dependent I
protein I
kinase I
signaling O
pathways.Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
mortality O
in O
the O
United O
States O
. O
Substantial O
human O
and O
animal O
data O
support O
the O
ability O
of O
nonsteroidal O
anti-inflammatory O
drugs O
to O
cause O
regression O
of O
existing O
colon O
tumors O
and O
prevent O
new O
tumor O
formation O
. O
The O
mechanism O
by O
which O
the O
nonsteroidal O
anti-inflammatory O
drug O
sulindac O
prevents O
tumor O
growth O
is O
poorly O
understood O
and O
seems O
complex O
as O
sulindac O
can O
modulate O
several O
growth-related O
signaling O
pathways O
. O
Sulindac O
metabolites O
simultaneously O
(a) O
increase O
cellular O
cyclic O
GMP O
and O
subsequently O
activate O
cyclic O
GMP-dependent O
protein O
kinase O
(PKG); O
(b) O
activate O
c-jun O
NH2-terminal O
kinase O
(JNK); O
(c) O
inhibit O
extracellular O
signal-regulated O
kinase O
1/2 O
(ERK1/2); O
and O
(d) O
decrease O
beta-catenin O
protein O
expression O
at O
times O
and O
doses O
consistent O
with O
apoptosis O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
PKG O
, O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
are O
independent O
targets O
for O
sulindac O
in O
vitro O
. O
Pharmacologic O
activation O
of O
PKG O
with O
YC-1 O
increases O
JNK O
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 O
phosphorylation O
or O
beta-catenin O
protein O
expression O
. O
Inhibition O
of O
ERK1/2 O
with O
U0126 O
induces O
apoptosis O
but O
fails O
to O
activate O
JNK O
phosphorylation O
or O
down-regulate O
beta-catenin O
protein O
expression O
. O
Cotreatment O
with O
U0126 O
and O
YC-1 O
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac O
treatment O
on O
ERK1/2 O
, O
JNK O
, O
and O
beta-catenin O
. O
These O
results O
indicate O
that O
sulindac O
metabolites O
modulate O
ERK1/2 O
and O
PKG O
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac O
is O
mediated O
by O
more O
than O
one O
pathway O
. O
Using O
similar O
combinatorial O
approaches O
in O
vivo O
may O
provide O
more O
effective O
, O
less O
toxic O
chemopreventive O
and O
chemotherapeutic O
strategies O
. O
Such O
therapies O
could O
dramatically O
reduce O
the O
incidence O
and O
death O
rate O
from O
colorectal O
cancer O
. O

resveratrol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
SIRT1 O
inhibits O
NADPH O
oxidase O
activation O
and O
protects O
endothelial O
function O
in O
the O
rat O
aorta O
: O
Implications O
for O
vascular O
aging.Vascular O
aging O
is O
characterized O
by O
up-regulation O
of O
NADPH O
oxidase O
, O
oxidative O
stress O
and O
endothelial O
dysfunction O
. O
Previous O
studies O
demonstrate O
that O
the O
activity O
of O
the O
evolutionarily O
conserved O
NAD(+)-dependent O
deacetylase O
SIRT1 O
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
(nicotinamide O
, O
sirtinol O
, O
EX527) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH B
oxidase I
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O
up-regulates O
NADPH O
oxidase-derived O
ROS O
production O
in O
the O
vascular O
wall O
, O
mimicking O
the O
vascular O
aging O
phenotype O
. O
Moreover O
, O
a O
new O
mechanism O
for O
controlling O
endothelial O
function O
after O
SIRT1 O
activation O
involves O
a O
decreased O
PGC-1α O
acetylation O
and O
the O
subsequent O
PPARα O
activation O
, O
resulting O
in O
both O
decreased O
NADPH O
oxidase-driven O
ROS O
production O
and O
NO O
inactivation O
. O

MPH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Methylphenidate O
administration O
to O
juvenile O
rats O
alters O
brain O
areas O
involved O
in O
cognition O
, O
motivated O
behaviors O
, O
appetite O
, O
and O
stress.Thousands O
of O
children O
receive O
methylphenidate O
(MPH; O
Ritalin) O
for O
attention O
deficit/hyperactivity O
disorder O
(ADHD) O
, O
yet O
the O
long-term O
neurochemical O
consequences O
of O
MPH O
treatment O
are O
unknown O
. O
To O
mimic O
clinical O
Ritalin O
treatment O
in O
children O
, O
male O
rats O
were O
injected O
with O
MPH O
(5 O
mg/kg) O
or O
vehicle O
twice O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine O
hydroxylase O
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine B
transporter I
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O
on O
select O
neurotransmitters O
in O
brain O
regions O
involved O
in O
motivated O
behaviors O
, O
cognition O
, O
appetite O
, O
and O
stress O
. O
Although O
the O
observed O
neuroanatomical O
changes O
largely O
resolve O
with O
time O
, O
chronic O
modulation O
of O
young O
brains O
with O
MPH O
may O
exert O
effects O
on O
brain O
neurochemistry O
that O
modify O
some O
behaviors O
even O
in O
adulthood O
. O

NaAsO(2) O
acts O
as O
NOT O
for O
what O
entity O
? O
Inhibition O
of O
neurite O
outgrowth O
and O
alteration O
of O
cytoskeletal O
gene O
expression O
by O
sodium O
arsenite.Arsenic O
compounds O
that O
are O
often O
found O
in O
drinking O
water O
increase O
the O
risk O
of O
developmental O
brain O
disorders O
. O
In O
this O
study O
, O
we O
performed O
live O
imaging O
analyses O
of O
Neuro-2a O
cells O
expressing O
SCAT3 O
, O
a O
caspase-3 O
cleavage O
peptide O
sequence O
linking O
two O
fluorescent O
proteins; O
enhanced O
cyan O
fluorescence O
protein O
(ECFP) O
and O
Venus O
, O
to O
determine O
whether O
sodium O
arsenite O
(NaAsO(2); O
0 O
, O
1 O
, O
5 O
, O
or O
10 O
μM) O
affects O
both O
neurite O
outgrowth O
and/or O
induces O
apoptosis O
with O
the O
same O
doses O
and O
in O
the O
same O
cell O
cultures O
. O
We O
observed O
that O
the O
area O
ratio O
of O
neurite O
to O
cell O
body O
in O
SCAT3-expressing O
cells O
was O
significantly O
reduced O
by O
5 O
and O
10 O
μM O
NaAsO(2) O
, O
but O
not O
by O
1 O
μM O
, O
although O
the O
emission O
ratio O
of O
ECFP O
to O
Venus O
, O
an O
endpoint O
of O
caspase-3 O
activity O
, O
was O
not O
changed O
. O
However O
, O
cytological O
assay O
using O
apoptotic O
and O
necrotic O
markers O
resulted O
in O
that O
apoptosis O
, O
but O
not O
necrosis O
, O
was O
significantly O
induced O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin B
. O
The O
changes O
in O
cytoskeletal O
gene O
expression O
are O
likely O
responsible O
for O
the O
inhibitory O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
. O

meclofenamic O
acid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Meclofenamic O
acid O
and O
diclofenac O
, O
novel O
templates O
of O
KCNQ2/Q3 O
potassium O
channel O
openers O
, O
depress O
cortical O
neuron O
activity O
and O
exhibit O
anticonvulsant O
properties.The O
voltage-dependent O
M-type O
potassium O
current O
(M-current) O
plays O
a O
major O
role O
in O
controlling O
brain O
excitability O
by O
stabilizing O
the O
membrane O
potential O
and O
acting O
as O
a O
brake O
for O
neuronal O
firing O
. O
The O
KCNQ2/Q3 O
heteromeric O
channel O
complex O
was O
identified O
as O
the O
molecular O
correlate O
of O
the O
M-current O
. O
Furthermore O
, O
the O
KCNQ2 O
and O
KCNQ3 O
channel O
alpha O
subunits O
are O
mutated O
in O
families O
with O
benign O
familial O
neonatal O
convulsions O
, O
a O
neonatal O
form O
of O
epilepsy O
. O
Enhancement O
of O
KCNQ2/Q3 O
potassium O
currents O
may O
provide O
an O
important O
target O
for O
antiepileptic O
drug O
development O
. O
Here O
, O
we O
show O
that O
meclofenamic O
acid O
(meclofenamate) O
and O
diclofenac O
, O
two O
related O
molecules O
previously O
used O
as O
anti-inflammatory O
drugs O
, O
act O
as O
novel O
KCNQ2/Q3 B
channel O
openers O
. O
Extracellular O
application O
of O
meclofenamate O
(EC(50) O
= O
25 O
microM) O
and O
diclofenac O
(EC(50) O
= O
2.6 O
microM) O
resulted O
in O
the O
activation O
of O
KCNQ2/Q3 O
K(+) O
currents O
, O
heterologously O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
. O
Both O
openers O
activated O
KCNQ2/Q3 O
channels O
by O
causing O
a O
hyperpolarizing O
shift O
of O
the O
voltage O
activation O
curve O
(-23 O
and O
-15 O
mV O
, O
respectively) O
and O
by O
markedly O
slowing O
the O
deactivation O
kinetics O
. O
The O
effects O
of O
the O
drugs O
were O
stronger O
on O
KCNQ2 O
than O
on O
KCNQ3 O
channel O
alpha O
subunits O
. O
In O
contrast O
, O
they O
did O
not O
enhance O
KCNQ1 O
K(+) O
currents O
. O
Both O
openers O
increased O
KCNQ2/Q3 O
current O
amplitude O
at O
physiologically O
relevant O
potentials O
and O
led O
to O
hyperpolarization O
of O
the O
resting O
membrane O
potential O
. O
In O
cultured O
cortical O
neurons O
, O
meclofenamate O
and O
diclofenac O
enhanced O
the O
M-current O
and O
reduced O
evoked O
and O
spontaneous O
action O
potentials O
, O
whereas O
in O
vivo O
diclofenac O
exhibited O
an O
anticonvulsant O
activity O
(ED(50) O
= O
43 O
mg/kg) O
. O
These O
compounds O
potentially O
constitute O
novel O
drug O
templates O
for O
the O
treatment O
of O
neuronal O
hyperexcitability O
including O
epilepsy O
, O
migraine O
, O
or O
neuropathic O
pain O
. O

NS-398 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Expression O
and O
selective O
inhibition O
of O
the O
constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase.The O
enzyme O
cyclo-oxygenase O
catalyses O
the O
oxygenation O
of O
arachidonic O
acid O
, O
leading O
to O
the O
formation O
of O
prostaglandins O
. O
Recently O
two O
forms O
of O
cyclo-oxygenase O
have O
been O
described O
: O
a O
constitutive O
(COX-1) O
enzyme O
present O
in O
most O
cells O
and O
tissues O
, O
and O
an O
inducible O
(COX-2) O
isoenzyme O
observed O
in O
many O
cells O
in O
response O
to O
pro-inflammatory O
cytokines O
. O
Constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase O
(hCOX-1 O
and O
hCOX-2) O
were O
cloned O
and O
expressed O
in O
insect O
cells O
, O
utilizing O
a O
baculovirus O
expression O
system O
. O
hCOX-1 O
had O
a O
specific O
activity O
of O
18.8 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 O
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 B
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

olanzapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cerebral O
D2 O
and O
5-HT2 O
receptor O
occupancy O
in O
Schizophrenic O
patients O
treated O
with O
olanzapine O
or O
clozapine.We O
report O
the O
results O
of O
a O
double-blind O
, O
randomized O
prospective O
trial O
on O
D2 O
and O
5-HT2 O
receptor O
occupancy O
and O
the O
clinical O
effects O
of O
olanzapine O
versus O
clozapine O
in O
a O
sample O
of O
neuroleptic-refractory O
schizophrenic O
patients O
. O
Receptor O
occupancy O
was O
evaluated O
in O
different O
cortical O
areas O
and O
in O
basal O
ganglia O
using O
[18F] O
fluoro-ethyl-spiperone O
([18F] O
FESP) O
and O
positron O
emission O
tomography O
(PET) O
. O
A O
total O
of O
15 O
neuroleptic-free O
patients O
completed O
the O
study O
undergoing O
a O
baseline O
and O
a O
post-treatment O
PET O
scan O
(olanzapine O
, O
nine O
patients O
, O
one O
female; O
clozapine O
, O
six O
patients O
, O
three O
female) O
8 O
weeks O
after O
starting O
treatment O
. O
PET O
data O
were O
analysed O
both O
by O
regions O
of O
interest O
and O
on O
a O
voxel-by-voxel O
basis O
using O
Statistical O
Parametric O
Mapping O
(SPM96) O
. O
Olanzapine O
and O
clozapine O
induced O
a O
similar O
and O
significant O
inhibition O
of O
[18F] O
FESP O
binding O
index O
in O
the O
cortex O
. O
In O
the O
basal O
ganglia O
, O
receptor O
occupancy O
was O
significantly O
higher O
with O
olanzapine O
than O
with O
clozapine O
(p=0.0018) O
. O
By O
contrast O
, O
no O
differences O
in O
receptor O
occupancy O
were O
detected O
at O
the O
level O
of O
the O
pituitary O
gland O
. O
Clinical O
outcomes O
, O
in O
particular O
a O
full O
extra O
pyramidal O
tolerability O
, O
were O
similar O
. O
In O
this O
sample O
of O
neuroleptic-refractory O
schizophrenic O
patients O
, O
olanzapine O
and O
clozapine O
showed O
a O
different O
pattern O
of O
occupancy O
of O
D2-like B
receptor I
despite O
a O
common O
lack O
of O
extrapyramidal O
side-effects O
. O

Angiotensin O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Angiotensin-converting O
enzyme O
inhibition O
and O
AT1 O
receptor O
blockade O
modify O
the O
pressure-natriuresis O
relationship O
by O
additive O
mechanisms O
in O
rats O
with O
human O
renin O
and O
angiotensinogen B
genes.The O
intrarenal O
factors O
responsible O
for O
hypertension O
in O
double-transgenic O
rats O
(dTGR) O
harboring O
human O
renin O
and O
human O
angiotensinogen O
genes O
are O
unclear O
. O
The O
pressure-natriuresis O
and O
-diuresis O
relationships O
in O
response O
to O
chronic O
angiotensin-converting O
enzyme O
(ACE) O
inhibition O
and O
AT1 O
receptor O
blockade O
were O
evaluated O
. O
Renal O
renin-angiotensin O
and O
nitric O
oxide O
(NO) O
system O
gene O
expression O
was O
also O
investigated O
. O
Six-week-old O
dTGR O
were O
treated O
for O
3 O
wk O
with O
submaximal O
doses O
of O
cilazapril O
(10 O
mg/kg O
, O
orally) O
or O
losartan O
(10 O
mg/kg O
, O
orally) O
or O
with O
the O
drug O
combination O
. O
In O
untreated O
dTGR O
, O
pressure-natriuresis O
relationships O
were O
maximally O
shifted O
rightward O
by O
approximately O
70 O
to O
80 O
mmHg O
, O
and O
both O
renal O
blood O
flow O
(RBF) O
and O
GFR O
were O
markedly O
decreased O
. O
Submaximal O
cilazapril O
and O
losartan O
dosages O
both O
decreased O
systolic O
BP O
by O
30 O
mmHg O
and O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
by O
25 O
to O
30 O
mmHg O
. O
Cilazapril O
increased O
RBF O
and O
GFR O
to O
values O
observed O
in O
normotensive O
control O
animals O
but O
did O
not O
significantly O
affect O
fractional O
sodium O
excretion O
(FENa) O
or O
fractional O
water O
excretion O
(FEH2O) O
curves O
. O
In O
contrast O
, O
losartan O
had O
no O
significant O
effect O
on O
RBF O
or O
GFR O
but O
shifted O
the O
FENa O
and O
FEH2O O
curves O
leftward O
. O
The O
cilazapril O
and O
losartan O
combination O
completely O
normalized O
BP O
and O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
more O
than O
did O
either O
drug O
alone O
. O
When O
cilazapril O
and O
losartan O
were O
administered O
at O
higher O
doses O
(30 O
mg/kg O
, O
orally) O
, O
the O
two O
drugs O
equally O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
, O
by O
50 O
mmHg O
. O
Both O
drugs O
increased O
RBF O
and O
GFR; O
however O
, O
only O
losartan O
shifted O
FENa O
and O
FEH2O O
curves O
leftward O
. O
Human O
and O
rat O
renin O
and O
angiotensinogen O
genes O
were O
downregulated O
in O
dTGR O
and O
were O
increased O
by O
losartan O
and O
cilazapril O
treatments O
, O
whereas O
no O
changes O
in O
the O
expression O
of O
rat O
ACE O
and O
AT1A O
receptor O
genes O
were O
observed O
. O
Endothelial O
NO O
synthase O
expression O
was O
increased O
by O
cilazapril O
but O
not O
by O
losartan O
. O
Neither O
inducible O
NO O
synthase O
nor O
neural O
NO O
synthase O
gene O
expression O
was O
affected O
by O
drug O
treatments O
. O
Therefore O
, O
submaximal O
ACE O
inhibition O
enhanced O
sodium O
excretion O
mainly O
by O
increasing O
RBF O
and O
GFR O
, O
whereas O
submaximal O
AT1 O
receptor O
blockade O
decreased O
tubular O
sodium O
and O
water O
reabsorption O
. O
The O
combination O
of O
the O
two O
drugs O
produced O
an O
additive O
effect O
. O
The O
ACE O
inhibitor O
effects O
may O
involve O
increased O
endothelial O
NO O
synthase O
expression O
, O
perhaps O
related O
to O
the O
inhibition O
of O
bradykinin O
degradation O
. O

acyl O
glucuronides O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine B
5'-diphosphate- I
glucuronosyltransferases I
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

Rivastigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Update O
on O
rivastigmine.BACKGROUND O
: O
Rivastigmine O
is O
a O
carbamate O
drug O
designed O
to O
inhibit O
both O
acetylcholinesterase B
and O
butyrylcholinesterase O
by O
reversibly O
covalently O
bonding O
to O
these O
enzymes O
. O
Butyrylcholinesterase O
in-creases O
as O
Alzheimer O
disease O
progresses O
, O
so O
its O
inhibition O
may O
become O
more O
important O
as O
the O
disease O
worsens O
. O
Metabolism O
of O
rivastigmine O
occurs O
at O
the O
synapse O
rather O
than O
at O
the O
liver O
and O
previous O
studies O
have O
demonstrated O
no O
drug-drug O
interactions O
. O
Rivastigmine O
has O
a O
half-life O
at O
the O
synapse O
of O
9 O
hours O
allowing O
for O
bid O
dosing O
. O
REVIEW O
SUMMARY O
: O
Effective O
therapy O
requires O
up-titration O
from O
initial O
dosage O
of O
3 O
mg/d O
to O
6 O
mg/d O
with O
additional O
increases O
to O
9 O
mg O
or O
12 O
mg/d O
giving O
additional O
benefits O
in O
some O
patients O
. O
Beneficial O
effects O
with O
rivastigmine O
therapy O
in O
the O
functioning O
of O
activities O
of O
daily O
living O
, O
behavior O
, O
cognition O
, O
and O
global O
functioning O
have O
been O
demonstrated O
in O
patients O
with O
mild O
to O
moderate O
Alzheimer O
disease O
in O
4 O
large O
double-blind O
, O
placebo-controlled O
multicenter O
clinical O
trials O
. O
Potential O
adverse O
effects O
of O
nausea O
, O
vomiting O
, O
or O
diarrhea O
in O
these O
original O
Alzheimer O
trials O
with O
rapid O
(every O
week) O
dosage O
increases O
occurred O
in O
up O
to O
34% O
of O
patients O
and O
can O
be O
minimized O
by O
slower O
monthly O
up-titrations O
. O
Rivastigmine O
also O
was O
proven O
effective O
in O
decreasing O
psychiatric O
symptoms O
and O
cognitive O
deficits O
in O
a O
large O
double-blind O
, O
placebo-controlled O
trial O
in O
patients O
with O
diffuse O
Lewy O
body O
disease O
. O
Other O
studies O
have O
suggested O
that O
rivastigmine O
improves O
symptoms O
in O
nursing O
home O
patients O
with O
more O
severe O
stage O
Alzheimer O
disease O
, O
Parkinson O
dementia O
, O
and O
subcortical O
dementia O
. O
Follow-up O
studies O
have O
suggested O
that O
rivastigmine O
may O
delay O
disease O
progression O
and O
, O
in O
patients O
discontinuing O
the O
drug O
, O
no O
withdrawal O
effects O
were O
seen O
. O
CONCLUSION O
: O
Rivastigmine O
is O
an O
effective O
therapeutic O
agent O
for O
treating O
cognitive O
and O
behavioral O
symptoms O
in O
Alzheimer O
disease O
and O
diffuse O
Lewy O
body O
disease O
and O
may O
also O
have O
beneficial O
effects O
in O
vascular O
and O
Parkinson O
dementias O
. O

VP-16 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Moxifloxacin O
enhances O
etoposide-induced O
cytotoxic O
, O
apoptotic O
and O
anti-topoisomerase O
II O
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line.Etoposide O
(VP-16) O
is O
a O
topoisomerase-II O
(topo O
II) O
inhibitor O
chemotherapeutic O
agent O
. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 O
with O
other O
drugs O
demonstrates O
better O
clinical O
responses O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin O
(MXF) O
and O
VP-16 O
on O
cellular O
topo O
II O
activity O
in O
drug-treated O
cells O
and O
evaluate O
the O
influence O
of O
MXF O
on O
the O
mode O
of O
action O
of O
VP-16 O
, O
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells O
. O
Decatenation O
assay O
, O
band O
depletion O
and O
Western O
blot O
analysis O
, O
cytotoxic O
assay O
(MTT) O
, O
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression) O
, O
apoptosis O
(DAPI-sulforhodamine O
staining O
and O
caspase O
3 O
activity) O
and O
IL-8 O
and O
VEGF O
secretion O
were O
determined O
. O
MXF O
or O
VP-16 O
slightly O
affected O
cellular O
topo O
II O
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo O
II O
. O
VP-16 O
induced O
cell O
cycle O
arrest O
at O
G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF O
. O
Apoptosis O
studies O
(DAPI O
staining O
and O
caspase B
3 I
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF O
and O
VP-16 O
compared O
to O
VP-16 O
alone O
. O
VP-16 O
induced O
the O
release O
of O
IL-8 O
, O
and O
addition O
of O
MXF O
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF O
from O
the O
cells O
. O
In O
conclusion O
, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo O
II O
activity O
by O
the O
combined O
MXF/VP-16 O
treatments O
was O
probably O
due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs O
. O
The O
unique O
combination O
of O
MXF/VP-16 O
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O
'sparing O
effect' O
and O
should O
be O
further O
studied O
in O
vivo O
. O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic B
receptors I
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase O
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O
high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O
whereas O
only O
ambenonium O
and O
tacrine O
displaced O
[3H]-quinuclinidyl O
benzilate O
binding O
. O
Inhibitors O
such O
as O
desoxypeganine O
, O
parathion O
and O
gramine O
demonstrated O
negligible O
inhibition O
of O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

cetirizine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Compared O
pharmacological O
characteristics O
in O
humans O
of O
racemic O
cetirizine O
and O
levocetirizine O
, O
two O
histamine O
H1-receptor O
antagonists.The O
potent O
histamine B
H(1)-receptor I
antagonist O
cetirizine O
(Zyrtec) O
is O
a O
racemic O
mixture O
of O
levocetirizine O
(now O
available O
under O
the O
trademark O
Xyzal O
and O
dextrocetirizine O
. O
In O
this O
Commentary O
, O
we O
examine O
some O
biological O
properties O
of O
cetirizine O
and O
levocetirizine O
, O
namely O
enantioselectivity O
in O
pharmacological O
activity O
and O
pharmacokinetic O
properties O
, O
with O
emphasis O
on O
the O
possibility O
of O
racemization O
, O
the O
compared O
behavior O
of O
the O
two O
enantiomers O
, O
and O
the O
potential O
for O
interactions O
with O
other O
drugs O
. O
Recent O
data O
demonstrate O
that O
the O
antihistaminergic O
activity O
of O
the O
racemate O
is O
primarily O
due O
to O
levocetirizine O
. O
Levocetirizine O
is O
rapidly O
and O
extensively O
absorbed O
, O
poorly O
metabolized O
, O
and O
not O
subject O
to O
racemization O
. O
Its O
pharmacokinetic O
characteristics O
are O
comparable O
after O
administration O
alone O
or O
in O
the O
racemate O
. O
Its O
apparent O
volume O
of O
distribution O
is O
smaller O
than O
that O
of O
dextrocetirizine O
(0.41 O
L O
kg(-1) O
vs O
. O
0.60 O
L O
kg(-1)) O
. O
Moreover O
, O
the O
non-renal O
(mostly O
hepatic) O
clearance O
of O
levocetirizine O
is O
also O
significantly O
lower O
than O
that O
of O
dextrocetirizine O
(11.8 O
mL O
min(-1) O
vs O
. O
29.2 O
mL O
min(-1)) O
. O
Our O
conclusion O
is O
that O
levocetirizine O
is O
indeed O
the O
eutomer O
of O
cetirizine O
. O
The O
evidence O
reviewed O
here O
confirms O
preclinical O
findings O
and O
offers O
a O
rationale O
for O
the O
chiral O
switch O
from O
the O
racemate O
to O
levocetirizine O
. O

desoxycorticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
rat O
brain O
aldosterone O
receptors O
reveals O
high O
affinity O
for O
corticosterone.The O
two O
[3H]aldosterone-binding O
proteins O
of O
rat O
brain O
cytosol O
were O
characterized O
by O
a O
dextran-coated O
charcoal O
method O
. O
With O
molybdate O
present O
to O
stabilize O
receptors O
, O
the O
affinities O
of O
the O
two O
sites O
for O
[3H]aldosterone O
in O
adrenalectomized O
perfused O
rat O
brain O
cytosols O
were O
0.28 O
and O
18.0 O
nM O
at O
4 O
C O
. O
High O
affinity O
sites O
comprised O
15% O
of O
the O
total O
receptor O
number O
. O
A O
small O
contamination O
of O
perfused O
brain O
cytosol O
preparations O
with O
corticosteroid-binding O
globulin O
(CBG) O
was O
found O
. O
However O
, O
due O
to O
the O
very O
high O
affinity O
of O
CBG O
for O
corticosterone O
at O
4 O
C O
, O
this O
slight O
contamination O
resulted O
in O
significant O
alterations O
in O
the O
apparent O
affinity O
of O
steroids O
competing O
for O
aldosterone-binding O
sites O
. O
Selective O
precipitation O
of O
cytosol O
receptors O
with O
36% O
(NH4)2SO4 O
reduced O
CBG O
concentrations O
to O
negligible O
levels O
. O
After O
blockade O
of O
low O
affinity O
sites O
with O
a O
highly O
selective O
glucocorticoid O
(RU O
26988) O
, O
the O
order O
of O
steroids O
in O
competing O
for O
the O
high O
affinity O
receptor O
was O
desoxycorticosterone O
greater O
than O
fludrocortisone O
greater O
than O
corticosterone O
greater O
than O
aldosterone O
greater O
than O
progesterone O
greater O
than O
dexamethasone O
. O
Readdition O
of O
a O
small O
quantity O
of O
dialyzed O
serum O
to O
cytosol O
preparations O
yielded O
a O
profile O
of O
steroid O
binding O
similar O
to O
that O
of O
the O
kidney O
mineralocorticoid B
receptor I
(aldosterone O
greater O
than O
desoxycorticosterone O
greater O
than O
corticosterone) O
. O
The O
distribution O
of O
both O
receptors O
in O
brain O
regions O
of O
adrenalectomized O
rats O
was O
determined O
. O
Both O
receptors O
were O
at O
greatest O
density O
in O
the O
hippocampus O
and O
lowest O
density O
in O
the O
hypothalamus O
. O
The O
high O
affinity O
site O
was O
at O
greatest O
density O
in O
limbic O
regions O
, O
whereas O
the O
low O
affinity O
receptor O
, O
apparently O
identical O
to O
the O
glucocorticoid O
type O
II O
receptor O
, O
was O
at O
greatest O
density O
in O
cortex O
and O
cerebellum O
. O
It O
is O
concluded O
that O
the O
high O
affinity O
aldosterone O
receptor O
of O
rat O
brain O
, O
which O
had O
been O
identified O
in O
preliminary O
studies O
as O
a O
mineralocorticoid O
receptor O
, O
may O
bind O
either O
corticosterone O
or O
aldosterone O
in O
vivo O
. O

1O2 O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
In O
vitro O
simulation O
of O
therapeutic O
plasmatic O
fibrinolysis.One O
type O
of O
therapy O
for O
thromboembolism O
is O
plasmatic O
thrombolysis O
. O
Several O
plasminogen O
activators O
(PA) O
are O
clinically O
available O
, O
including O
urokinase O
(u-PA) O
, O
tissue O
plasminogen O
activator O
(t-PA) O
, O
streptokinase O
(SK) O
, O
plasminogen-streptokinase-activator-complex O
(PSAC) O
, O
or O
mutants O
of O
t-PA O
such O
as O
reteplase O
(RP) O
or O
tenecteplase O
(TP) O
. O
Therapeutic O
plasmatic O
fibrinolysis O
was O
simulated O
, O
using O
the O
PA O
at O
relevant O
plasma O
concentrations O
, O
and O
plasmin O
(Pli) O
and O
PA O
activities O
were O
determined O
. O
Normal O
citrated O
plasma O
was O
supplemented O
with O
31 O
to O
1,000 O
IU/mL O
u-PA O
, O
0.31 O
to O
20 O
microg/mL O
t-PA O
, O
125 O
to O
4,000 O
IU/mL O
SK O
, O
12.5 O
to O
400 O
U/mL O
PSAC O
, O
125 O
to O
4,000 O
U/mL O
RP O
, O
or O
0.31 O
to O
10 O
microg/mL O
TP O
. O
Ten O
IU/mL O
urokinase O
was O
also O
incubated O
with O
pooled O
plasma O
of O
stroke O
patients O
, O
that O
was O
previously O
oxidized O
with O
the O
singlet O
oxygen O
(1O2) O
donor O
chloramine O
T O
(CT) O
, O
to O
destroy O
plasmatic B
PAI-1 I
and O
alpha2-antiplasmin O
. O
After O
0 O
to O
80 O
minutes O
(37 O
degrees O
C) O
, O
50-microL O
samples O
were O
withdrawn O
and O
added O
to O
100 O
microL O
1.5 O
M O
arginine O
, O
pH O
8.7 O
, O
and O
oxidized O
with O
50 O
microL O
of O
20 O
mM O
CT O
. O
For O
determination O
of O
plasmin O
activity O
, O
10 O
microL O
thereof O
was O
incubated O
with O
150 O
microL O
1.5 O
M O
arginine O
, O
pH O
8.7 O
, O
and O
100 O
microL O
20 O
mM O
CT O
preoxidized O
(15 O
minutes O
37 O
degrees O
C) O
pooled O
normal O
citrate O
buffered O
EDTA-plasma O
for O
30 O
minutes O
(37 O
degrees O
C) O
. O
For O
determination O
of O
[PA+Pli]-activity O
, O
arginine O
was O
added O
after O
this O
incubation O
. O
25-microL O
6 O
mM O
Val-Leu-Lys-pNA O
were O
added O
and O
deltaA/h O
at O
room O
temperature O
(RT) O
was O
monitored O
, O
using O
a O
microtiterplate O
reader O
. O
[PA+Pli]-Pli O
= O
PA O
. O
The O
PA O
concentration O
required O
to O
induce O
25% O
[ED25] O
of O
the O
maximally O
inducible O
Pli-activity O
in O
plasma O
(= O
1 O
U/mL O
= O
45 O
mg/L O
= O
0.53 O
micromol/L O
active O
Pli; O
deltaA O
= O
363 O
+/- O
8 O
mA/h O
RT) O
after O
10 O
minutes O
(37 O
degrees O
C) O
were O
320 O
IU/mL O
u-PA O
, O
8 O
microg/mL O
t-PA O
, O
140 O
U/mL O
PSAC O
, O
6,000 O
IU/mL O
SK O
, O
720 O
U/mL O
RP O
, O
and O
approximately O
150 O
microg/mL O
TP O
. O
The O
approximate O
activity O
half-lives O
of O
the O
PA O
in O
plasma O
were O
30 O
minutes O
for O
u-PA O
, O
30 O
minutes O
for O
t-PA O
, O
greater O
than O
80 O
minutes O
for O
SK O
, O
greater O
than O
80 O
minutes O
for O
PSAC O
, O
50 O
minutes O
for O
RP O
, O
and O
80 O
minutes O
for O
TP O
. O
The O
present O
study O
shows--for O
the O
first O
time--a O
combined O
kinetic O
in O
vitro O
simulation O
of O
the O
plasmatic O
activity O
of O
six O
different O
PAs O
. O
At O
clinically O
used O
concentrations O
, O
RP O
induces O
the O
highest O
plasmatic O
Pli O
activity O
. O
Due O
to O
unselective O
generation O
of O
plasmin O
in O
plasma O
, O
all O
PA O
are O
of O
some O
danger O
in O
inducing O
severe O
hemorrhagias O
. O
Clinical O
thrombolysis O
might O
be O
improved O
by O
usage O
of O
more O
physiologic O
activators O
of O
thrombolysis O
, O
such O
as O
activators O
of O
polymorphonuclear O
neutrophils O
. O

quercetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme O
carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O
in O
mammals O
, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O
medicinally O
relevant O
CAs O
. O

Amitriptyline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Amitriptyline O
is O
a O
TrkA O
and O
TrkB O
receptor O
agonist O
that O
promotes O
TrkA/TrkB O
heterodimerization O
and O
has O
potent O
neurotrophic O
activity.Neurotrophins O
, O
the O
cognate O
ligands O
for O
the O
Trk O
receptors O
, O
are O
homodimers O
and O
induce O
Trk O
dimerization O
through O
a O
symmetric O
bivalent O
mechanism O
. O
We O
report O
here O
that O
amitriptyline O
, O
an O
antidepressant O
drug O
, O
directly O
binds O
TrkA O
and O
TrkB O
and O
triggers O
their O
dimerization O
and O
activation O
. O
Amitriptyline O
, O
but O
not O
any O
other O
tricyclic O
or O
selective O
serotonin O
reuptake O
inhibitor O
antidepressants O
, O
promotes O
TrkA O
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells O
. O
Amitriptyline O
binds O
the O
extracellular O
domain O
of O
both O
TrkA O
and O
TrkB O
and O
promotes O
TrkA- O
TrkB B
receptor O
heterodimerization O
. O
Truncation O
of O
amitriptyline O
binding O
motif O
on O
TrkA O
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline O
. O
Administration O
of O
amitriptyline O
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic O
acid-triggered O
neuronal O
cell O
death O
. O
Inhibition O
of O
TrkA O
, O
but O
not O
TrkB O
, O
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity O
. O
Thus O
, O
amitriptyline O
acts O
as O
a O
TrkA O
and O
TrkB O
agonist O
and O
possesses O
marked O
neurotrophic O
activity O
. O

Paclitaxel O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Furanodiene O
Presents O
Synergistic O
Anti-proliferative O
Activity O
With O
Paclitaxel O
Via O
Altering O
Cell O
Cycle O
and O
Integrin B
Signaling O
in O
95-D O
Lung O
Cancer O
Cells.Furanodiene O
(FUR) O
is O
a O
natural O
terpenoid O
isolated O
from O
Rhizoma O
Curcumae O
, O
a O
well-known O
Chinese O
medicinal O
herb O
that O
presents O
anti-proliferative O
activities O
in O
several O
cancer O
cell O
lines O
. O
Recently O
, O
we O
found O
that O
the O
combined O
treatment O
of O
FUR O
with O
paclitaxel O
(TAX) O
showed O
synergetic O
anti-proliferative O
activities O
in O
95-D O
lung O
cancer O
cells O
. O
Herein O
, O
we O
showed O
that O
FUR O
reduced O
the O
cell O
numbers O
distributed O
in O
mitosis O
phase O
induced O
by O
TAX O
while O
increased O
those O
in O
G1 O
phase O
. O
The O
protein O
levels O
of O
cyclin O
D1 O
, O
cyclin O
B1 O
, O
CDK6 O
and O
c-Myc O
were O
all O
down-regulated O
in O
the O
group O
of O
combined O
treatment O
. O
The O
dramatically O
down-regulated O
expression O
of O
integrin O
β4 O
, O
focal O
adhesion O
kinase O
and O
paxillin O
might O
partially O
contribute O
to O
the O
synergic O
effect O
. O
Though O
FUR O
alone O
obviously O
induced O
endoplasmic O
reticulum O
stress O
, O
this O
signaling O
pathway O
may O
not O
contribute O
to O
the O
synergetic O
anti-proliferative O
effect O
as O
the O
protein O
expression O
of O
CHOP O
and O
BIP O
was O
similar O
in O
FUR O
alone O
and O
combined O
treatment O
group O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

L-serine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mouse O
brain O
serine O
racemase O
catalyzes O
specific O
elimination O
of O
L-serine O
to O
pyruvate.D-Serine O
was O
previously O
identified O
in O
mammalian O
brain O
and O
was O
shown O
to O
be O
a O
co-agonist O
at O
the O
'glycine' O
site O
of O
the O
N-methyl-D-aspartate O
(NMDA)-type O
receptors O
. O
Racemization O
of O
serine O
is O
catalyzed O
by O
serine O
racemase O
, O
a O
pyridoxal O
5'-phosphate-dependent O
enzyme O
expressed O
mainly O
in O
brain O
and O
liver O
. O
NMDA O
receptor O
overactivation O
has O
been O
implicated O
in O
a O
number O
of O
pathological O
conditions O
and O
inhibitors O
of O
serine O
racemase O
are O
thus O
potentially O
interesting O
targets O
for O
therapy O
. O
We O
expressed O
recombinant O
mouse O
serine O
racemase O
in O
insect O
cells O
and O
purified O
it O
to O
near O
homogeneity O
. O
The O
enzyme O
is O
a O
non-covalent O
homodimer O
in O
solution O
and O
requires O
divalent O
cations O
Mg(2+) O
, O
Ca(2+) O
or O
Mn(2+) O
for O
activity O
but O
not O
for O
dimerization O
. O
In O
addition O
to O
the O
racemization O
it O
also O
catalyzes O
specific O
elimination O
of O
L-Ser O
to O
pyruvate O
. O
D-Serine O
is O
eliminated O
much O
less O
efficiently O
. O
Both O
L-serine O
racemization O
and O
elimination O
activities O
of O
serine O
racemase O
are O
of O
comparable O
magnitude O
, O
display O
alkaline O
pH O
optimum O
and O
are O
negligible O
below O
pH O
6.5 O
catalyzes O
specific O
elimination O
of O
L-serine O
to O
pyruvate.D-Serine O
was O
previously O
identified O
in O
mammalian O
brain O
and O
was O
shown O
to O
be O
a O
co-agonist O
at O
the O
'glycine' O
site O
of O
the O
N-methyl-D-aspartate O
(NMDA)-type O
receptors O
. O
Racemization O
of O
serine O
is O
catalyzed O
by O
serine O
racemase O
, O
a O
pyridoxal O
5'-phosphate-dependent O
enzyme O
expressed O
mainly O
in O
brain O
and O
liver O
. O
NMDA O
receptor O
overactivation O
has O
been O
implicated O
in O
a O
number O
of O
pathological O
conditions O
and O
inhibitors O
of O
serine O
racemase O
are O
thus O
potentially O
interesting O
targets O
for O
therapy O
. O
We O
expressed O
recombinant O
mouse O
serine O
racemase O
in O
insect O
cells O
and O
purified O
it O
to O
near O
homogeneity O
. O
The O
enzyme O
is O
a O
non-covalent O
homodimer O
in O
solution O
and O
requires O
divalent O
cations O
Mg(2+) O
, O
Ca(2+) O
or O
Mn(2+) O
for O
activity O
but O
not O
for O
dimerization O
. O
In O
addition O
to O
the O
racemization O
it O
also O
catalyzes O
specific O
elimination O
of O
L-Ser O
to O
pyruvate O
. O
D-Serine O
is O
eliminated O
much O
less O
efficiently O
. O
Both O
L-serine O
racemization O
and O
elimination O
activities O
of O
serine O
racemase O
are O
of O
comparable O
magnitude O
, O
display O
alkaline O
pH O
optimum O
and O
are O
negligible O
below O
pH O
6.5 O
. O

ethanol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
ALDH2 B
with O
ethanol O
attenuates O
diabetes O
induced O
myocardial O
injury O
in O
rats.This O
study O
assessed O
changes O
in O
myocardial O
ALDH2 O
expression O
in O
the O
diabetic O
rat O
, O
in O
particular O
the O
diabetic O
rat O
pretreated O
with O
ALDH2 O
activator O
ethanol O
(EtOH) O
. O
The O
rats O
were O
divided O
into O
six O
groups O
: O
control O
, O
EtOH O
control O
, O
diabetic O
rat O
at O
4th O
week O
(DM4W) O
, O
8th O
week O
(DM8W) O
, O
12th O
week O
(DM12W) O
and O
EtOH+DM8W O
groups O
. O
Compared O
with O
control O
group O
, O
fasting O
blood O
glucose O
(FBG) O
and O
glycosylated O
hemoglobin O
(HbA1c) O
levels O
were O
increased O
in O
DM O
groups O
. O
HbA1c O
level O
in O
DM12W O
group O
was O
higher O
than O
in O
DM4W O
group O
, O
HbA1c O
level O
in O
EtOH+DM8W O
group O
was O
lower O
than O
in O
DM8W O
group O
. O
Compared O
with O
control O
group O
, O
there O
were O
no O
changes O
of O
LVDP O
, O
HR O
and O
±dp/dtmax O
in O
DM4W O
group O
, O
but O
there O
were O
decreased O
in O
DM8W O
and O
DM12W O
groups O
, O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD O
activity O
, O
ALDH2 O
mRNA O
and O
protein O
levels O
were O
reduced O
, O
MDA O
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed O
. O
Compared O
with O
DM8W O
group O
, O
SOD O
and O
ALDH2 O
in O
EtOH+DM8W O
group O
was O
increased O
, O
MDA O
was O
decreased O
. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes O
, O
myocardial O
ALDH2 O
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function O
. O
However O
, O
activation O
of O
ALDH2 O
can O
decrease O
diabetes O
induced O
myocardial O
injury O
. O
ALDH2 O
may O
be O
one O
key O
endogenous O
cardiac O
protective O
factor O
in O
diabetic O
individuals O
. O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
( O
iNOS) B
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O
(GAS) O
, O
nuclear O
factor-kappaB O
(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O
CCAAT/enhancer-binding O
protein O
beta O
(C/EBPbeta); O
therefore O
, O
we O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

atomoxetine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Atomoxetine O
increases O
extracellular O
levels O
of O
norepinephrine O
and O
dopamine O
in O
prefrontal O
cortex O
of O
rat O
: O
a O
potential O
mechanism O
for O
efficacy O
in O
attention O
deficit/hyperactivity O
disorder.The O
selective O
norepinephrine O
(NE) O
transporter O
inhibitor O
atomoxetine O
(formerly O
called O
tomoxetine O
or O
LY139603) O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O
of O
action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O
atomoxetine O
with O
monoamine O
transporters O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O
, O
and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
in O
brain O
regions O
. O
Atomoxetine O
inhibited O
binding O
of O
radioligands O
to O
clonal O
cell O
lines O
transfected O
with O
human O
NE O
, O
serotonin O
(5-HT) O
and O
dopamine O
(DA) O
transporters O
with O
dissociation O
constants O
(K(i)) O
values O
of O
5 O
, O
77 O
and O
1451 O
nM O
, O
respectively O
, O
demonstrating O
selectivity O
for O
NE O
transporters O
. O
In O
microdialysis O
studies O
, O
atomoxetine O
increased O
extracellular O
(EX) O
levels O
of O
NE O
in O
prefrontal O
cortex O
(PFC) O
3-fold O
, O
but O
did O
not O
alter O
5-HT(EX) O
levels O
. O
Atomoxetine O
also O
increased O
DA(EX) O
concentrations O
in O
PFC O
3-fold O
, O
but O
did O
not O
alter O
DA(EX) O
in O
striatum O
or O
nucleus O
accumbens O
. O
In O
contrast O
, O
the O
psychostimulant O
methylphenidate O
, O
which O
is O
used O
in O
ADHD O
therapy O
, O
increased O
NE(EX) O
and O
DA(EX) O
equally O
in O
PFC O
, O
but O
also O
increased O
DA(EX) O
in O
the O
striatum O
and O
nucleus O
accumbens O
to O
the O
same O
level O
. O
The O
expression O
of O
the O
neuronal O
activity O
marker O
Fos B
was O
increased O
3.7-fold O
in O
PFC O
by O
atomoxetine O
administration O
, O
but O
was O
not O
increased O
in O
the O
striatum O
or O
nucleus O
accumbens O
, O
consistent O
with O
the O
regional O
distribution O
of O
increased O
DA(EX) O
. O
We O
hypothesize O
that O
the O
atomoxetine-induced O
increase O
of O
catecholamines O
in O
PFC O
, O
a O
region O
involved O
in O
attention O
and O
memory O
, O
mediates O
the O
therapeutic O
effects O
of O
atomoxetine O
in O
ADHD O
. O
In O
contrast O
to O
methylphenidate O
, O
atomoxetine O
did O
not O
increase O
DA O
in O
striatum O
or O
nucleus O
accumbens O
, O
suggesting O
it O
would O
not O
have O
motoric O
or O
drug O
abuse O
liabilities O
. O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvin O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K B
/ O
Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells O
. O

[(dihydroindenyl)oxy] O
alkanoic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Functional O
and O
molecular O
characterization O
of O
multiple O
K-Cl O
cotransporter O
isoforms O
in O
corneal O
epithelial O
cells.The O
dependence O
of O
regulatory O
volume O
decrease O
(RVD) O
activity O
on O
potassium-chloride O
cotransporter O
(KCC) O
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC) O
. O
During O
exposure O
to O
a O
50% O
hypotonic O
challenge O
, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC) O
. O
A O
KCC B
inhibitor-[(dihydroindenyl)oxy] O
alkanoic O
acid O
(DIOA)-blocked O
RVD O
more O
in O
HCEC O
than O
RCEC O
. O
Under O
isotonic O
conditions O
, O
N-ethylmaleimide O
(NEM) O
produced O
KCC O
activation O
and O
transient O
cell O
shrinkage O
. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC O
. O
Immunoblot O
analysis O
of O
HCEC O
, O
RCEC O
, O
primary O
human O
CEC O
(pHCEC) O
, O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O
KCC1 O
, O
KCC3 O
, O
and O
KCC4 O
isoform O
expression O
, O
whereas O
KCC2 O
was O
undetectable O
. O
During O
a O
hypotonic O
challenge O
, O
KCC1 O
membrane O
content O
increased O
more O
rapidly O
in O
HCEC O
than O
in O
RCEC O
. O
Such O
a O
challenge O
induced O
a O
larger O
increase O
and O
more O
transient O
p44/42MAPK O
activation O
in O
HCEC O
than O
RCEC O
. O
On O
the O
other O
hand O
, O
HCEC O
and O
RCEC O
p38MAPK O
phosphorylation O
reached O
peak O
activations O
at O
2.5 O
and O
15 O
min O
, O
respectively O
. O
Only O
in O
HCEC O
, O
pharmacological O
manipulation O
of O
KCC O
activity O
modified O
the O
hypotonicity-induced O
activation O
of O
p44/42MAPK O
, O
whereas O
p38MAPK O
phosphorylation O
was O
insensitive O
to O
such O
procedures O
in O
both O
cell O
lines O
. O
Larger O
increases O
in O
HCEC O
KCC1 O
membrane O
protein O
content O
correlated O
with O
their O
ability O
to O
undergo O
faster O
and O
more O
complete O
RVD O
. O
Furthermore O
, O
pharmacological O
activation O
of O
KCC O
increased O
p44/42MAPK O
phosphorylation O
in O
HCEC O
but O
not O
in O
RCEC O
, O
presumably O
a O
reflection O
of O
low O
KCC1 O
membrane O
expression O
in O
RCEC O
. O
These O
findings O
suggest O
that O
KCC1 O
plays O
a O
role O
in O
(i) O
maintaining O
isotonic O
steady-state O
cell O
volume O
homeostasis O
, O
(ii) O
recovery O
of O
isotonic O
cell O
volume O
after O
a O
hypotonic O
challenge O
through O
RVD O
, O
and O
(iii) O
regulating O
hypotonicity-induced O
activation O
of O
the O
p44/42MAPK O
signaling O
pathway O
required O
for O
cell O
proliferation O
. O

Pyrrolidine O
dithiocarbamate O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS B
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

Nitrogen O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim B
-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O
Ras-variable O
tumors O
. O
This O
is O
the O
first O
study O
to O
show O
that O
the O
specific O
molecular O
pathways O
of O
N-BP-induced O
apoptosis O
. O

ATP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Atp-bound O
topoisomerase O
ii O
as O
a O
target O
for O
antitumor O
drugs.Topoisomerase O
II O
(TOP2) O
poisons O
interfere O
with O
the O
breakage/reunion O
reaction O
of O
TOP2 O
resulting O
in O
DNA O
cleavage O
. O
In O
the O
current O
studies O
, O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase B
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

resveratrol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Resveratrol O
attenuates O
hepatotoxicity O
of O
rats O
exposed O
to O
arsenic O
trioxide.Arsenic O
trioxide O
(As(2)O(3)) O
is O
an O
environmental O
pollutant O
and O
potent O
toxicant O
to O
humans O
. O
However O
, O
it O
also O
shows O
substantial O
anti-cancer O
activity O
in O
individuals O
with O
acute O
promyelocytic O
leukemia O
(APL) O
. O
Unfortunately O
, O
As(2)O(3)-treated O
leukemia O
patients O
suffer O
hepatotoxicity O
. O
Resveratrol O
has O
been O
demonstrated O
to O
have O
efficient O
antioxidant O
and O
antineoplastic O
activities O
. O
The O
study O
that O
how O
As(2)O(3) O
in O
combination O
with O
resveratrol O
affects O
hepatotoxicity O
and O
arsenic O
accumulation O
in O
the O
liver O
is O
lacking O
, O
and O
the O
present O
study O
tackles O
this O
question O
. O
Wistar O
rats O
were O
injected O
with O
3mg/kg O
As(2)O(3) O
on O
alternate O
days; O
resveratrol O
(8mg/kg) O
was O
administered O
1h O
before O
As(2)O(3) O
. O
Rats O
were O
killed O
on O
the O
8th O
day O
to O
determine O
histological O
liver O
damage O
, O
the O
antioxidant O
enzymes O
in O
serum O
, O
the O
ratio O
of O
reduced O
glutathione O
(GSH) O
to O
oxidized O
glutathione O
(GSSG) O
, O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
In O
the O
resveratrol+As(2)O(3) O
group O
, O
activities O
of O
superoxide B
dismutase I
, O
catalase O
in O
serum O
and O
GSH/GSSG O
were O
significantly O
increased O
, O
histopathological O
effects O
were O
reduced O
, O
and O
arsenic O
accumulation O
markedly O
decreased O
in O
the O
liver O
, O
compared O
with O
the O
As(2)O(3)-treated O
group O
. O
Thus O
, O
resveratrol O
attenuated O
As(2)O(3)-induced O
hepatotoxicity O
by O
decreasing O
oxidative O
stress O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
These O
data O
suggest O
that O
use O
of O
resveratrol O
as O
post-remission O
therapy O
of O
APL O
and O
adjunctive O
therapy O
in O
patients O
with O
chronic O
exposure O
to O
arsenic O
may O
decrease O
arsenic O
hepatotoxicity O
. O

WAL O
801CL O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic B
receptors I
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

dihydropyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
(GABA(A)R) O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 B
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

serine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Tissue-type O
plasminogen O
activator O
acts O
as O
a O
cytokine O
that O
triggers O
intracellular O
signal O
transduction O
and O
induces O
matrix O
metalloproteinase-9 O
gene O
expression.Tissue-type O
plasminogen O
activator O
(tPA) O
, O
a O
serine O
protease O
well O
known O
for O
generating O
plasmin O
, O
has O
been O
demonstrated O
to O
induce O
matrix B
metalloproteinase-9 I
(MMP-9) O
gene O
expression O
and O
protein O
secretion O
in O
renal O
interstitial O
fibroblasts O
. O
However O
, O
exactly O
how O
tPA O
transduces O
its O
signal O
into O
the O
nucleus O
to O
control O
gene O
expression O
is O
unknown O
. O
This O
study O
investigated O
the O
mechanism O
by O
which O
tPA O
induces O
MMP-9 O
gene O
expression O
. O
Both O
wild-type O
and O
non-enzymatic O
mutant O
tPA O
were O
found O
to O
induce O
MMP-9 O
expression O
in O
rat O
kidney O
interstitial O
fibroblasts O
(NRK-49F) O
, O
indicating O
that O
the O
actions O
of O
tPA O
are O
independent O
of O
its O
proteolytic O
activity O
. O
tPA O
bound O
to O
the O
low O
density O
lipoprotein O
receptor-related O
protein-1 O
(LRP-1) O
in O
NRK-49F O
cells O
, O
and O
this O
binding O
was O
competitively O
abrogated O
by O
the O
LRP-1 O
antagonist O
, O
the O
receptor-associated O
protein O
. O
In O
mouse O
embryonic O
fibroblasts O
(PEA-13) O
lacking O
LRP-1 O
, O
tPA O
failed O
to O
induce O
MMP-9 O
expression O
. O
Furthermore O
, O
tPA O
induced O
rapid O
tyrosine O
phosphorylation O
on O
the O
beta O
subunit O
of O
LRP-1 O
, O
which O
was O
followed O
by O
the O
activation O
of O
Mek1 O
and O
its O
downstream O
Erk-1 O
and O
-2 O
. O
Blockade O
of O
Erk-1/2 O
activation O
by O
the O
Mek1 O
inhibitor O
abolished O
MMP-9 O
induction O
by O
tPA O
in O
NRK-49F O
cells O
. O
Conversely O
, O
overexpression O
of O
constitutively O
activated O
Mek1 O
induced O
Erk-1/2 O
phosphorylation O
and O
MMP-9 O
expression O
. O
In O
mouse O
obstructed O
kidney O
, O
tPA O
, O
LRP-1 O
, O
and O
MMP-9 O
were O
concomitantly O
induced O
in O
the O
renal O
interstitium O
. O
Collectively O
, O
these O
results O
suggest O
that O
besides O
its O
classical O
proteolytic O
activity O
, O
tPA O
acts O
as O
a O
cytokine O
that O
binds O
to O
the O
cell O
membrane O
receptor O
LRP-1 O
, O
induces O
its O
tyrosine O
phosphorylation O
, O
and O
triggers O
intracellular O
signal O
transduction O
, O
thereby O
inducing O
specific O
gene O
expression O
in O
renal O
interstitial O
fibroblasts O
. O

(+/-)- O
, O
R- O
, O
and O
S-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O
R-modafinil O
displays O
an O
in O
vitro O
profile O
different O
from O
cocaine O
. O
Future O
trials O
with O
R-modafinil O
as O
a O
substitute O
therapy O
with O
the O
potential O
benefit O
of O
cognitive O
enhancement O
for O
psychostimulant O
addiction O
are O
warranted O
. O

AACOCF3 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Phospholipase O
A2 O
inhibitors O
p-bromophenacyl O
bromide O
and O
arachidonyl O
trifluoromethyl O
ketone O
suppressed O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes.Phospholipase O
A2 O
(PLA2) O
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine O
expression O
. O
Therefore O
, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 O
inhibitors O
p-bromophenacyl O
bromide O
(BPB) O
and O
arachidonyl O
trifluoromethyl O
ketone O
(AACOCF3) O
on O
interleukin-2 O
(IL-2) O
expression O
in O
murine O
primary O
splenocytes O
. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB O
and O
AACOCF3 O
suppressed O
phorbol O
12-myristate O
13-acetate O
plus O
ionomycin-induced O
IL-2 O
secretion O
in O
a O
concentration-dependent O
manner O
. O
Inhibition O
> O
90% O
of O
IL-2 O
secretion O
was O
observed O
at O
1 O
microM O
BPB O
and O
10 O
microM O
AACOCF3 O
compared O
to O
the O
respective O
vehicle O
control O
. O
Likewise O
, O
IL-2 B
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 O
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB O
and O
20 O
microM O
AACOCF3 O
. O
Taken O
together O
, O
these O
data O
demonstrated O
that O
PLA2 O
inhibitors O
BPB O
and O
AACOCF3 O
are O
robust O
inhibitors O
of O
IL-2 O
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes O
. O
Moreover O
, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 O
may O
have O
marked O
effects O
on O
T-cell O
function O
. O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cerebral O
D2 O
and O
5-HT2 O
receptor O
occupancy O
in O
Schizophrenic O
patients O
treated O
with O
olanzapine O
or O
clozapine.We O
report O
the O
results O
of O
a O
double-blind O
, O
randomized O
prospective O
trial O
on O
D2 O
and O
5-HT2 O
receptor O
occupancy O
and O
the O
clinical O
effects O
of O
olanzapine O
versus O
clozapine O
in O
a O
sample O
of O
neuroleptic-refractory O
schizophrenic O
patients O
. O
Receptor O
occupancy O
was O
evaluated O
in O
different O
cortical O
areas O
and O
in O
basal O
ganglia O
using O
[18F] O
fluoro-ethyl-spiperone O
([18F] O
FESP) O
and O
positron O
emission O
tomography O
(PET) O
. O
A O
total O
of O
15 O
neuroleptic-free O
patients O
completed O
the O
study O
undergoing O
a O
baseline O
and O
a O
post-treatment O
PET O
scan O
(olanzapine O
, O
nine O
patients O
, O
one O
female; O
clozapine O
, O
six O
patients O
, O
three O
female) O
8 O
weeks O
after O
starting O
treatment O
. O
PET O
data O
were O
analysed O
both O
by O
regions O
of O
interest O
and O
on O
a O
voxel-by-voxel O
basis O
using O
Statistical O
Parametric O
Mapping O
(SPM96) O
. O
Olanzapine O
and O
clozapine O
induced O
a O
similar O
and O
significant O
inhibition O
of O
[18F] O
FESP O
binding O
index O
in O
the O
cortex O
. O
In O
the O
basal O
ganglia O
, O
receptor O
occupancy O
was O
significantly O
higher O
with O
olanzapine O
than O
with O
clozapine O
(p=0.0018) O
. O
By O
contrast O
, O
no O
differences O
in O
receptor O
occupancy O
were O
detected O
at O
the O
level O
of O
the O
pituitary O
gland O
. O
Clinical O
outcomes O
, O
in O
particular O
a O
full O
extra O
pyramidal O
tolerability O
, O
were O
similar O
. O
In O
this O
sample O
of O
neuroleptic-refractory O
schizophrenic O
patients O
, O
olanzapine O
and O
clozapine O
showed O
a O
different O
pattern O
of O
occupancy O
of O
D2-like B
receptor I
despite O
a O
common O
lack O
of O
extrapyramidal O
side-effects O
. O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
CASK O
is O
a O
new O
intracellular O
modulator O
of O
P2X3 O
receptors.ATP-gated O
P2X3 O
receptors O
of O
sensory O
ganglion O
neurons O
are O
important O
transducers O
of O
painful O
stimuli O
and O
are O
modulated O
by O
extracellular O
algogenic O
substances O
, O
via O
changes O
in O
the O
receptor O
phosphorylation O
state O
. O
The O
present O
study O
investigated O
the O
role O
of O
calcium/calmodulin-dependent O
serine O
protein O
kinase O
CASK O
in O
interacting O
and O
controlling O
P2X3 O
receptor O
expression O
and O
function O
in O
mouse O
trigeminal O
ganglia O
. O
Most O
ganglion O
neurons O
in O
situ O
or O
in O
culture O
co-expressed O
P2X3 O
and O
CASK O
. O
CASK O
was O
immunoprecipitated O
with O
P2X3 O
receptors O
from O
trigeminal O
ganglia O
and O
from O
P2X3/CASK-cotransfected O
HEK O
cells O
. O
Recombinant O
P2X3/CASK O
expression O
in O
HEK O
cells O
increased O
serine O
phosphorylation O
of O
P2X3 B
receptors O
, O
typically O
associated O
with O
receptor O
upregulation O
. O
CASK O
deletion O
mutants O
also O
enhanced O
P2X3 O
subunit O
expression O
. O
After O
silencing O
CASK O
, O
cell O
surface O
P2X3 O
receptor O
expression O
was O
decreased O
, O
which O
is O
consistent O
with O
depressed O
P2X3 O
currents O
. O
The O
reduction O
of O
P2X3 O
expression O
levels O
was O
reversed O
by O
the O
proteasomal O
inhibitor O
MG-132 O
. O
Moreover O
, O
neuronal O
CASK/P2X3 O
interaction O
was O
upregulated O
by O
NGF O
signaling O
and O
downregulated O
by O
P2X3 O
agonist-induced O
desensitization O
. O
These O
data O
suggest O
a O
novel O
interaction O
between O
CASK O
and O
P2X3 O
receptors O
with O
positive O
outcome O
for O
receptor O
stability O
and O
function O
. O
As O
CASK-mediated O
control O
of O
P2X3 O
receptors O
was O
dependent O
on O
the O
receptor O
activation O
state O
, O
CASK O
represents O
an O
intracellular O
gateway O
to O
regulate O
purinergic O
nociceptive O
signaling O
. O
This O
article O
is O
protected O
by O
copyright O
. O
All O
rights O
reserved O
. O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Neoechinulin O
A O
suppresses O
amyloid-β O
oligomer-induced O
microglia O
activation O
and O
thereby O
protects O
PC-12 O
cells O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 B
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O
further O
studies O
neoechinulin O
A O
have O
a O
potential O
to O
be O
developed O
as O
a O
modulator O
of O
neuroinflammatory O
process O
in O
AD O
. O

CGP O
12177A O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Overexpression O
of O
beta O
1-adrenoceptors O
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP O
12177A O
cardiostimulation O
: O
implications O
for O
'putative' O
beta O
4-adrenoceptor O
pharmacology.1 O
. O
CGP O
12177A O
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor; O
however O
, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O
beta(1)-adrenoceptor O
gene O
abolishes O
this O
effect O
. O
We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors O
in O
isolated O
, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline O
and O
CGP O
12177A O
(in O
the O
presence O
of O
1 O
microm O
propranolol) O
. O
2 O
. O
Isoprenaline O
was O
a O
full O
inotropic O
agonist O
at O
rat O
ventricular O
myocytes O
(pD(2) O
7.69+/-0.12) O
. O
CGP O
12177A O
was O
a O
nonconventional O
partial O
agonist O
(pD(2) O
6.34+/-0.09) O
, O
increasing O
inotropy O
and O
lusitropy O
, O
with O
an O
intrinsic O
activity O
of O
0.34 O
and O
antagonised O
by O
bupranolol O
. O
3 O
. O
beta(1)-adrenoceptor O
overexpression O
enhanced O
the O
inotropic O
potency O
of O
isoprenaline O
by O
11.7-fold O
(pD(2) O
8.76+/-0.14) O
and O
CGP O
12177A O
by O
5.9-fold O
(7.11+/-0.10) O
, O
respectively O
. O
Green O
fluorescent O
protein O
(GFP) O
overexpression O
did O
not O
alter O
the O
potency O
of O
isoprenaline O
or O
CGP O
12177A O
(pD(2) O
7.41+/-0.24 O
and O
pD(2) O
6.60+/-0.50 O
, O
respectively) O
. O
4 O
. O
The O
cardiostimulant O
effects O
of O
CGP O
12177A O
were O
enhanced O
by O
IBMX O
(phosphodiesterase O
inhibitor) O
and O
decreased O
by O
Rp-cAMPS O
(cAMP O
antagonist) O
. O
CGP O
12177A O
also O
increased O
cAMP O
levels O
. O
CGP O
12177A O
but O
not O
isoprenaline O
initiated O
arrhythmias O
at O
lower O
concentrations O
following O
beta(1)-adrenoceptor B
overexpression O
. O
5 O
. O
(125)I-Cyanopindolol O
saturation O
binding O
in O
Adv.beta(1) O
myocytes O
demonstrated O
approximately O
18-fold O
increase O
in O
beta(1)-adrenoceptors O
. O
(3)H-CGP O
12177A O
saturation O
binding O
, O
in O
the O
presence O
of O
propranolol O
, O
increased O
approximately O
5-fold O
following O
overexpression O
of O
beta(1)-adrenoceptors O
. O
6 O
. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP O
12177A O
(in O
the O
presence O
of O
propranolol) O
in O
rat O
ventricular O
myocytes O
overexpressing O
beta(1)-adrenoceptors O
, O
mediated O
by O
a O
Gs/cAMP O
signalling O
pathway O
. O
'Putative' O
beta(4)-adrenoceptor O
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor O
. O

felbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Felbamate O
block O
of O
recombinant O
N-methyl-D-aspartate O
receptors O
: O
selectivity O
for O
the O
NR2B O
subunit.The O
anticonvulsant O
felbamate O
blocks O
N-methyl-D-asparate O
(NMDA) O
receptors O
but O
fails O
to O
exhibit O
the O
neurobehavioral O
toxicity O
characteristic O
of O
other O
NMDA O
receptor O
antagonists O
. O
To O
investigate O
the O
possibility O
that O
felbamate's O
favorable O
toxicity O
profile O
could O
be O
related O
to O
NMDA O
receptor O
subtype O
selectivity O
, O
we O
examined O
the O
specificity O
of O
felbamate O
block O
of O
recombinant O
NMDA O
receptors O
composed O
of O
the O
NR1a O
subunit O
and O
various O
NR2 O
subunits O
. O
Felbamate O
produced O
a O
rapid O
, O
concentration-dependent O
block O
of O
currents O
evoked O
by O
50 O
microM O
NMDA O
and O
10 O
microM O
glycine O
in O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
rat O
NR1a O
subunit O
, O
and O
either O
the O
NR2A O
, O
NR2B O
or O
NR2C O
subunits; O
the O
IC50 O
values O
for O
block O
were O
2.6 O
, O
0.52 O
and O
2.4 O
mM O
, O
respectively O
(holding O
potential O
, O
- O
60 O
mV) O
. O
The O
Hill O
coefficient O
values O
were O
< O
1 O
and O
, O
in O
kinetic O
analyses O
, O
onset O
and O
recovery O
from O
block O
were O
well O
fit O
by O
double O
exponential O
functions O
, O
indicating O
binding O
to O
more O
than O
one O
blocking O
site O
on O
the O
NMDA O
receptor O
channel O
complex O
. O
The O
higher O
affinity O
of O
felbamate O
block O
of O
NMDA O
receptors O
containing O
the O
NR2B O
subunit O
could O
be O
accounted O
for O
by O
more O
rapid O
association O
and O
slower O
dissociation O
from O
these O
sites O
. O
We O
conclude O
that O
felbamate O
exhibits O
modest O
selectivity O
for O
NMDA O
receptors O
composed O
of O
NR1a B
/ O
NR2B O
subunits O
. O
This O
selectivity O
could O
, O
in O
part O
, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate O
in O
comparison O
with O
NMDA O
receptor O
antagonists O
that O
do O
not O
show O
subunit O
selectivity O
. O

glyburide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cross-inhibition O
of O
SR-BI- O
and O
ABCA1-mediated O
cholesterol O
transport O
by O
the O
small O
molecules O
BLT-4 O
and O
glyburide.Scavenger O
receptor O
class O
B O
type O
I O
(SR-BI) O
and O
ABCA1 O
are O
structurally O
dissimilar O
cell O
surface O
proteins O
that O
play O
key O
roles O
in O
HDL O
metabolism O
. O
SR-BI O
is O
a O
receptor O
that O
binds O
HDL O
with O
high O
affinity O
and O
mediates O
both O
the O
selective O
lipid O
uptake O
of O
cholesteryl O
esters O
from O
lipid-rich O
HDL O
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol O
from O
cells O
to O
HDL O
. O
ABCA1 O
mediates O
the O
efflux O
of O
unesterified O
cholesterol O
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein O
A-I O
(apoA-I) O
. O
The O
activities O
of O
ABCA1 O
and O
other O
ATP O
binding O
cassette O
superfamily O
members O
are O
inhibited O
by O
the O
drug O
glyburide O
, O
and O
SR-BI-mediated O
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs O
. O
Here O
, O
we O
show O
that O
one O
BLT O
, O
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] O
(BLT-4) O
, O
blocked O
ABCA1-mediated O
cholesterol O
efflux O
to O
lipid-poor O
apoA-I O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI O
(IC(50) O
approximately O
55-60 O
microM) O
. O
Reciprocally O
, O
glyburide O
blocked O
SR-BI-mediated O
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 O
(IC(50) O
approximately O
275-300 O
microM) O
. O
As O
is O
the O
case O
with O
BLTs O
, O
glyburide O
increased O
the O
apparent O
affinity O
of O
HDL O
binding O
to O
SR-BI B
. O
The O
reciprocal O
inhibition O
of O
SR-BI O
and O
ABCA1 O
by O
BLT-4 O
and O
glyburide O
raises O
the O
possibility O
that O
these O
proteins O
may O
share O
similar O
or O
common O
steps O
in O
their O
mechanisms O
of O
lipid O
transport O
. O

U50,488H O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Mechanisms O
of O
agonist-induced O
down-regulation O
of O
the O
human O
kappa-opioid O
receptor O
: O
internalization O
is O
required O
for O
down-regulation.Previously O
, O
we O
showed O
that O
the O
human O
kappa-opioid O
receptor O
(hkor) O
stably O
expressed O
in O
Chinese O
hamster O
ovary O
(CHO) O
cells O
underwent O
down-regulation O
after O
prolonged O
U50,488H O
treatment O
. O
In O
the O
present O
study O
, O
we O
determined O
the O
mechanisms O
underlying O
this O
process O
. O
U50 O
, O
488H O
caused O
a O
significant O
down-regulation O
of O
the O
hkor O
, O
although O
etorphine O
did O
not O
. O
Neither O
U50,488H O
nor O
etorphine O
caused O
down-regulation O
of O
the O
rat O
kappa-opioid O
receptor O
. O
Thus O
, O
similar O
to O
internalization O
, O
there O
are O
agonist O
and O
species O
differences O
in O
down-regulation O
of O
kappa-opioid O
receptors O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
arrestin-2(319-418) O
or O
dynamin O
I-K44A O
significantly O
reduced O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
. O
Coexpression O
of O
GRK2 O
or O
GRK2 O
and O
arrestin-2 O
permitted O
etorphine O
to O
induce O
down-regulation O
of O
the O
hkor O
, O
although O
expression O
of O
arrestin-2 O
or O
dynamin O
I O
alone O
did O
not O
. O
Expression O
of O
the O
dominant O
negative O
mutants O
rab5A- O
N133I B
or O
rab7-N125I O
blunted O
U50,488H-induced O
down-regulation O
. O
Pretreatment O
with O
lysosomal O
enzyme O
inhibitors O
[(2S O
, O
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane O
ethyl O
ester O
or O
chloroquine] O
or O
proteasome O
inhibitors O
(proteasome O
inhibitor O
I O
, O
MG-132 O
, O
or O
lactacystin) O
decreased O
the O
extent O
of O
U50,488H-induced O
down-regulation O
. O
A O
combination O
of O
chloroquine O
and O
proteasome O
inhibitor O
I O
abolished O
U50,488H-induced O
down-regulation O
. O
These O
results O
indicate O
that O
U50,488H-induced O
down-regulation O
of O
the O
hkor O
involves O
GRK- O
, O
arrestin-2- O
, O
dynamin- O
, O
rab5- O
, O
and O
rab7-dependent O
mechanisms O
and O
receptors O
seem O
to O
be O
trafficked O
to O
lysosomes O
and O
proteasomes O
for O
degradation O
. O
Thus O
, O
U50,488H-induced O
internalization O
and O
down-regulation O
of O
the O
hkor O
share O
initial O
common O
mechanisms O
. O
To O
the O
best O
of O
our O
knowledge O
, O
these O
results O
represent O
the O
first O
report O
on O
the O
involvement O
of O
both O
rab5 O
and O
rab7 O
in O
agonist-induced O
down-regulation O
of O
a O
G O
protein-coupled O
receptor O
. O
In O
addition O
, O
this O
study O
is O
among O
the O
first O
to O
show O
the O
involvement O
of O
proteasomes O
in O
agonist-induced O
down-regulation O
of O
a O
G O
protein-coupled O
receptor O
. O

amiodarone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Na+/Ca2+ O
exchange O
inhibitors O
: O
a O
new O
class O
of O
calcium O
regulators.The O
Na(+)/Ca(2+) O
exchanger O
(NCX) O
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) O
from O
the O
cell O
(forward O
mode) O
, O
but O
also O
brings O
Ca(2+) O
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) O
(Na(+)(i)) O
accumulation O
or O
membrane O
depolarization O
. O
There O
are O
three O
mammalian O
NCX O
isoforms O
: O
NCX1 O
is O
widely O
expressed O
in O
the O
heart O
, O
kidney O
, O
brain O
, O
blood O
vessels O
, O
and O
so O
on; O
whereas O
the O
expression O
of O
NCX2 O
and O
NCX3 O
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle O
. O
The O
pharmacology O
of O
NCX O
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943 O
, O
a O
prototype O
benzyloxyphenyl O
NCX O
inhibitor O
, O
in O
1996 O
. O
Currently O
, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors O
: O
SEA0400 O
, O
SN-6 O
, O
and O
YM-244769 O
. O
Intriguingly O
, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl O
NCX O
inhibitors O
is O
directly O
coupled O
to O
the O
rate O
of O
Na(+)(i)-dependent O
inactivation O
. O
Therefore O
, O
the O
benzyloxyphenyl O
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)) O
, O
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)) O
. O
This O
should O
be O
an O
ideal O
profile O
for O
calcium O
regulators O
against O
Na(+)(i)-related O
diseases O
, O
such O
as O
ischemia/reperfusion O
injuries O
, O
salt-dependent O
hypertension O
, O
and O
digitalis O
arrhythmia O
. O
Existing O
ion B
channel I
blockers O
, O
such O
as O
amiodarone O
, O
dronedarone O
, O
bepridil O
, O
aprindine O
, O
and O
cibenzoline O
, O
have O
been O
found O
to O
have O
an O
NCX O
inhibitory O
action O
. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects O
. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX O
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium O
regulator O
. O

Thiazolidinediones O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Effect O
of O
thiazolidinediones O
on O
equilibrative O
nucleoside O
transporter-1 O
in O
human O
aortic O
smooth O
muscle O
cells.Thiazolidinediones O
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin B
sensitivity O
by O
binding O
to O
the O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPAR(gamma)) O
and O
stimulating O
the O
expression O
of O
insulin-responsive O
genes O
involved O
in O
glucose O
and O
lipid O
metabolism O
. O
These O
drugs O
also O
have O
vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells O
. O
However O
the O
mechanisms O
for O
these O
actions O
are O
not O
fully O
understood O
. O
Adenosine O
is O
a O
vasodilator O
and O
a O
substrate O
of O
equilibrative O
nucleoside O
transporters O
(ENT) O
. O
The O
present O
study O
studied O
the O
effects O
of O
three O
thiazolidinediones O
, O
troglitazone O
, O
pioglitazone O
and O
ciglitazone O
, O
on O
ENT1 O
in O
the O
human O
aortic O
smooth O
muscle O
cells O
(HASMCs) O
. O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones O
had O
no O
effect O
on O
ENT1 O
mRNA O
and O
protein O
levels O
, O
troglitazone O
acutely O
inhibited O
[3H]adenosine O
uptake O
and O
[3H]NBMPR O
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM O
, O
respectively O
. O
The O
effect O
of O
troglitazone O
on O
ENT1 O
was O
PPAR(gamma)-independent O
and O
kinetic O
studies O
revealed O
that O
troglitazone O
was O
a O
competitive O
inhibitor O
of O
ENT1 O
. O
In O
contrast O
, O
pioglitazone O
and O
ciglitazone O
had O
minimal O
effects O
on O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Troglitazone O
differs O
from O
pioglitazone O
and O
ciglitazone O
in O
that O
its O
side-chain O
contains O
a O
Vitamin O
E O
moiety O
. O
The O
difference O
in O
structure O
of O
troglitazone O
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 O
because O
Vitamin O
E O
did O
not O
inhibit O
[3H]adenosine O
uptake O
by O
HASMCs O
. O
Using O
the O
nucleoside O
transporter O
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 O
and O
ENT2 O
, O
it O
was O
found O
that O
troglitazone O
inhibited O
ENT1 O
but O
had O
no O
effect O
on O
ENT2 O
. O
From O
these O
results O
, O
it O
is O
suggested O
that O
troglitazone O
may O
enhance O
the O
vasodilatory O
effect O
of O
adenosine O
by O
inhibiting O
ENT1 O
. O
Pharmacologically O
, O
troglitazone O
is O
a O
novel O
inhibitor O
of O
ENT1 O
. O

lysine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transcriptional O
control O
of O
the O
arginine/lysine O
transporter O
, O
cat-1 O
, O
by O
physiological O
stress.Cells O
respond O
to O
physiological O
stress O
by O
phosphorylating O
the O
alpha O
subunit O
of O
the O
translation O
initiation O
factor O
eIF2 O
. O
This O
adaptive O
response O
inhibits O
protein O
synthesis O
and O
up-regulates O
genes O
essential O
for O
cell O
survival O
. O
Cat-1 B
, O
the O
transporter O
for O
the O
essential O
amino O
acids O
, O
arginine O
and O
lysine O
, O
is O
one O
of O
the O
up-regulated O
genes O
. O
We O
previously O
showed O
that O
stress O
increases O
cat-1 O
expression O
by O
coordinated O
stabilization O
of O
the O
mRNA O
and O
increased O
mRNA O
translation O
. O
This O
induction O
is O
triggered O
by O
amino O
acid O
depletion O
and O
the O
unfolded O
protein O
response O
(UPR) O
, O
which O
is O
caused O
by O
unfolded O
proteins O
in O
the O
endoplasmic O
reticulum O
. O
We O
show O
here O
that O
cat-1 O
gene O
transcription O
is O
also O
increased O
by O
cellular O
stress O
. O
Our O
studies O
demonstrate O
that O
the O
cat-1 O
gene O
promoter/regulatory O
region O
is O
TATA-less O
and O
is O
located O
in O
a O
region O
that O
includes O
94 O
bases O
of O
the O
first O
exon O
. O
Transcription O
from O
this O
promoter O
is O
stimulated O
8-fold O
by O
cellular O
stress O
. O
An O
amino O
acid O
response O
element O
within O
the O
first O
exon O
is O
shown O
to O
be O
required O
for O
the O
response O
to O
amino O
acid O
depletion O
but O
not O
to O
the O
UPR O
. O
The O
stimulation O
of O
transcription O
by O
amino O
acid O
depletion O
requires O
activation O
of O
GCN2 O
kinase O
, O
which O
phosphorylates O
eIF2alpha O
. O
This O
phosphorylation O
also O
induces O
translation O
of O
the O
cat-1 O
mRNA O
, O
demonstrating O
that O
stress-induced O
transcriptional O
and O
translational O
control O
of O
cat-1 O
are O
downstream O
targets O
of O
a O
signaling O
pathway O
initiating O
with O
eIF2alpha O
phosphorylation O
. O
Our O
studies O
show O
that O
the O
increase O
in O
cat-1 O
gene O
expression O
by O
cellular O
stress O
involves O
at O
least O
three O
types O
of O
coordinate O
regulation O
: O
regulation O
of O
transcription O
, O
regulation O
of O
mRNA O
stability O
, O
and O
regulation O
of O
mRNA O
translation O
. O

glycine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Investigating O
the O
regulation O
of O
one-carbon O
metabolism O
in O
Arabidopsis O
thaliana.Serine O
(Ser) O
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways O
. O
One O
major O
route O
involves O
the O
tetrahydrofolate O
(THF)-dependent O
activities O
of O
the O
glycine O
decarboxylase O
complex O
(GDC O
, O
EC B
2.1.1.10) I
and O
serine O
hydroxymethyltransferase O
(SHMT O
, O
EC O
2.1.2.1) O
with O
glycine O
(Gly) O
as O
one-carbon O
(1-C) O
source O
. O
An O
alternative O
THF-dependent O
pathway O
involves O
the O
C1-THF O
synthase/SHMT O
activities O
with O
formate O
as O
1-C O
source O
. O
Here O
, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh O
. O
Columbia O
using O
two O
approaches O
. O
Firstly O
, O
transgenic O
plants O
overexpressing O
formate O
dehydrogenase O
(FDH O
, O
EC O
1.2.1.2) O
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH O
in O
formate O
metabolism O
. O
The O
formate O
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate O
. O
Transgenic O
plants O
produced O
more O
(13)CO(2) O
from O
supplied O
[(13)C]formate O
than O
did O
WT O
plants O
but O
were O
not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser O
. O
We O
concluded O
that O
FDH O
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser O
synthesis; O
the O
breakdown O
of O
formate O
to O
CO(2) O
by O
the O
FDH O
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis O
. O
The O
ratio O
between O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
of O
Ser O
synthesis O
from O
[alpha-(13)C]Gly O
and O
[(13)C]formate O
, O
respectively O
, O
in O
Arabidopsis O
shoots O
was O
21 O
 O
: O
1; O
in O
roots O
, O
9 O
 O
: O
1 O
. O
In O
shoots O
, O
therefore O
, O
the O
pathway O
from O
formate O
plays O
only O
a O
small O
role O
in O
Ser O
synthesis; O
in O
the O
case O
of O
roots O
, O
results O
indicated O
that O
the O
9 O
 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C O
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF O
synthase/SHMT O
route O
than O
in O
shoots O
. O
We O
also O
examined O
the O
synthesis O
of O
Ser O
in O
a O
GDC-deficient O
mutant O
of O
Arabidopsis O
(glyD) O
where O
the O
GDC/SHMT O
pathway O
was O
impaired O
. O
Compared O
with O
WT O
, O
glyD O
plants O
accumulated O
5-fold O
more O
Gly O
than O
WT O
after O
supplying O
[alpha-(13)C]Gly O
for O
24 O
h; O
the O
accumulation O
of O
Ser O
from O
[alpha-(13)C]Gly O
was O
reduced O
by O
25% O
in O
the O
same O
time O
period O
. O
On O
the O
other O
hand O
, O
the O
accumulation O
of O
Ser O
through O
the O
C1-THF O
synthase/SHMT O
pathway O
in O
glyD O
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants O
. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT O
and O
C1-THF O
synthase/SHMT O
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O
when O
the O
primary O
GDC/SHMT O
pathway O
is O
impaired O
the O
alternative O
C1-THF O
synthase/SHMT O
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser O
. O

STA2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated O
(HVA) O
Ca2+ O
channels O
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA B
Ca2+ I
channels I
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

rilmenidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Species-specific O
pharmacological O
properties O
of O
human O
alpha(2A)-adrenoceptors.On O
the O
basis O
of O
data O
obtained O
in O
rabbits O
, O
the O
imidazoline O
receptor O
ligand O
rilmenidine O
has O
been O
suggested O
to O
decrease O
blood O
pressure O
in O
humans O
by O
activating O
central O
alpha(2A)-adrenoceptors O
. O
A O
prerequisite O
for O
this O
hypothesis O
was O
the O
unproved O
assumption O
that O
rabbit O
and O
human O
alpha(2A)-adrenoceptors O
are O
equally O
activated O
by O
rilmenidine O
. O
Because O
alpha(2A)-adrenoceptors O
in O
the O
brain O
and O
on O
cardiovascular O
sympathetic O
nerve O
terminals O
are O
identical O
, O
the O
latter O
were O
used O
as O
a O
model O
for O
the O
former O
to O
confirm O
or O
disprove O
this O
assumption O
. O
Human O
atrial O
appendages O
and O
rabbit O
pulmonary O
arteries O
were O
used O
to O
determine O
the O
potencies O
of O
alpha(2)-adrenoceptor O
agonists O
in O
inhibiting O
the O
electrically O
(2 O
Hz) O
evoked O
[(3)H]norepinephrine O
release O
and O
of O
antagonists O
in O
counteracting O
the O
alpha(2)-adrenoceptor-mediated O
inhibition O
induced O
by O
moxonidine O
. O
In O
the O
rabbit O
pulmonary O
artery O
, O
rilmenidine O
and O
oxymetazoline O
are O
potent O
full O
agonists O
, O
whereas O
in O
the O
human O
atrial O
appendages O
they O
are O
antagonists O
at O
the O
alpha(2)-autoreceptors O
, O
sharing O
this O
property O
with O
rauwolscine O
, O
phentolamine O
, O
and O
idazoxan O
. O
In O
contrast O
, O
prazosin O
is O
ineffective O
. O
In O
addition O
, O
a O
partial O
nucleotide O
and O
amino O
acid O
sequence O
of O
the O
rabbit O
alpha(2A)-adrenoceptor O
(a O
region O
known O
to O
substantially O
influence O
the O
pharmacological O
characteristics O
of O
the O
alpha(2)-adrenoceptor) O
revealed O
marked O
differences O
between O
the O
rabbit O
and O
the O
human O
alpha(2A)-adrenoceptor O
. O
The O
sympathetic O
nerves O
of O
both O
the O
human O
atrial O
appendages O
and O
rabbit O
pulmonary O
artery O
are O
endowed O
with O
alpha(2A)-autoreceptors O
, O
at O
which O
, O
however O
, O
both O
rilmenidine O
and O
oxymetazoline O
exhibit O
different O
properties O
(antagonism O
and O
agonism O
, O
respectively) O
. O
The O
antagonistic O
property O
of O
rilmenidine O
at O
human O
alpha(2A)-adrenoceptors O
indicates O
that O
in O
contrast O
to O
the O
suggestion O
based O
on O
rabbit O
data O
, O
the O
hypotensive O
property O
of O
the O
drug O
in O
humans O
is O
not O
due O
to O
activation O
of O
alpha(2A)-adrenoceptors O
but O
other O
, O
presumably O
I(1)-imidazoline B
receptors I
, O
are O
probably O
involved O
. O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Expression O
and O
selective O
inhibition O
of O
the O
constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase.The O
enzyme O
cyclo-oxygenase O
catalyses O
the O
oxygenation O
of O
arachidonic O
acid O
, O
leading O
to O
the O
formation O
of O
prostaglandins O
. O
Recently O
two O
forms O
of O
cyclo-oxygenase O
have O
been O
described O
: O
a O
constitutive O
(COX-1) O
enzyme O
present O
in O
most O
cells O
and O
tissues O
, O
and O
an O
inducible O
(COX-2) O
isoenzyme O
observed O
in O
many O
cells O
in O
response O
to O
pro-inflammatory O
cytokines O
. O
Constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase O
(hCOX-1 O
and O
hCOX-2) O
were O
cloned O
and O
expressed O
in O
insect O
cells O
, O
utilizing O
a O
baculovirus O
expression O
system O
. O
hCOX-1 O
had O
a O
specific O
activity O
of O
18.8 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 O
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 B
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

theophylline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Modulation O
of O
TNF O
and O
GM-CSF O
release O
from O
dispersed O
human O
nasal O
polyp O
cells O
and O
human O
whole O
blood O
by O
inhibitors O
of O
different O
PDE O
isoenzymes O
and O
glucocorticoids.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
role O
of O
the O
inhibitors O
of O
different O
PDE O
isoenzymes O
(PDE O
1-5) O
on O
the O
production O
of O
two O
pro-inflammatory O
cytokines O
- O
tumor O
necrosis O
factor O
alpha O
(TNF) O
and O
granulocyte-macrophage O
colony-stimulating O
factor O
(GM-CSF) O
. O
Two O
in O
vitro O
models O
were O
used O
to O
compare O
the O
antiinflammatory O
properties O
of O
PDE O
inhibitors O
with O
that O
of O
glucocorticoids O
. O
The O
effect O
on O
TNF O
release O
from O
diluted O
human O
blood O
following O
lipopolysaccharide O
(LPS O
from O
Salmonella O
abortus O
equi) O
stimulation O
as O
well O
as O
the O
GM-CSF O
and O
TNF O
release O
from O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE B
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE O
4 O
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

bleomycin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Suppression O
of O
nuclear O
factor O
erythroid O
2-related O
factor O
2 O
via O
extracellular O
signal-regulated O
kinase O
contributes O
to O
bleomycin-induced O
oxidative O
stress O
and O
fibrogenesis.Pulmonary O
fibrosis O
is O
a O
serious O
and O
irreversible O
lung O
injury O
with O
obscure O
etiologic O
mechanisms O
and O
no O
effective O
treatment O
to O
date O
. O
This O
study O
explored O
a O
crucial O
link O
between O
oxidative O
stress O
and O
pulmonary O
fibrogenesis O
, O
focusing O
on O
nuclear O
factor O
erythroid O
2-related O
factor O
2 O
(Nrf2) O
, O
a O
core O
transcription O
factor O
in O
antioxidative O
regulation O
systems O
. O
Treatment O
of O
C57 O
BL/6 O
mice O
with O
bleomycin O
increased O
fibroblast O
viability O
and O
collagen B
production O
and O
significantly O
downregulated O
Nrf2 O
. O
In O
addition O
, O
prominent O
oxidative O
stress O
was O
indicated O
by O
changes O
in O
superoxide O
dismutase O
, O
catalase O
activity O
, O
and O
glutathione O
and O
thiobarbituric O
acid-reactive O
substance O
levels O
. O
In O
a O
cell-based O
model O
, O
bleomycin O
suppressed O
Nrf2 O
activation O
via O
extracellular O
signal-related O
kinase O
phosphorylation O
, O
enhancing O
intracellular O
reactive O
oxygen O
species O
in O
lung O
fibroblasts O
and O
stimulating O
abnormal O
cell O
proliferation O
and O
collagen O
secretion O
. O
To O
confirm O
this O
novel O
mechanism O
of O
bleomycin-induced O
fibrogenesis O
, O
we O
attempted O
to O
upregulate O
Nrf2 O
and O
related O
antioxidant O
proteins O
in O
bleomycin-treated O
fibroblasts O
using O
a O
putative O
Nrf2 O
activator O
, O
caffeic O
acid O
phenethyl O
ester O
, O
and O
the O
results O
showed O
that O
bleomycin-induced O
fibroblast O
proliferation O
and O
collagen O
content O
were O
attenuated O
through O
improved O
redox O
balance O
. O
Collectively O
, O
these O
results O
disclose O
a O
potential O
regulatory O
mechanism O
in O
pulmonary O
fibrosis O
that O
will O
aid O
the O
development O
of O
new O
therapies O
. O

EETs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CYP2J2 O
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
(EETs) O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O
in O
apoE-deficient O
mice O
. O
rAAV-CYP2J2 O
delivery O
led O
to O
an O
abundant O
aortic O
CYP2J2 O
expression O
and O
increased O
EETs O
generation O
. O
It O
was O
shown O
that O
CYP2J2 O
overexpression O
attenuated O
matrix O
metalloproteinase O
expression O
and O
activity O
, O
elastin O
degradation O
, O
and O
AAA O
formation O
, O
which O
was O
associated O
with O
reduced O
aortic O
inflammation O
and O
macrophage O
infiltration O
. O
In O
cultured O
vascular O
smooth O
muscle O
cells O
(VSMCs) O
, O
rAAV-mediated O
CYP2J2 O
overexpression O
and O
EETs O
markedly O
suppressed O
Ang B
II- I
induced O
inflammatory O
cytokine O
expression O
. O
Moreover O
, O
overexpressed O
CYP2J2 O
and O
EETs O
inhibited O
Ang O
II-induced O
macrophage O
migration O
in O
a O
VSMC-macrophage O
coculture O
system O
. O
We O
further O
indicated O
that O
these O
protective O
effects O
were O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
(PPAR)γ O
activation O
. O
Taken O
together O
, O
these O
results O
provide O
evidence O
that O
rAAV-mediated O
CYP2J2 O
overexpression O
prevents O
AAA O
development O
which O
is O
likely O
via O
PPARγ O
activation O
and O
anti-inflammatory O
action O
, O
suggesting O
that O
increasing O
EETs O
levels O
could O
be O
considered O
as O
a O
potential O
strategy O
to O
prevent O
and O
treat O
AAA O
. O

RSD1235 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
role O
of O
late O
I O
and O
antiarrhythmic O
drugs O
in O
EAD O
formation O
and O
termination O
in O
Purkinje O
fibers.Multiple O
components O
of O
cardiac O
Na O
current O
play O
a O
role O
in O
determining O
electrical O
excitation O
in O
the O
heart O
. O
Recently O
, O
the O
role O
of O
nonequilibrium O
components O
in O
controlling O
cardiac O
action O
potential O
plateau O
duration O
, O
and O
their O
importance O
in O
regulating O
the O
occurrence O
of O
afterdepolarizations O
and O
arrhythmias O
have O
garnered O
more O
attention O
. O
In O
particular O
, O
late O
Na O
current O
(late O
I(Na)) O
has O
been O
shown O
to O
be O
important O
in O
LQT2 O
and O
LQT3 O
arrhythmias O
. O
Class O
III O
agents O
like O
dofetilide O
, O
clofilium O
, O
and O
sotalol O
, O
which O
can O
all O
cause O
a O
drug-induced O
form O
of O
LQT2 O
, O
significantly O
lengthen O
action O
potential O
duration O
at O
50% O
and O
90% O
repolarization O
in O
isolated O
rabbit O
Purkinje O
fibers O
, O
and O
can O
initiate O
the O
formation O
of O
early O
afterdepolarizations O
, O
and O
extra O
beats O
. O
These O
actions O
can O
lead O
to O
the O
development O
of O
a O
serious O
ventricular O
tachycardia O
, O
torsades O
de O
pointes O
, O
in O
animal O
models O
and O
patients O
. O
However O
, O
pretreatment O
with O
agents O
that O
block O
late O
I(Na) O
, O
like O
lidocaine O
, O
mexiletine O
, O
and O
RSD1235 O
, O
a O
novel O
mixed O
ion B
channel I
blocker O
for O
the O
rapid O
pharmacologic O
conversion O
of O
atrial O
fibrillation O
, O
significantly O
attenuates O
the O
prolonging O
effects O
of O
Class O
III O
agents O
or O
those O
induced O
by O
ATX-II O
, O
a O
specific O
toxin O
that O
delays O
Na O
channel O
inactivation O
and O
amplifies O
late O
I(Na) O
greatly O
, O
mimicking O
LQT3 O
. O
The O
Na O
channel O
block O
caused O
by O
lidocaine O
and O
RSD1235 O
can O
be O
through O
the O
open O
or O
inactivated O
states O
of O
the O
channel O
, O
but O
both O
equivalently O
inhibit O
a O
late O
component O
of O
Na O
current O
(I(Na)) O
, O
recorded O
at O
22 O
degrees O
C O
using O
whole-cell O
patch O
clamp O
of O
Nav O
1.5 O
expressed O
in O
HEK O
cells O
. O
These O
protective O
actions O
of O
lidocaine O
, O
mexiletine O
, O
and O
RSD1235 O
may O
result O
, O
at O
least O
in O
part O
, O
from O
their O
ability O
to O
inhibit O
late O
I(Na) O
during O
action O
potential O
repolarization O
, O
and O
inhibition O
of O
the O
inward O
currents O
contributing O
to O
EAD O
and O
arrhythmia O
formation O
. O

Ca2+ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin B
light I
chain I
kinase) I
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

steppogenin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Characterization O
of O
tyrosinase O
inhibitors O
in O
the O
twigs O
of O
Cudrania O
tricuspidata O
and O
their O
structure-activity O
relationship O
study.The O
twigs O
of O
Cudrania O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase O
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol O
glucoside O
, O
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside O
(1) O
, O
plus O
twenty-seven O
known O
compounds O
(2-28) O
. O
Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
ESI-MS O
and O
NMR O
spectral O
data O
. O
Among O
the O
isolated O
compounds O
, O
trans-dihydromorin O
(8) O
, O
oxyresveratrol O
(9) O
, O
and O
steppogenin O
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase B
inhibition O
activities O
. O
Moreover O
, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed O
. O

calcium O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Involvement O
of O
regucalcin O
in O
lipid O
metabolism O
and O
diabetes.Regucalcin O
(RGN O
/ O
SMP30) B
was O
originally O
discovered O
in O
1978 O
as O
a O
unique O
calcium-binding O
protein O
that O
does O
not O
contain O
the O
EF-hand O
motif O
of O
calcium-binding O
domain O
. O
The O
regucalcin O
gene O
(rgn) O
is O
localized O
on O
the O
X O
chromosome O
and O
is O
identified O
in O
over O
15 O
species O
consisting O
the O
regucalcin O
family O
. O
Regucalcin O
has O
been O
shown O
to O
play O
a O
multifunctional O
role O
in O
cell O
regulation; O
maintaining O
of O
intracellular O
calcium O
homeostasis O
and O
suppressing O
of O
signal O
transduction O
, O
translational O
protein O
synthesis O
, O
nuclear O
deoxyribonucleic O
acid O
(DNA) O
and O
ribonucleic O
acid O
(RNA) O
synthesis O
, O
proliferation O
, O
and O
apoptosis O
in O
many O
cell O
types O
. O
Moreover O
, O
regucalcin O
may O
play O
a O
pathophysiological O
role O
in O
metabolic O
disorder O
. O
The O
expression O
of O
regucalcin O
is O
stimulated O
through O
the O
action O
of O
insulin O
in O
liver O
cells O
in O
vitro O
and O
in O
vivo O
and O
it O
is O
decreased O
in O
the O
liver O
of O
rats O
with O
type O
I O
diabetes O
induced O
by O
streptozotocin O
administration O
in O
vivo O
. O
Overexpression O
of O
endogenous O
regucalcin O
stimulates O
glucose O
utilization O
and O
lipid O
production O
in O
liver O
cells O
with O
glucose O
supplementation O
in O
vitro O
. O
Regucalcin O
reveals O
insulin O
resistance O
in O
liver O
cells O
. O
Deficiency O
of O
regucalcin O
induces O
an O
impairment O
of O
glucose O
tolerance O
and O
lipid O
accumulation O
in O
the O
liver O
of O
mice O
in O
vivo O
. O
Overexpression O
of O
endogenous O
regucalcin O
has O
been O
shown O
to O
decrease O
triglyceride O
, O
total O
cholesterol O
and O
glycogen O
contents O
in O
the O
liver O
of O
rats O
, O
inducing O
hyperlipidemia O
. O
Leptin O
and O
adiponectin O
mRNA O
expressions O
in O
the O
liver O
tissues O
are O
decreased O
in O
regucalcin O
transgenic O
rats O
. O
Decrease O
in O
hepatic O
regucalcin O
is O
associated O
with O
the O
development O
and O
progression O
of O
nonalcoholic O
fatty O
liver O
disease O
and O
fibrosis O
in O
human O
patients O
. O
Regucalcin O
may O
be O
a O
key O
molecule O
in O
lipid O
metabolic O
disorder O
and O
diabetes O
. O

toloxatone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Comparison O
of O
the O
monoamine B
oxidase I
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine O
oxidase-A O
inhibitors O
moclobemide O
and O
toloxatone O
, O
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects.1 O
. O
The O
effects O
of O
two O
reversible O
, O
predominantly O
monoamine O
oxidase-A O
(MAO-A) O
inhibitors O
, O
moclobemide O
(150 O
mg O
three O
times O
daily) O
and O
toloxatone O
(400-200-400 O
mg O
day-1) O
on O
monoamine O
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O
12 O
healthy O
subjects O
. O
2 O
. O
After O
7 O
days O
of O
moclobemide/toloxatone/placebo O
administration O
subjects O
were O
hospitalized O
for O
24 O
h O
on O
day O
8 O
. O
Blood O
samples O
were O
drawn O
every O
2 O
h O
for O
determination O
of O
plasma O
noradrenaline O
(NA) O
, O
3,4-dihydroxyphenylglycol O
(DHPG) O
, O
homovanillic O
acid O
(HVA) O
and O
5-hydroxyindolacetic O
acid O
(5-HIAA) O
. O
Urine O
was O
collected O
for O
measurements O
of O
normetanephrine O
and O
3-methoxytyramine O
excretion O
. O
Psychometric O
performance O
(short- O
and O
long-term O
memory O
, O
critical O
flicker O
fusion O
frequency O
, O
choice O
reaction O
time) O
and O
subjective O
feelings O
were O
assessed O
before O
each O
drug O
intake O
(in O
the O
morning O
, O
at O
noon O
, O
in O
the O
evening) O
. O
3 O
. O
Compared O
with O
placebo O
, O
both O
reversible O
monoamine O
oxidase O
inhibitors O
decreased O
the O
plasma O
concentration O
of O
DHPG O
and O
HVA O
. O
The O
overall O
fall O
in O
DHPG O
(AUC O
from O
0 O
to O
24 O
h) O
was O
44% O
during O
moclobemide O
and O
12% O
during O
toloxatone O
(P O
less O
than O
0.001) O
and O
the O
overall O
decrease O
in O
HVA O
was O
38% O
and O
20% O
(P O
less O
than O
0.005) O
on O
moclobemide O
and O
toloxatone O
, O
respectively O
. O
4 O
. O
Before O
the O
next O
drug O
intake O
, O
MAO-A O
inhibition O
, O
as O
judged O
by O
the O
decrease O
of O
plasma O
DHPG O
concentration O
, O
was O
significantly O
different O
from O
placebo O
with O
moclobemide O
but O
not O
with O
toloxatone O
. O
5 O
. O
Moclobemide O
, O
but O
not O
toloxatone O
, O
exerted O
a O
moderate O
, O
but O
significant O
inhibition O
of O
the O
deamination O
of O
5-hydroxytryptamine O
(5-HT) O
as O
judged O
by O
the O
fall O
in O
plasma O
5-HIAA O
concentration O
. O
Neither O
drug O
influenced O
plasma O
NA O
concentration O
. O
6 O
. O
A O
significant O
rise O
in O
urinary O
excretion O
of O
normetanephrine O
was O
observed O
on O
moclobemide O
and O
to O
a O
lesser O
extent O
on O
toloxatone O
. O
The O
urinary O
excretion O
of O
3-methoxytyramine O
was O
significantly O
raised O
by O
moclobemide O
but O
not O
by O
toloxatone O
. O
7 O
. O
Neither O
moclobemide O
nor O
toloxatone O
altered O
memory O
function O
, O
vigilance O
, O
subjective O
feelings O
or O
sleep O
characteristics O
of O
the O
subjects O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Comparative O
genomics O
, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 O
and O
ALDH2.Vertebrate O
ALDH2 O
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde O
and O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 B
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O
many O
mammalian O
species O
and O
in O
frogs O
(Xenopus O
tropicalis); O
no O
evidence O
was O
found O
for O
ALDH1B1 O
in O
the O
genomes O
of O
birds O
, O
reptiles O
or O
fish O
. O
Predicted O
vertebrate O
ALDH2 O
and O
ALDH1B1 O
subunit O
sequences O
and O
structures O
were O
highly O
conserved O
, O
including O
residues O
previously O
shown O
to O
be O
involved O
in O
catalysis O
and O
coenzyme O
binding O
for O
human O
ALDH2 O
. O
Studies O
of O
ALDH1B1 O
sequences O
supported O
the O
hypothesis O
that O
the O
ALDH1B1 O
gene O
originated O
in O
early O
vertebrates O
from O
a O
retrotransposition O
of O
the O
vertebrate O
ALDH2 O
gene O
. O
Given O
the O
high O
degree O
of O
similarity O
between O
ALDH2 O
and O
ALDH1B1 O
, O
it O
is O
surprising O
that O
individuals O
with O
an O
inactivating O
mutation O
in O
ALDH2 O
(ALDH2*2) O
do O
not O
exhibit O
a O
compensatory O
increase O
in O
ALDH1B1 O
activity O
. O
We O
hypothesized O
that O
the O
similarity O
between O
the O
two O
ALDHs O
would O
allow O
for O
dominant O
negative O
heterotetramerization O
between O
the O
inactive O
ALDH2 O
mutants O
and O
ALDH1B1 O
. O
Computational-based O
molecular O
modeling O
studies O
examining O
predicted O
protein-protein O
interactions O
indicated O
that O
heterotetramerization O
between O
ALDH2 O
and O
ALDH1B1 O
subunits O
was O
highly O
probable O
and O
may O
partially O
explain O
a O
lack O
of O
compensation O
by O
ALDH1B1 O
in O
ALDH2(∗)2 O
individuals O
. O

caffeic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Inhibition O
of O
mammalian O
isoforms O
I-XIV O
with O
a O
series O
of O
natural O
product O
polyphenols O
and O
phenolic O
acids.A O
series O
of O
phenolic O
acids O
and O
phenol O
natural O
products O
, O
such O
as O
p-hydroxybenzoic O
acid O
, O
p-coumaric O
acid O
, O
caffeic O
acid O
, O
ferulic O
acid O
, O
gallic O
acid O
, O
syringic O
acid O
, O
quercetin O
, O
and O
ellagic O
acid O
, O
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B
carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
. O
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O
(m) O
origin O
hCA O
I-hCA O
XII O
, O
mCA O
XIII O
and O
hCA O
XIV O
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM) O
. O
p-Hydroxybenzoic O
acid O
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives O
. O
Phenols O
like O
the O
ones O
investigated O
here O
possess O
a O
CA O
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates O
used O
clinically O
or O
the O
coumarins O
. O
Unlike O
the O
sulfonamides O
, O
which O
bind O
to O
the O
catalytic O
zinc O
ion O
, O
phenols O
are O
anchored O
at O
the O
Zn(II)-coordinated O
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity O
, O
making O
contacts O
with O
various O
amino O
acid O
residues O
. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA O
isozymes O
found O
in O
mammals O
, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O
medicinally O
relevant O
CAs O
. O

thiourea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Degradation O
of O
MAC13243 O
and O
studies O
of O
the O
interaction O
of O
resulting O
thiourea O
compounds O
with O
the O
lipoprotein O
targeting O
chaperone O
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O
novel O
small O
molecule O
, O
MAC13243 O
, O
as O
a O
likely O
inhibitor O
of O
the O
bacterial O
lipoprotein O
targeting O
chaperone O
, O
LolA O
. O
Here O
, O
we O
report O
on O
the O
degradation O
of O
MAC13243 O
into O
the O
active O
species O
, O
S-(4-chlorobenzyl)isothiourea O
. O
Analogs O
of O
this O
compound O
(e.g. O
, O
A22) O
have O
previously O
been O
characterized O
as O
inhibitors O
of O
the O
bacterial O
actin-like O
protein O
, O
MreB O
. O
Herein O
, O
we O
demonstrate O
that O
the O
antibacterial O
activity O
of O
MAC13243 O
and O
the O
thiourea O
compounds O
are O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA O
copy O
number O
, O
respectively O
. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA B
and O
the O
thiourea O
degradation O
product O
of O
MAC13243 O
, O
with O
a O
Kd O
of O
~150 O
μM O
. O
Taken O
together O
, O
we O
conclude O
that O
the O
thiourea O
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O
that O
includes O
interaction O
with O
LolA O
in O
addition O
to O
the O
well-characterized O
target O
MreB O
. O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O
(GAS) O
, O
nuclear O
factor-kappaB O
(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O
CCAAT/enhancer-binding O
protein O
beta O
(C/EBPbeta); O
therefore O
, O
we O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 B
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

Fc11a O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
novel O
benzo[d]imidazole O
derivate O
prevents O
the O
development O
of O
dextran O
sulfate O
sodium-induced O
murine O
experimental O
colitis O
via O
inhibition O
of O
NLRP3 O
inflammasome.NLRP3 O
inflammasome O
has O
been O
reported O
to O
be O
associated O
with O
various O
kinds O
of O
immunological O
diseases O
including O
colitis O
. O
However O
, O
there O
are O
few O
drug O
candidates O
targeting O
inflammasomes O
for O
the O
treatment O
of O
colitis O
. O
In O
the O
present O
study O
, O
we O
aimed O
at O
examining O
the O
effect O
of O
1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole O
, O
a O
synthetic O
small O
molecular O
compound O
also O
named O
Fc11a-2 O
, O
for O
the O
treatment O
of O
dextran O
sulfate O
sodium O
(DSS)-induced O
experimental O
colitis O
in O
mice O
via O
targeting O
NLRP3 O
inflammasome O
. O
Treatment O
with O
Fc11a-2 O
dose-dependently O
attenuated O
the O
loss O
of O
body O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 B
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

PGE1 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
prostaglandin O
E O
series O
modulates O
high-voltage-activated O
calcium O
channels O
probably O
through O
the O
EP3 O
receptor O
in O
rat O
paratracheal O
ganglia.The O
modulation O
of O
high-voltage-activated B
(HVA) I
Ca2+ I
channels I
by O
the O
prostaglandin O
E O
series O
(PGE1 O
and O
PGE2) O
was O
studied O
in O
the O
paratracheal O
ganglion O
cells O
. O
Prostaglandin O
E1 O
, O
E2 O
, O
STA2 O
(a O
stable O
analogue O
of O
thromboxane O
A2) O
, O
17-phenyl-trinor-PGE2 O
(an O
EP1-selective O
agonist) O
and O
sulprostone O
(an O
EP3-selective O
agonist) O
inhibited O
the O
HVA O
Ca2+ O
current O
(HVA O
ICa) O
dose-dependently O
, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA O
Ca2+ O
channels O
was O
sulprostone>PGE2 O
, O
PGE1>STA2>>17-phenyl-trinor-PGE2 O
. O
SC-51089 O
(10(-5) O
M) O
, O
a O
selective O
EP1-receptor O
antagonist O
, O
showed O
no O
effect O
on O
the O
PGE1- O
or O
PGE2-induced O
inhibition O
of O
the O
HVA O
ICa O
, O
thereby O
indicating O
that O
PGE1- O
and O
PGE2-induced O
inhibition O
of O
the O
HVA O
Ca2+ O
channels O
is O
possibly O
mediated O
by O
the O
EP3 O
receptor O
. O
The O
PGE1-sensitive O
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O
omega-conotoxin-GVIA O
(3x10(-6) O
M) O
, O
but O
not O
with O
nifedipine O
(3x10(-6) O
M) O
. O
PGE1 O
and O
PGE2 O
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine O
, O
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC O
, O
suggesting O
that O
R-type O
Ca2+ O
channels O
are O
involved O
. O
The O
inhibitory O
effect O
of O
PGE1 O
or O
sulprostone O
was O
prevented O
by O
pretreatment O
with O
pertussis O
toxin O
[islet O
activating O
protein O
(IAP)] O
or O
phorbol-12-myristate-13-acetate O
(PMA) O
, O
and O
the O
protein O
kinase O
C O
(PKC) O
inhibitor O
chelerythrine O
blocked O
the O
action O
of O
PMA O
. O
It O
was O
concluded O
that O
PGE1 O
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ O
currents O
by O
activating O
a O
G-protein O
probably O
through O
the O
EP3 O
receptor O
in O
paratracheal O
ganglion O
cells O
. O

triglycerides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cellular O
insulin O
signaling O
and O
PTP1B O
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells.Normal O
glucose O
regulation O
is O
achieved O
by O
having O
adequate O
insulin O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

Afinitor((R)) O
Novartis O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Everolimus O
: O
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib O
and/or O
sorafenib.Everolimus O
(RAD001 O
, O
Afinitor((R)) O
Novartis) O
is O
the O
first O
oral O
inhibitor O
of O
mTOR B
(mammalian O
target O
of O
rapamycin) O
to O
reach O
the O
oncology O
clinic O
. O
Everolimus O
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients O
. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus O
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR O
tyrosine O
kinase O
inhibitors O
sunitinib O
and/or O
sorafenib O
. O
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O
4.9 O
months O
(hazard O
ratio O
0.33 O
, O
P O
< O
0.001) O
and O
25% O
were O
still O
progression-free O
after O
10 O
months O
of O
everolimus O
therapy O
. O
There O
was O
a O
delay O
in O
time O
to O
decline O
of O
performance O
status O
and O
trends O
to O
improvement O
in O
quality O
of O
life O
, O
disease-related O
symptoms O
, O
and O
overall O
survival O
despite O
crossover O
of O
the O
majority O
of O
patients O
assigned O
to O
placebo O
. O
In O
2009 O
, O
everolimus O
was O
approved O
in O
the O
US O
and O
Europe O
as O
the O
only O
validated O
option O
for O
this O
indication O
. O
Toxicities O
are O
usually O
mild O
to O
moderate O
and O
can O
be O
managed O
with O
dose O
reduction O
or O
interruption O
if O
necessary O
. O
Opportunistic O
infections O
and O
non-infectious O
pneumonitis O
are O
seen O
as O
a O
class O
effect O
. O
Management O
of O
common O
practical O
management O
issues O
are O
discussed O
. O
Clinical O
trials O
are O
in O
progress O
to O
examine O
additional O
roles O
for O
everolimus O
in O
renal O
cancer O
, O
alone O
and O
in O
combination O
with O
other O
agents O
. O

Ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Withdrawal O
from O
free-choice O
ethanol O
consumption O
results O
in O
increased O
packing O
density O
of O
glutamine O
synthetase-immunoreactive O
astrocytes O
in O
the O
prelimbic O
cortex O
of O
alcohol-preferring O
rats.Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol O
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances O
, O
and O
to O
alcohol O
craving O
. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate O
and O
its O
conversion O
to O
glutamine O
through O
the O
enzyme O
glutamine O
synthetase O
(GS) O
. O
However O
, O
it O
is O
unclear O
if O
withdrawal O
from O
free-choice O
ethanol O
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS O
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial O
fibrillary O
acidic O
protein O
(GFAP) O
. O
Alcohol-preferring O
(P) O
rats O
exposed O
to O
free-choice O
ethanol O
drinking O
were O
either O
maintained O
without O
forced O
interruption O
of O
ethanol O
drinking O
, O
subjected O
to O
a O
3-day O
withdrawal O
period O
at O
the O
end O
of O
2 O
months O
, O
or O
subjected O
to O
three O
3-day O
withdrawal O
periods O
along O
6 O
months O
. O
At O
2 O
months O
, O
P O
rats O
were O
also O
compared O
with O
alcohol-naive O
alcohol O
non-preferring O
rats O
(NP) O
rats O
. O
Packing O
density O
of O
GS O
and O
GFAP-immunoreactive O
(IR) O
astrocytes O
was O
measured O
in O
sections O
from O
the O
prelimbic O
cortex O
(PLC) O
using O
the O
optical O
disector O
probe O
. O
An O
alcohol O
deprivation O
effect O
was O
observed O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period O
. O
Ethanol O
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- O
and O
GFAP- B
IR O
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol O
. O
In O
addition O
, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O
ethanol O
consumption O
and O
the O
packing O
density O
of O
GS-IR O
astrocytes O
. O
The O
present O
results O
suggest O
the O
involvement O
of O
astrocytes O
in O
the O
regulation O
of O
the O
glutamatergic O
activation O
associated O
with O
withdrawal O
from O
free-choice O
ethanol O
consumption O
and O
point O
to O
differential O
adaptations O
of O
GS O
and O
GFAP O
to O
prolonged O
alcohol O
drinking O
in O
the O
PLC O
of O
P O
rats O
. O

Vandetanib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
(Caprelsa(®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine O
kinase O
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor O
receptor O
tyrosine O
kinase O
RET B
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal O
growth-factor O
receptors O
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O
benefits O
in O
advanced O
MTC O
, O
and O
it O
has O
recently O
been O
approved O
for O
locally O
advanced O
or O
metastatic O
MTC O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
(April O
2011) O
and O
the O
European O
Medicines O
Agency O
(February O
2012) O
. O
This O
review O
, O
starting O
from O
the O
phases O
II O
and O
III O
efficacy O
and O
safety O
data O
that O
led O
to O
these O
approvals O
, O
explores O
important O
issues O
related O
to O
dosing O
, O
patient O
selection O
, O
and O
strategies O
for O
managing O
the O
substantial O
risk O
of O
toxicity O
associated O
with O
the O
drug O
(including O
life-threatening O
cardiac O
events O
that O
are O
the O
subject O
of O
a O
black-box O
warning O
in O
the O
United O
States) O
. O
All O
these O
issues O
still O
remain O
to O
be O
defined O
. O
Vandetanib O
is O
becoming O
a O
standard O
of O
care O
for O
symptomatic O
, O
progressive O
, O
metastatic O
MTCs O
, O
to O
be O
used O
selectively O
in O
those O
patients O
who O
are O
likely O
to O
benefit O
from O
it O
. O

kainate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
pharmacology O
at O
AMPA O
and O
kainate O
preferring O
glutamate B
receptors I
of O
4-heteroarylmethylidene O
glutamate O
analogues.2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic O
acid O
(1) O
is O
a O
potent O
AMPA O
receptor O
agonist O
with O
moderate O
affinity O
for O
native O
kainic O
acid O
(KA) O
receptors O
, O
whereas O
(S)-E-4-(2,2-dimethylpropylidene)glutamic O
acid O
(3) O
show O
high O
affinity O
for O
the O
GluR5 O
subtype O
of O
KA O
receptors O
and O
much O
lower O
affinity O
for O
the O
GluR2 O
subtype O
of O
AMPA O
receptors O
. O
As O
an O
attempt O
to O
develop O
new O
pharmacological O
tools O
for O
studies O
of O
GluR5 O
receptors O
, O
(S)-E-4-(2-thiazolylmethylene)glutamic O
acid O
(4a) O
was O
designed O
as O
a O
structural O
hybrid O
between O
1 O
and O
3 O
. O
4a O
was O
shown O
to O
be O
a O
potent O
GluR5 O
agonist O
and O
a O
high O
affinity O
ligand O
and O
to O
indiscriminately O
bind O
to O
the O
AMPA O
receptor O
subtypes O
GluR1-4 O
with O
lower O
affinities O
. O
Compounds O
4b-h O
, O
in O
which O
the O
2-thiazolyl O
substituent O
of O
4a O
was O
replaced O
by O
other O
heterocyclic O
rings O
, O
which O
have O
previously O
been O
incorporated O
as O
5-substituents O
in O
AMPA O
analogues O
, O
as O
exemplified O
by O
1 O
were O
also O
synthesized O
. O
Compounds O
4b-h O
were O
either O
inactive O
(4e,f) O
or O
weaker O
than O
4a O
as O
affinity O
ligands O
for O
GluR1-4 O
and O
GluR5 O
with O
relative O
potencies O
comparable O
with O
those O
of O
the O
corresponding O
AMPA O
analogues O
as O
AMPA O
receptor O
agonists O
. O
Compounds O
4a-h O
may O
be O
useful O
tools O
for O
the O
progressing O
pharmacophore O
mapping O
of O
the O
GluR5 O
agonist O
binding O
site O
. O

DXM O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
IL-4 O
stimulates O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
VEGF O
, O
and O
inducible O
nitric O
oxide O
synthase O
mRNA O
by O
equine O
pulmonary O
artery O
endothelial O
cells.Little O
is O
known O
concerning O
the O
possible O
contribution O
of O
T O
helper O
2 O
(Th2)-type O
cytokines O
to O
the O
recruitment O
of O
neutrophils O
into O
the O
lung O
tissue O
. O
In O
the O
present O
study O
, O
endothelial O
cells O
from O
equine O
pulmonary O
arteries O
were O
cultured O
in O
the O
presence O
of O
recombinant O
equine O
(re) O
IL-4 O
and O
reIL-5 O
, O
and O
the O
cytokine O
mRNA O
expression O
of O
molecules O
implicated O
in O
the O
chemotaxis O
and O
migration O
of O
neutrophils O
was O
studied O
using O
real-time O
RT-PCR O
. O
The O
functional O
response O
of O
reIL-4-induced O
endothelial O
cell O
stimulation O
on O
neutrophil O
migration O
was O
also O
studied O
using O
a O
chemotaxis O
chamber O
. O
ReIL-4 O
either O
increased O
the O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
vascular O
endothelial O
growth O
factor O
(VEGF) O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor O
necrosis O
factor-alpha O
(TNF-alpha) O
on O
CXCL-8 O
. O
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 O
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner O
. O
Dexamethasone O
(DXM) O
decreased O
the O
expression O
of O
CXCL-8 B
, O
VEGF O
, O
and O
iNOS O
induced O
by O
reIL-4 O
, O
while O
1400W O
dihydrochloride O
(1400W) O
, O
a O
selective O
inhibitor O
of O
iNOS O
, O
decreased O
the O
expression O
of O
E-selectin O
, O
VEGF O
, O
and O
iNOS O
. O
DXM O
and O
1400W O
attenuated O
the O
mRNA O
expression O
of O
E-selectin O
and O
iNOS O
induced O
by O
the O
costimulation O
of O
reIL-4 O
, O
reTNF-alpha O
, O
and O
LPS O
. O
Neither O
equine O
nor O
human O
recombinant O
IL-5 O
influenced O
the O
mRNA O
expression O
of O
CXCL-8 O
, O
E-selectin O
, O
or O
VEGF O
. O
These O
findings O
suggest O
that O
Th2-type O
cytokines O
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O
expression O
of O
neutrophil O
chemokines O
and O
adhesion O
molecules O
by O
endothelial O
cells O
. O
DXM O
and O
the O
iNOS O
inhibitors O
may O
decrease O
pulmonary O
neutrophilia O
due O
, O
in O
part O
, O
to O
a O
direct O
inhibition O
of O
some O
of O
these O
factors O
. O

Dioscin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Dioscin-induced O
autophagy O
mitigates O
cell O
apoptosis O
through O
modulation O
of O
PI3K/Akt O
and O
ERK O
and O
JNK O
signaling O
pathways O
in O
human O
lung O
cancer O
cell O
lines.Our O
previous O
study O
has O
revealed O
that O
dioscin O
, O
a O
compound O
with O
anti-inflammatory O
, O
lipid-lowering O
, O
anticancer O
and O
hepatoprotective O
effects O
, O
may O
induce O
autophagy O
in O
hepatoma O
cells O
. O
Autophagy O
is O
a O
lysosomal O
degradation O
pathway O
that O
is O
essential O
for O
cell O
survival O
and O
tissue O
homeostasis O
. O
In O
this O
study O
, O
the O
role O
of O
autophagy O
and O
related O
signaling O
pathways O
during O
dioscin-induced O
apoptosis O
in O
human O
lung O
cancer O
cells O
was O
investigated O
. O
Results O
from O
4'-6-diamidino-2-phenylindole O
and O
annexin-V/PI O
double-staining O
assay O
showed O
that O
caspase-3- O
and O
caspase-8-dependent O
, O
and O
dose-dependent O
apoptoses O
were O
detected O
after O
a O
24-h O
dioscin O
treatment O
. O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
, O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II O
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O
and O
JNK1/2 B
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin-induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction O
. O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Effects O
of O
17α-ethynylestradiol-induced O
cholestasis O
on O
the O
pharmacokinetics O
of O
doxorubicin O
in O
rats O
: O
reduced O
biliary O
excretion O
and O
hepatic O
metabolism O
of O
doxorubicin.Abstract O
1 O
. O
Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen O
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein O
(P-gp) O
and O
multidrug O
resistance-associated O
protein O
2 O
( O
Mrp2) B
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
(CYP) O
3A O
subfamily O
. O
Also O
the O
hepatic O
Mrp2 O
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats O
. O
Thus O
, O
we O
herein O
report O
the O
pharmacokinetic O
changes O
of O
doxorubicin O
with O
respect O
to O
the O
changes O
in O
its O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
EEC O
rats O
. O
2 O
. O
The O
pharmacokinetic O
study O
of O
doxorubicin O
after O
intravenous O
administration O
of O
its O
hydrochloride O
was O
conducted O
along O
with O
the O
investigation O
of O
bile O
flow O
rate O
and O
hepatobiliary O
excretion O
of O
doxorubicin O
in O
control O
and O
EEC O
rats O
. O
3 O
. O
The O
significantly O
greater O
AUC O
(58.7% O
increase) O
of O
doxorubicin O
in O
EEC O
rats O
was O
due O
to O
the O
slower O
CL O
(32.9% O
decrease) O
. O
The O
slower O
CL O
was O
due O
to O
the O
reduction O
of O
hepatic O
biliary O
excretion O
(67.0% O
decrease) O
and O
hepatic O
CYP3A O
subfamily-mediated O
metabolism O
(21.9% O
decrease) O
of O
doxorubicin O
. O
These O
results O
might O
have O
broader O
implications O
to O
understand O
the O
altered O
pharmacokinetics O
and/or O
pharmacologic O
effects O
of O
doxorubicin O
via O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
experimental O
and O
clinical O
estrogen-induced O
cholestasis O
. O

1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
and O
related O
compounds O
as O
cyclooxygenase-2 B
inhibiting O
nitric O
oxide O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 O
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O
ethers O
(9 O
, O
10) O
into O
corresponding O
alcohols O
, O
derivatives O
17 O
and O
18 O
were O
also O
studied O
. O
Nitrooxy O
derivatives O
showed O
NO-dependent O
vasorelaxing O
properties O
, O
while O
most O
of O
the O
compounds O
proved O
to O
be O
very O
potent O
and O
selective O
COX-2 O
inhibitors O
in O
in O
vitro O
experimental O
models O
. O
Further O
in O
vivo O
studies O
on O
compounds O
9a,c O
and O
17a O
highlighted O
good O
anti-inflammatory O
and O
antinociceptive O
activities O
. O
Compound O
9c O
was O
able O
to O
inhibit O
glycosaminoglycan O
(GAG) O
release O
induced O
by O
interleukin-1β O
(IL-1β) O
, O
showing O
cartilage O
protective O
properties O
. O
Finally O
, O
molecular O
modeling O
and O
(1)H- O
and O
(13)C-NMR O
studies O
performed O
on O
compounds O
6c,d O
, O
9c O
, O
and O
10b O
allowed O
the O
right O
conformation O
of O
nitrooxyalkyl O
ester O
and O
ether O
side O
chain O
of O
these O
molecules O
within O
the O
COX-2 O
active O
site O
to O
be O
assessed O
. O

Ca O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Antithrombin O
binding O
of O
low O
molecular O
weight O
heparins O
and O
inhibition O
of O
factor O
Xa.Fluorescence O
and O
stopped O
flow O
methods O
were O
used O
to O
compare O
clinically O
used O
heparins O
with O
regard O
to O
their O
ability O
to O
bind O
to O
antithrombin O
and O
to O
accelerate O
the O
inactivation O
of O
factor O
Xa O
. O
Titration O
of O
antithrombin O
with O
both O
low O
molecular O
weight O
heparin O
(LMWH) O
(enoxaparin O
, O
fragmin O
and O
ardeparin) O
and O
unfractionated O
heparin O
(UFH) O
produced O
an O
equivalent O
fluorescence O
increase O
and O
indicates O
similar O
affinity O
of O
all O
heparin O
preparations O
to O
antithrombin O
. O
However O
, O
relative O
to O
UFH O
enoxaparin O
, O
the O
LMWH O
with O
the O
smallest O
average O
molecular O
mass O
, O
contained O
only O
12% O
material O
with O
high O
affinity O
for O
antithrombin O
. O
The O
rate O
of O
factor O
Xa O
inhibition O
by O
antithrombin O
increased O
with O
the O
concentration O
of O
the O
examined O
heparins O
to O
the O
same O
limiting O
value O
, O
but O
the O
concentration O
required O
for O
maximal O
acceleration O
depended O
on O
the O
preparation O
. O
According O
to O
these O
data O
the O
high O
affinity O
fraction O
of O
the O
heparin O
preparations O
increased O
the O
intrinsic O
fluorescence O
and O
inhibitory O
activity O
equally O
without O
additional O
effects O
by O
variations O
in O
chain O
length O
and O
chemical O
composition O
. O
In O
contrast O
, O
in O
the O
presence O
of O
Ca O
UFH O
accelerated O
the O
inhibition O
of O
factor O
Xa O
by O
antithrombin B
10-fold O
more O
efficiently O
than O
comparable O
concentrations O
of O
the O
high O
affinity O
fractions O
of O
enoxaparin O
and O
fragmin O
. O
The O
bell-shaped O
dependence O
of O
this O
accelerating O
effect O
suggests O
simultaneous O
binding O
of O
both O
proteins O
to O
heparin O
. O
In O
conclusion O
, O
under O
physiologic O
conditions O
the O
anti-factor O
Xa O
activity O
of O
heparin O
results O
from O
a O
composite O
effect O
of O
chain O
length O
and O
the O
content O
of O
material O
with O
high O
affinity O
to O
antithrombin O
. O
Thus O
, O
the O
reduced O
antithrombotic O
activity O
of O
LMWH O
relative O
to O
UFH O
results O
from O
a O
smaller O
content O
of O
high O
affinity O
material O
and O
the O
absence O
of O
a O
stimulating O
effect O
of O
calcium O
. O

Leucyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Functional O
divergence O
of O
a O
unique O
C-terminal O
domain O
of O
leucyl-tRNA O
synthetase O
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles O
. O
Leucyl-tRNA B
synthetase I
(LeuRS) O
performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria O
. O
Deletions O
of O
the O
C O
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo O
. O
Herein O
, O
we O
determined O
that O
a O
fiveamino O
acid O
C-terminal O
deletion O
of O
LeuRS O
, O
which O
does O
not O
complement O
a O
null O
strain O
, O
can O
form O
a O
ternary O
complex O
with O
the O
bI4 O
intron O
and O
its O
maturase O
splicing O
partner O
. O
However O
, O
the O
complex O
fails O
to O
stimulate O
splicing O
activity O
. O
The O
x-ray O
co-crystal O
structure O
of O
LeuRS O
showed O
that O
a O
C-terminal O
extension O
of O
about O
60 O
amino O
acids O
forms O
a O
discrete O
domain O
, O
which O
is O
unique O
among O
the O
LeuRSs O
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu O
. O
Interestingly O
, O
deletion O
of O
the O
entire O
yeast O
mitochondrial O
LeuRS O
C-terminal O
domain O
enhanced O
its O
aminoacylation O
and O
amino O
acid O
editing O
activities O
. O
In O
striking O
contrast O
, O
deletion O
of O
the O
corresponding O
C-terminal O
domain O
of O
Escherichia O
coli O
LeuRS O
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino O
acid O
editing O
of O
mischarged O
tRNA O
molecules O
. O
These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific O
C-terminal O
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino O
acid O
editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects O
. O
We O
propose O
that O
the O
secondary O
role O
of O
yeast O
mitochondrial O
LeuRS O
in O
RNA O
splicing O
has O
impacted O
the O
functional O
evolution O
of O
this O
critical O
C-terminal O
domain O
. O

Iressa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine O
kinase O
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2 B
-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O
EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O
sensitivity O
to O
ZD1839 O
have O
been O
studied O
. O
In O
a O
panel O
of O
human O
breast O
cancer O
and O
other O
epithelial O
tumor O
cell O
lines O
, O
HER2-overexpressing O
tumors O
were O
particularly O
sensitive O
to O
ZD1839 O
. O
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR O
, O
HER2 O
, O
and O
HER3 O
, O
accompanied O
by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol O
3-kinase O
, O
and O
down-regulation O
of O
Akt O
activity O
. O
These O
studies O
suggest O
that O
HER2-overexpressing O
tumors O
are O
particularly O
susceptible O
to O
the O
inhibition O
of O
HER O
family O
tyrosine O
kinase O
signaling O
and O
suggest O
novel O
strategies O
to O
treat O
these O
particularly O
aggressive O
tumors O
. O

aurothioglucose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Reduction O
of O
dimethylarsinic O
acid O
to O
the O
highly O
toxic O
dimethylarsinous O
acid O
by O
rats O
and O
rat O
liver O
cytosol.Dimethylarsinic O
acid O
(DMAs(V)) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic O
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous O
acid O
(DMAs(III)) O
, O
is O
highly O
toxic O
. O
Although O
glutathione O
S-transferase O
omega O
1 O
(GSTO1) O
and O
arsenic O
methyltransferase O
have O
been O
shown O
or O
thought O
to O
catalyze O
DMAs(V) O
reduction O
, O
their O
role O
in O
DMAs(V) O
reduction O
in O
vivo O
, O
or O
in O
cell O
extracts O
is O
uncertain O
. O
Therefore O
, O
the O
reduction O
of O
DMAs(V) O
to O
DMAs(III) O
in O
rats O
and O
in O
rat O
liver O
cytosol O
was O
studied O
to O
better O
understand O
its O
mechanism O
. O
To O
assess O
DMAs(V) O
reduction O
in O
rats O
, O
a O
novel O
procedure O
was O
devised O
based O
on O
following O
the O
accumulation O
of O
red O
blood O
cell O
(RBC)-bound O
dimethylarsenic O
(DMAs) O
, O
which O
represents O
DMAs(III) O
, O
in O
the O
blood O
of O
DMAs(V)-injected O
anesthetized O
rats O
. O
These O
studies O
indicated O
that O
rats O
reduced O
DMAs(V) O
to O
DMAs(III) O
to O
a O
significant O
extent O
, O
as O
in O
90 O
min O
31% O
of O
the O
injected O
50 O
μmol/kg O
DMAs(V) O
dose O
was O
converted O
to O
DMAs(III) O
that O
was O
sequestered O
by O
the O
circulating O
erythrocytes O
. O
Pretreatment O
of O
rats O
with O
glutathione O
(GSH) O
depletors O
(phorone O
or O
BSO) O
delayed O
the O
elimination O
of O
DMAs(V) O
and O
the O
accumulation O
of O
RBC-bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase O
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin O
reductase O
( O
TRR) B
inhibitors O
(aurothioglucose O
and O
Sb(III)) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH O
. O
Such O
experiments O
also O
suggested O
that O
the O
reducing O
enzyme O
was O
larger O
than O
100 O
kDa O
and O
was O
not O
GSTO1 O
. O
In O
summary O
, O
reduction O
of O
DMAs(V) O
to O
the O
highly O
toxic O
DMAs(III) O
in O
rats O
and O
rat O
liver O
cytosol O
is O
a O
GSH-dependent O
enzymatic O
process O
, O
yet O
its O
mechanism O
remains O
uncertain O
. O

rifampicin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Roles O
of O
rifampicin O
in O
drug-drug O
interactions O
: O
underlying O
molecular O
mechanisms O
involving O
the O
nuclear B
pregnane I
X I
receptor I
.Rifampicin O
, O
an O
important O
drug O
in O
the O
treatment O
of O
tuberculosis O
, O
is O
used O
extensively O
despite O
its O
broad O
effects O
on O
drug-drug O
interactions O
, O
creating O
serious O
problems O
. O
The O
clinical O
importance O
of O
such O
interactions O
includes O
autoinduction O
leading O
to O
suboptimal O
or O
failed O
treatment O
. O
The O
concomitantly O
administered O
effects O
of O
rifampicin O
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes O
P450 O
or O
transported O
by O
p-glycoprotein O
in O
the O
gastrointestinal O
tract O
and O
liver O
. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions O
. O
In O
general O
, O
rifampicin O
can O
act O
on O
a O
pattern O
: O
rifampicin O
activates O
the O
nuclear O
pregnane O
X O
receptor O
that O
in O
turn O
affects O
cytochromes O
P450 O
, O
glucuronosyltransferases O
and O
p-glycoprotein O
activities O
. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin O
inducing O
drug-drug O
interactions O
. O
However O
, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O
of O
such O
drug-drug O
interactions O
more O
complex O
. O

Gal O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K-Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T B
reaction O
. O

Catecholamines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline O
with O
the O
catalytic O
site O
of O
phenylalanine O
4-monooxygenase.Catecholamines O
(adrenaline O
, O
noradrenaline O
and O
dopamine) O
are O
potent O
inhibitors O
of O
phenylalanine O
4-monooxygenase O
(phenylalanine O
hydroxylase O
, O
EC B
1.14.16.1) I
 O
. O
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O
the O
active O
site O
(charge O
transfer O
interaction) O
, O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy O
. O
Experimental O
evidence O
is O
presented O
that O
a O
group O
with O
an O
apparent O
pKa O
value O
of O
about O
5.1 O
(20 O
degrees O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine O
and O
the O
enzyme O
. O
The O
high-affinity O
binding O
of O
L-noradrenaline O
to O
phenylalanine O
hydroxylase O
, O
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically) O
, O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O
pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol O
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline O
. O
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed O
. O
The O
affinity O
decreases O
with O
decreasing O
pH O
, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine O
, O
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O
the O
activator O
N-ethylmaleimide O
. O
Preincubation O
of O
the O
enzyme O
with O
L-phenylalanine O
also O
leads O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline O
binding O
(h O
= O
1.0) O
. O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline O
and O
the O
activator/substrate O
L-phenylalanine O
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site O
. O
The O
high-affinity O
of O
catecholamines O
to O
phenylalanine O
hydroxylase O
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O
the O
homologous O
enzyme O
tyrosine O
hydroxylase O
, O
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) O
complex O
. O

Licofelone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Licofelone O
, O
a O
balanced O
inhibitor O
of O
cyclooxygenase B
and O
5-lipoxygenase O
, O
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis.Licofelone O
, O
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase O
(LOX) O
and O
cyclooxygenase O
(COX) O
enzymes O
, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 O
inhibitors O
due O
to O
cycloxygenase-1 O
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability O
. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone O
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O
whole O
blood O
of O
rabbits O
compared O
with O
a O
selective O
inhibitor O
of O
COX-2 O
, O
rofecoxib O
. O
We O
also O
assessed O
the O
antithrombotic O
effect O
of O
licofelone O
in O
rabbit O
platelet-rich O
plasma O
. O
For O
this O
purpose O
, O
30 O
rabbits O
underwent O
injury O
of O
femoral O
arteries O
, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone O
or O
5 O
mg/kg/day O
rofecoxib O
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases O
. O
Ten O
healthy O
rabbits O
were O
used O
as O
controls O
. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies O
. O
Licofelone O
reduced O
intima/media O
ratio O
in O
injured O
arteries O
, O
the O
macrophages O
infiltration O
in O
the O
neointimal O
area O
, O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
gene O
expression O
, O
and O
the O
activation O
of O
nuclear O
factor-kappaB O
in O
rabbit O
atheroma O
. O
Moreover O
, O
licofelone O
inhibited O
COX-2 O
and O
5-LOX O
protein O
expression O
in O
vascular O
lesions O
. O
Rofecoxib O
only O
diminished O
COX-2 O
protein O
expression O
and O
MCP-1 O
gene O
expression O
in O
vascular O
atheroma O
. O
Prostaglandin O
E(2) O
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs O
. O
Licofelone O
almost O
abolished O
5-LOX O
activity O
by O
inhibiting O
leukotriene O
B4 O
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane O
B2 O
production O
from O
whole O
blood O
. O
Licofelone O
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib O
. O
This O
effect O
, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone O
, O
suggests O
that O
this O
drug O
may O
have O
a O
favorable O
cardiovascular O
profile O
. O

imatinib O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dasatinib O
(BMS-354825) O
inhibits O
KITD816V O
, O
an O
imatinib-resistant O
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis.Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT O
oncoprotein O
(KITD816V) O
that O
results O
in O
autophosphorylation O
of O
the O
KIT O
receptor O
in O
a O
ligand-independent O
manner O
. O
This O
mutation O
is O
inherently O
resistant O
to O
imatinib O
and O
, O
to O
date O
, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V O
. O
Dasatinib O
(BMS-354825) O
is O
a O
novel O
orally O
bioavailable O
SRC/ABL O
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant O
BCR-ABL O
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML) O
. O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O
concentrations O
of O
dasatinib O
can O
be O
achieved O
safely O
in O
humans O
. O
In O
this O
study O
, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib O
against O
both O
wild-type O
KIT O
and O
the O
KITD816V O
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase O
assays O
. O
Additionally O
, O
dasatinib O
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring O
human O
masto-cytosis O
cell O
line O
. O
Significantly O
, O
dasatinib O
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O
sparing O
other O
hematopoietic O
cells O
. O
Computer O
modeling O
suggests O
that O
the O
KITD B
816V O
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT O
activation O
loop O
to O
which O
imatinib O
binds O
, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT O
by O
dasatinib O
. O
Based O
upon O
our O
results O
, O
further O
evaluation O
of O
dasatinib O
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted O
. O
Moreover O
, O
dasatinib O
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT O
mutations O
. O

cobalamin O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Co-C O
bond O
activation O
in O
methylmalonyl-CoA B
mutase I
by O
stabilization O
of O
the O
post-homolysis O
product O
Co2+ O
cobalamin.Despite O
decades O
of O
research O
, O
the O
mechanism O
by O
which O
coenzyme O
B12 O
(adenosylcobalamin O
, O
AdoCbl)-dependent O
enzymes O
promote O
homolytic O
cleavage O
of O
the O
cofactor's O
Co-C O
bond O
to O
initiate O
catalysis O
has O
continued O
to O
elude O
researchers O
. O
In O
this O
work O
, O
we O
utilized O
magnetic O
circular O
dichroism O
spectroscopy O
to O
explore O
how O
the O
electronic O
structure O
of O
the O
reduced O
B12 O
cofactor O
(i.e. O
, O
the O
post-homolysis O
product O
Co2+ O
Cbl) O
is O
modulated O
by O
the O
enzyme O
methylmalonyl-CoA O
mutase O
. O
Our O
data O
reveal O
a O
fairly O
uniform O
stabilization O
of O
the O
Co O
3d O
orbitals O
relative O
to O
the O
corrin O
pi/pi*-based O
molecular O
orbitals O
when O
Co2+ O
Cbl O
is O
bound O
to O
the O
enzyme O
active O
site O
, O
particularly O
in O
the O
presence O
of O
substrate O
. O
Contrastingly O
, O
our O
previous O
studies O
(Brooks O
, O
A O
. O
J.; O
Vlasie O
, O
M.; O
Banerjee O
, O
R.; O
Brunold O
, O
T O
. O
C O
. O
J O
. O
Am O
. O
Chem O
. O
Soc O
. O
2004 O
, O
126 O
, O
8167-8180.) O
showed O
that O
when O
AdoCbl O
is O
bound O
to O
the O
MMCM O
active O
site O
, O
no O
enzymatic O
perturbation O
of O
the O
Co3+ O
Cbl O
electronic O
structure O
occurs O
, O
even O
in O
the O
presence O
of O
substrate O
(analogues) O
. O
Collectively O
, O
these O
observations O
provide O
direct O
evidence O
that O
enzymatic O
Co-C O
bond O
activation O
involves O
stabilization O
of O
the O
post-homolysis O
product O
, O
Co2+ O
Cbl O
, O
rather O
than O
destabilization O
of O
the O
Co3+ O
Cbl O
"ground" O
state O
. O

UDP-Gal O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mutation O
of O
arginine O
228 O
to O
lysine O
enhances O
the O
glucosyltransferase O
activity O
of O
bovine O
beta-1,4-galactosyltransferase O
I.Beta-1,4-galactosyltransferase O
I O
(beta4Gal-T1) O
normally O
transfers O
Gal O
from O
UDP-Gal O
to O
GlcNAc O
in O
the O
presence O
of O
Mn(2+) O
ion O
(Gal-T O
activity) O
and O
also O
transfers O
Glc O
from O
UDP-Glc O
to O
GlcNAc O
(Glc-T O
activity) O
, O
albeit O
at O
only O
0.3% O
efficiency O
. O
In O
addition O
, O
alpha-lactalbumin O
(LA) O
enhances O
this O
Glc-T O
activity O
more O
than O
25 O
times O
. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- O
and O
UDP-Glc-bound O
beta4Gal-T1 O
reveals O
that O
the O
O4 O
hydroxyl O
group O
in O
both O
Gal O
and O
Glc O
moieties O
forms O
a O
hydrogen O
bond O
with O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
. O
The O
orientation O
of O
the O
O4 O
hydroxyl O
of O
glucose O
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate O
group O
of O
Glu317 O
, O
accounting O
for O
the O
enzyme's O
low O
Glc-T O
activity O
. O
In O
this O
study O
, O
we O
show O
that O
mutation O
of O
Arg228 O
, O
a O
residue O
in O
the O
vicinity O
of O
Glu317 O
, O
to O
lysine O
(R228K-Gal-T1) O
results O
in O
a O
15-fold O
higher O
Glc-T O
activity O
, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T O
activity O
of O
the O
wild O
type O
. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine O
is O
on O
the O
k(cat) O
of O
Glc-T O
, O
which O
increases O
3-4-fold O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously O
, O
the O
k(cat) O
for O
the O
Gal-T O
reaction O
is O
reduced O
30-fold O
. O
The O
crystal O
structure O
of O
R228K- B
Gal-T1 O
complexed O
with O
LA O
, O
UDP-Gal O
, O
and O
Mn(2+) O
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation O
, O
compared O
to O
that O
in O
the O
wild O
type O
. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 O
hydroxyl O
group O
of O
the O
Gal O
moiety O
of O
UDP-Gal O
, O
probably O
causing O
the O
dissociation O
of O
UDP-Gal O
and O
the O
reduced O
k(cat) O
of O
the O
Gal-T O
reaction O
. O

clofibrate O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS B
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O
(GAS) O
, O
nuclear O
factor-kappaB O
(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O
CCAAT/enhancer-binding O
protein O
beta O
(C/EBPbeta); O
therefore O
, O
we O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

eformoterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Arformoterol O
: O
(R,R)-eformoterol O
, O
(R,R)-formoterol O
, O
arformoterol O
tartrate O
, O
eformoterol-sepracor O
, O
formoterol-sepracor O
, O
R,R-eformoterol O
, O
R,R-formoterol.Sepracor O
in O
the O
US O
is O
developing O
arformoterol O
[R,R-formoterol] O
, O
a O
single O
isomer O
form O
of O
the O
beta(2)-adrenoceptor B
agonist O
formoterol O
[eformoterol] O
. O
This O
isomer O
contains O
two O
chiral O
centres O
and O
is O
being O
developed O
as O
an O
inhaled O
preparation O
for O
the O
treatment O
of O
respiratory O
disorders O
. O
Sepracor O
believes O
that O
arformoterol O
has O
the O
potential O
to O
be O
a O
once-daily O
therapy O
with O
a O
rapid O
onset O
of O
action O
and O
a O
duration O
of O
effect O
exceeding O
12 O
hours O
. O
In O
1995 O
, O
Sepracor O
acquired O
New O
England O
Pharmaceuticals O
, O
a O
manufacturer O
of O
metered-dose O
and O
dry O
powder O
inhalers O
, O
for O
the O
purpose O
of O
preparing O
formulations O
of O
levosalbutamol O
and O
arformoterol O
. O
Phase O
II O
dose-ranging O
clinical O
studies O
of O
arformoterol O
as O
a O
longer-acting O
, O
complementary O
bronchodilator O
were O
completed O
successfully O
in O
the O
fourth O
quarter O
of O
2000 O
. O
Phase O
III O
trials O
of O
arformoterol O
began O
in O
September O
2001 O
. O
The O
indications O
for O
the O
drug O
appeared O
to O
be O
asthma O
and O
chronic O
obstructive O
pulmonary O
disease O
(COPD) O
. O
However O
, O
an O
update O
of O
the O
pharmaceutical O
product O
information O
on O
the O
Sepracor O
website O
in O
September O
2003 O
listed O
COPD O
maintenance O
therapy O
as O
the O
only O
indication O
for O
arformoterol O
. O
In O
October O
2002 O
, O
Sepracor O
stated O
that O
two O
pivotal O
phase O
III O
studies O
were O
ongoing O
in O
1600 O
patients O
. O
Sepracor O
estimates O
that O
its O
NDA O
submission O
for O
arformoterol O
, O
which O
is O
projected O
for O
the O
first O
half O
of O
2004 O
, O
will O
include O
approximately O
3000 O
adult O
subjects O
. O
Sepracor O
stated O
in O
July O
2003 O
that O
it O
had O
completed O
more O
than O
100 O
preclinical O
studies O
and O
initiated O
or O
completed O
15 O
clinical O
studies O
for O
arformoterol O
inhalation O
solution O
for O
the O
treatment O
of O
bronchospasm O
in O
patients O
with O
COPD O
. O
In O
addition O
, O
Sepracor O
stated O
that O
the O
two O
pivotal O
phase O
III O
studies O
in O
1600 O
patients O
were O
still O
progressing O
. O
In O
1995 O
, O
European O
patents O
were O
granted O
to O
Sepracor O
for O
the O
use O
of O
arformoterol O
in O
the O
treatment O
of O
asthma O
, O
and O
the O
US O
patent O
application O
was O
pending O
. O

m-CPBG O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Central O
5-HT3 O
receptor O
stimulation O
by O
m-CPBG O
increases O
blood O
glucose O
in O
rats.The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
role O
of O
central O
5-HT3 O
receptors O
on O
the O
control O
of O
blood O
glucose O
in O
stressed O
and O
non-stressed O
rats O
in O
both O
fasted O
and O
fed O
states O
. O
Adult O
Wistar O
male O
rats O
had O
each O
their O
third O
ventricle O
cannulated O
7 O
days O
before O
the O
experiments O
. O
Injections O
of O
m-CPBG O
, O
a O
selective O
5-HT3 O
receptor O
agonist O
, O
induced O
a O
significant O
increase O
in O
blood O
glucose O
in O
non-stressed O
rats O
in O
both O
fasted O
and O
in O
fed O
states O
. O
The O
same O
procedure O
was O
unable O
to O
modify O
stress-induced O
hyperglycemia O
. O
The O
hyperglycemic O
effect O
of O
m-CPBG O
central O
administration O
was O
blocked O
by O
pretreatment O
with O
ondansetron O
, O
a O
specific O
5-HT3 O
receptor O
antagonist O
, O
indicating O
that O
the O
effects O
here O
obtained O
with O
m-CPBG O
were O
a O
result O
of O
its O
interaction O
with O
5-HT3 B
receptors O
. O
Third O
ventricle O
injections O
of O
ondansetron O
alone O
were O
not O
able O
to O
modify O
blood O
glucose O
in O
non-stressed O
animals O
and O
did O
not O
change O
the O
hyperglycemic O
responses O
observed O
after O
immobilization O
stress O
. O
We O
conclude O
that O
pharmacological O
activation O
of O
the O
central O
5-HT3 O
receptor O
induces O
a O
hyperglycemic O
effect O
in O
non-stressed O
animals O
. O

fluorescein O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil-Based O
Fluorescein O
Conjugates O
as O
GluN1/GluN2B O
N-Methyl-D-aspartate O
Receptor O
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O
the O
relationships O
between O
receptor O
localisation O
and O
physiological O
importance O
. O
Ifenprodil O
, O
known O
as O
the O
GluNR2B O
antagonist O
of O
reference O
, O
was O
chosen O
as O
the O
template O
for O
the O
elaboration O
of O
probes O
. O
We O
had O
previously O
reported O
a O
fluorescein O
conjugate O
that O
was O
shown O
(by O
confocal O
microscopy O
imaging O
of O
DS-red-labelled O
cortical O
neurons) O
to O
bind O
specifically O
to O
GluN2B B
. O
To O
elaborate O
this O
probe O
, O
we O
explored O
the O
influence O
of O
both O
the O
nature O
and O
the O
attachment O
point O
of O
the O
spacer O
between O
the O
fluorophore O
and O
the O
parent O
compound O
, O
ifenprodil O
. O
We O
performed O
chemical O
modifications O
of O
ifenprodil O
at O
the O
benzylic O
position O
and O
on O
the O
phenol O
ring O
by O
introducing O
secondary O
amine O
or O
amide O
functions O
and O
evaluated O
alkyl O
chains O
from O
two O
to O
20 O
bonds O
either O
including O
or O
not O
including O
secondary O
amide O
functions O
as O
spacers O
. O
The O
previously O
developed O
probe O
was O
found O
to O
display O
the O
greatest O
activity O
in O
the O
inhibition O
of O
NMDA-induced O
Ca(2+) O
influx O
by O
calcium O
imaging O
experiments O
on O
HEK293 O
cells O
transfected O
with O
the O
cDNA O
encoding O
for O
GluN1-1A O
and O
GluN2B O
. O
Further O
investigations O
revealed O
that O
this O
probe O
had O
a O
neuroprotective O
effect O
equivalent O
to O
that O
of O
ifenprodil O
in O
a O
standard O
test O
for O
neurotoxicity O
. O
Despite O
effects O
of O
lesser O
amplitude O
with O
these O
probes O
relative O
to O
ifenprodil O
, O
we O
demonstrated O
that O
they O
displaced O
[(3) O
H]ifenprodil O
in O
mouse O
brain O
slices O
in O
a O
similar O
manner O
. O

Oxysterols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Oxysterols O
in O
cancer O
cell O
proliferation O
and O
death.Oxysterols O
have O
been O
shown O
to O
interfere O
with O
proliferation O
and O
cause O
the O
death O
of O
many O
cancer O
cell O
types O
, O
such O
as O
leukaemia O
, O
glioblastoma O
, O
colon O
, O
breast O
and O
prostate O
cancer O
cells O
, O
while O
they O
have O
little O
or O
no O
effect O
on O
senescent O
cells O
. O
The O
mechanisms O
by O
which O
oxysterols O
may O
influence O
proliferation O
are O
manifold O
: O
they O
control O
the O
transcription O
and O
the O
turnover O
of O
the O
key O
enzyme O
in O
cholesterol O
synthesis O
, O
3-hydroxy-3-methylglutaryl O
CoA O
reductase O
, O
by O
binding O
to O
Insig-1 O
, O
Insig-2 O
and O
liver O
X O
receptors O
. O
Oxysterols O
are O
thought O
to O
be O
generated O
in O
proportion O
to O
the O
rate O
of O
cholesterol O
synthesis O
. O
Although O
there O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols O
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
. O
Oxysterols O
interfere O
with O
ERK O
, O
hedgehog O
and O
wnt B
pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols O
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O
Perhaps O
is O
it O
sufficient O
to O
stop O
proliferation O
of O
a O
cancer O
to O
provoke O
its O
eradication O
. O
Therefore O
, O
the O
two O
facets O
of O
oxysterol O
action O
that O
seem O
important O
for O
cancer O
treatment O
, O
cytostaticity O
and O
cytotoxicity O
, O
will O
be O
discussed O
. O

cicaprost O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Prostacyclin O
analogues O
inhibit O
tissue O
factor O
expression O
in O
the O
human O
monocytic O
cell O
line O
THP-1 O
via O
a O
cyclic O
AMP-dependent O
mechanism.Increased O
expression O
of O
tissue O
factor O
procoagulant O
by O
peripheral O
blood O
monocytes O
has O
been O
implicated O
in O
a O
number O
of O
thrombotic O
disorders O
. O
The O
present O
studies O
were O
undertaken O
to O
determine O
whether O
stable O
analogues O
of O
prostacyclin O
, O
a O
potent O
endothelium-derived O
platelet O
inhibitor O
and O
vasodilator O
, O
could O
inhibit O
tissue O
factor O
expression O
by O
human O
monocytic O
cells O
. O
Exposure O
of O
monocytic O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin O
, O
2 O
units/ml O
interleukin-1 O
beta O
, O
or O
5 O
ng/ml O
tumor O
necrosis O
factor-alpha O
for O
4 O
hours O
led O
to O
increased O
tissue O
factor O
procoagulant O
activity O
. O
Preincubation O
for O
30 O
minutes O
with O
iloprost O
, O
ciprostene O
, O
and O
carbacyclin O
led O
to O
a O
dose-dependent O
inhibition O
of O
tissue O
factor O
expression O
induced O
by O
all O
three O
challenging O
agents O
. O
Iloprost O
was O
the O
most O
potent O
: O
50% O
inhibition O
occurred O
at O
5 O
nM O
, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost O
binding O
to O
the O
platelet O
prostacyclin O
receptor O
. O
An O
orally O
active O
analogue O
, O
cicaprost O
, O
was O
equally O
effective O
against O
endotoxin-induced O
tissue B
factor I
expression O
. O
Carbacyclin O
and O
ciprostene O
were O
100 O
times O
less O
potent O
. O
Iloprost O
prevented O
the O
endotoxin-induced O
expression O
of O
tissue O
factor O
antigen O
on O
the O
surface O
of O
THP-1 O
cells O
, O
as O
determined O
by O
flow O
cytometry O
. O
Iloprost O
(500 O
pM-50 O
nM) O
increased O
intracellular O
levels O
of O
cyclic O
AMP O
. O
This O
effect O
was O
potentiated O
by O
isobutylmethylxanthine O
, O
an O
inhibitor O
of O
phosphodiesterase O
. O
The O
inhibitory O
effects O
of O
iloprost O
on O
tissue O
factor O
expression O
were O
also O
potentiated O
by O
isobutylmethylxanthine O
and O
mimicked O
by O
forskolin O
and O
dibutyryl O
cyclic O
AMP O
but O
not O
dibutyryl O
cyclic O
GMP O
. O
These O
results O
suggest O
that O
prostacyclin O
may O
play O
a O
role O
in O
downregulating O
tissue O
factor O
expression O
in O
monocytes O
, O
at O
least O
in O
part O
via O
elevation O
of O
intracellular O
levels O
of O
cyclic O
AMP O
. O

NO O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dynamics O
of O
NO O
rebinding O
to O
the O
heme O
domain O
of O
NO O
synthase-like O
proteins O
from O
bacterial O
pathogens.Some O
Gram-positive O
bacterial O
pathogens O
harbor O
a O
gene O
that O
encodes O
a O
protein O
(HNS O
, O
Heme O
domain O
of O
NO O
Synthase-like O
proteins) O
with O
striking O
sequence O
identity O
to O
the O
oxygenase O
domain O
of O
mammalian O
NO O
synthases O
(NOS) O
. O
However O
, O
they O
lack O
the O
N-terminal O
and O
the O
Zn-cysteine O
motif O
participating O
to O
the O
stability O
of O
an O
active O
dimer O
in O
the O
mammalian O
isoforms O
. O
The O
unique O
properties O
of O
HNS O
make O
it O
an O
excellent O
model O
system O
for O
probing O
how O
the O
heme O
environment O
tunes O
NO O
dynamics O
and O
for O
comparing O
it O
to O
the O
endothelial O
NO O
synthase O
heme O
domain O
(eNOS(HD)) O
using O
ultrafast O
transient O
spectroscopy O
. O
NO O
rebinding O
in O
HNS O
from O
Staphylococcus O
aureus O
(SA-HNS) O
is O
faster O
than O
that O
measured O
for O
either O
Bacillus O
anthracis O
( O
BA-HNS) B
or O
for O
eNOS(HD) O
in O
both O
oxidized O
and O
reduced O
forms O
in O
the O
presence O
of O
arginine O
. O
To O
test O
whether O
these O
distinct O
rates O
arise O
from O
different O
energy O
barriers O
for O
NO O
recombination O
, O
we O
measured O
rebinding O
kinetics O
at O
several O
temperatures O
. O
Our O
data O
are O
consistent O
with O
different O
barriers O
for O
NO O
recombination O
in O
SA-HNS O
and O
BA-HNS O
and O
the O
presence O
of O
a O
second O
NO-binding O
site O
. O
The O
hypothesis O
that O
an O
additional O
NO-binding O
cavity O
is O
present O
in O
BA-HNS O
is O
also O
consistent O
with O
the O
effect O
of O
the O
NO O
concentration O
on O
its O
rebinding O
. O
The O
lack O
of O
the O
effect O
of O
NO O
concentration O
on O
the O
geminate O
rebinding O
in O
SA-HNS O
could O
be O
due O
to O
an O
isolated O
second O
site O
. O
We O
confirm O
the O
existence O
of O
a O
second O
NO O
site O
in O
the O
oxygenase O
domain O
of O
the O
reduced O
eNOS O
as O
previously O
hypothesized O
[A O
. O
Slama-Schwok O
, O
M O
. O
Negrerie O
, O
V O
. O
Berka O
, O
J.C O
. O
Lambry O
, O
A.L O
. O
Tsai O
, O
M.H O
. O
Vos O
, O
J.L O
. O
Martin O
, O
Nitric O
oxide O
(NO) O
traffic O
in O
endothelial O
NO O
synthase O
. O
Evidence O
for O
a O
new O
NO O
binding O
site O
dependent O
on O
tetrahydrobiopterin O
? O
J O
. O
Biol O
. O
Chem O
. O
277 O
(2002) O
7581-7586] O
. O
This O
site O
requires O
the O
presence O
of O
arginine O
and O
BH(4); O
and O
we O
propose O
that O
NO O
dynamic O
and O
escape O
from O
eNOS O
is O
regulated O
by O
the O
active O
site O
H-bonding O
network O
connecting O
between O
the O
heme O
, O
the O
substrate O
, O
and O
cofactor O
. O

Enalkiren O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
pharmacology O
of O
enalkiren O
, O
a O
novel O
, O
dipeptide O
renin O
inhibitor.Enalkiren O
(A-64662) O
, O
a O
potent O
, O
dipeptide O
renin O
inhibitor O
, O
mimics O
the O
transition O
state O
of O
the O
human B
renin I
substrate O
, O
angiotensinogen O
. O
Enalkiren O
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin O
activity O
(PRA) O
and O
angiotensin O
II O
when O
administered O
intravenously O
. O
Doses O
of O
enalkiren O
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O
marked O
suppression O
of O
PRA O
. O
However O
, O
at O
doses O
of O
0.3 O
and O
1.2 O
mg/kg O
, O
enalkiren O
produced O
significant O
, O
dose-related O
decreases O
in O
systolic O
and O
diastolic O
blood O
pressure O
(BP) O
in O
hypertensive O
patients O
, O
and O
the O
BP O
response O
was O
enhanced O
by O
pretreatment O
with O
hydrochlorothiazide O
. O
The O
effects O
of O
enalkiren O
on O
PRA O
and O
BP O
are O
prolonged O
despite O
its O
relatively O
short O
elimination O
phase O
plasma O
half-life O
(1.6 O
h) O
. O
Persistent O
pharmacologic O
activity O
without O
evidence O
of O
tachyphylaxis O
was O
demonstrated O
during O
1 O
week O
of O
treatment O
in O
hypertensive O
patients O
. O
The O
observed O
dissociation O
between O
suppression O
of O
PRA O
and O
BP O
response O
and O
the O
recruitment O
of O
dose-related O
BP O
decrements O
, O
despite O
complete O
suppression O
of O
PRA O
, O
are O
unexplained O
phenomena O
. O
The O
results O
of O
clinical O
trials O
with O
enalkiren O
are O
encouraging O
, O
and O
suggest O
that O
renin O
inhibitors O
may O
be O
safe O
, O
useful O
therapeutic O
agents O
in O
the O
management O
of O
hypertension O
. O

Antofine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Antofine-induced O
connexin43 B
gap O
junction O
disassembly O
in O
rat O
astrocytes O
involves O
protein O
kinase O
Cβ.Antofine O
, O
a O
phenanthroindolizidine O
alkaloid O
derived O
from O
Cryptocaryachinensis O
and O
Ficusseptica O
in O
the O
Asclepiadaceae O
milkweed O
family O
, O
is O
cytotoxic O
for O
various O
cancer O
cell O
lines O
. O
In O
this O
study O
, O
we O
demonstrated O
that O
treatment O
of O
rat O
primary O
astrocytes O
with O
antofine O
induced O
dose-dependent O
inhibition O
of O
gap O
junction O
intercellular O
communication O
(GJIC) O
, O
as O
assessed O
by O
scrape-loading O
6-carboxyfluorescein O
dye O
transfer O
. O
Levels O
of O
Cx43 O
protein O
were O
also O
decreased O
in O
a O
dose- O
and O
time-dependent O
manner O
following O
antofine O
treatment O
. O
Double-labeling O
immunofluorescence O
microscopy O
showed O
that O
antofine O
(10ng/ml) O
induced O
endocytosis O
of O
surface O
gap O
junctions O
into O
the O
cytoplasm O
, O
where O
Cx43 O
was O
co-localized O
with O
the O
early O
endosome O
marker O
EEA1 O
. O
Inhibition O
of O
lysosomes O
or O
proteasomes O
by O
co-treatment O
with O
antofine O
and O
their O
respective O
specific O
inhibitors O
, O
NH4Cl O
or O
MG132 O
, O
partially O
inhibited O
the O
antofine-induced O
decrease O
in O
Cx43 O
protein O
levels O
, O
but O
did O
not O
inhibit O
the O
antofine-induced O
inhibition O
of O
GJIC O
. O
After O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca(2+) O
concentration O
and O
activation O
of O
protein O
kinase O
C O
(PKC)α/βII O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O
Co-treatment O
of O
astrocytes O
with O
antofine O
and O
the O
intracellular O
Ca(2+) O
chelator O
BAPTA-AM O
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O
Moreover O
, O
co-treatment O
with O
antofine O
and O
a O
specific O
PKCβ O
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 O
, O
and O
inhibition O
of O
GJIC O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
antofine O
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O
PKCβ O
signaling O
pathway O
. O
Inhibition O
of O
GJIC O
by O
antofine O
may O
undermine O
the O
neuroprotective O
effect O
of O
astrocytes O
in O
CNS O
. O

Na(+) O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Underexpression O
of O
the O
Na+-dependent O
neutral O
amino O
acid O
transporter O
ASCT2 O
in O
the O
spontaneously O
hypertensive O
rat O
kidney.This O
study O
examined O
the O
inward O
transport O
of O
l-[(14)C]alanine O
, O
an O
ASCT2 O
preferential O
substrate O
, O
in O
monolayers O
of O
immortalized O
renal O
proximal O
tubular O
epithelial O
(PTE) O
cells O
from O
Wistar-Kyoto O
(WKY) O
and O
spontaneously O
hypertensive O
(SHR) O
rats O
. O
The O
expression O
of O
ASCT2 O
in O
WKY O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated O
. O
l-[(14)C]alanine O
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+) O
. O
Replacement O
of O
NaCl O
by O
LiCl O
or O
choline O
chloride O
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells O
. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH O
, O
Na(+)-dependent O
l-alanine O
uptake O
in O
WKY O
and O
SHR O
PTE O
cells O
was O
inhibited O
by O
alanine O
, O
serine O
, O
and O
cysteine O
, O
which O
is O
consistent O
with O
amino O
acid O
transport O
through O
ASCT2 O
. O
The O
saturable O
component O
of O
Na(+)-dependent O
l-alanine O
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells O
, O
with O
similar O
K(m) O
values O
. O
Differences O
in O
magnitude O
of O
Na(+)-dependent O
l-alanine O
uptake O
through O
ASCT2 O
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 O
protein O
expression O
, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells O
. O
Abundance O
of O
ASCT2 O
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats O
. O
In O
conclusion O
, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine O
mainly O
through O
a O
high-affinity O
Na(+)-dependent O
amino O
acid O
transporter O
, O
with O
functional O
features O
of O
ASCT2 B
transport O
. O
The O
activity O
and O
expression O
of O
the O
ASCT2 O
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells O
. O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
is O
mediated O
by O
Ras O
homologous O
A O
protein O
(Rho O
A) O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms.Despite O
the O
availability O
of O
melanoma O
treatment O
at O
the O
primary O
site O
, O
the O
recurrence O
of O
local O
melanoma O
can O
metastasize O
to O
any O
distant O
organ O
. O
Currently O
, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit O
. O
Thus O
, O
the O
functional O
analysis O
of O
conventional O
therapies O
may O
help O
to O
improve O
their O
efficiency O
in O
the O
treatment O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal B
kinase I
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O
present O
study O
addresses O
for O
the O
first O
time O
a O
central O
role O
for O
Rho O
A O
in O
the O
modulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
and O
thereby O
provides O
an O
insight O
into O
the O
molecular O
action O
of O
vinblastine O
in O
melanoma O
treatment O
. O

F3(d)Thd O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
mechanisms O
of O
acquired O
resistance O
to O
fluorinated O
pyrimidines O
in O
human O
colorectal O
cancer O
cells.5-Fluorouracil O
(5-FU) O
, O
5-fluoro-2'-deoxyuridine O
(FdUrd) O
and O
5-trifluorothymidine O
(F3(d)Thd) O
are O
antimetabolites O
which O
are O
metabolized O
to O
their O
corresponding O
active O
forms O
which O
inhibit O
DNA O
synthesis O
via O
inhibition O
of O
thymidylate O
synthase O
(TS) O
. O
To O
investigate O
ways O
of O
overcoming O
5-FU-resistance O
, O
we O
established O
acquired-resistant O
colorectal O
cancer O
cell O
lines O
against O
these O
three O
drugs O
by O
continuous O
and O
step-wise O
escalation O
of O
drugs O
, O
and O
analyzed O
the O
cytotoxicity O
and O
the O
mechanism O
of O
resistance O
to O
the O
drugs O
. O
When O
cells O
were O
incubated O
with O
the O
3 O
drugs O
for O
72 O
h O
, O
the O
resistance O
ratio O
to O
parental O
DLD-1 O
human O
colorectal O
tumor O
cells O
was O
65.2 O
for O
DLD-1/5-FU O
, O
9.7 O
for O
DLD-1/FdUrd O
and O
448.6 O
for O
DLD-1/F3(d)Thd O
cells O
. O
DLD-1/5-FU O
cells O
did O
not O
show O
any O
cross-resistance O
against O
FdUrd O
and O
F(3)dThd O
. O
However O
, O
DLD-1/FdUrd O
cells O
showed O
3- O
and O
9-fold O
increased O
resistance O
to O
5-FU O
and O
F3(d)Thd O
, O
respectively O
, O
and O
DLD-1/F3(d)Thd O
cells O
also O
showed O
about O
90-fold O
resistance O
to O
FdUrd O
. O
Analysis O
of O
enzyme O
activities O
and O
gene O
expression O
associated O
with O
pyrimidine O
metabolism O
indicated O
that O
a O
significant O
decrease O
in O
orotate O
phosphoribosyltransferase O
activity O
in O
DLD-1/5-FU O
cells O
, O
a O
7-fold O
increase O
of O
TS O
mRNA O
in O
DLD-1/FdUrd O
cells O
, O
and O
a O
37-fold O
decrease O
in O
thymidine O
kinase O
activity O
of O
DLD-1/F3(d)Thd O
cells O
were O
the O
major O
mechanisms O
of O
drug O
resistance O
. O
These O
findings O
were O
closely O
associated O
with O
the O
cytotoxicity O
of O
5-FU O
, O
FdUrd O
and O
F3(d)Thd O
against O
the O
established O
5-FU- O
, O
FdUrd- O
or O
F3(d)Thd-resistant O
cells O
. O
When O
DLD-1/FdUrd O
cells O
expressing O
increased O
TS O
mRNA O
were O
treated O
with O
FdUrd O
and O
F3(d)Thd O
for O
only O
4 O
h O
, O
the O
resistance O
ratios O
of O
DLD-1/FdUrd O
cells O
to O
parental O
DLD-1 O
cells O
were O
markedly O
different O
for O
FdUrd O
and O
F3(d)Thd O
, O
suggesting O
that O
the O
cytotoxicity O
with O
short-time O
exposure O
to O
F3(d)Thd O
is O
due O
to O
a O
mechanism O
other O
than O
TS B
inhibition O
, O
although O
the O
cytotoxicity O
of O
F3(d)Thd O
in O
the O
short-time O
is O
low O
compared O
to O
that O
of O
long-time O
exposure O
. O
In O
conclusion O
, O
F3(d)Thd O
, O
an O
antimetabolite O
that O
inhibits O
TS O
activity O
, O
may O
be O
effective O
against O
5-FU O
and/or O
FdUrd-resistance O
in O
colorectal O
cancer O
cells O
caused O
by O
amplification O
of O
TS O
and/or O
deletion O
of O
orotate O
phosphoribosyltransferase O
. O

phentolamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O
alpha O
1D-adrenoceptors O
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha B
1A I
and I
alpha I
1D I
adrenoceptors I
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha O
1B O
adrenoceptors O
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha O
1A O
adrenoceptors O
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human O
and O
rat1D O
adrenoceptors O
were O
almost O
identical O
(r O
= O
0.99 O
, O
slope O
= O
1.08) O
. O
4 O
. O
Prazosin O
, O
doxazosin O
and O
5-methyl-urapidil O
were O
potent O
, O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
(pA2 O
values O
of O
9.8 O
, O
8.8 O
and O
7.8 O
respectively) O
. O
The O
selective O
alpha O
1D O
antagonist O
BMY O
7378 O
was O
also O
a O
potent O
antagonist O
on O
rat O
aorta O
(pKB O
= O
8.3 O
+/- O
0.1) O
but O
the O
interaction O
of O
this O
compound O
was O
not O
consistent O
with O
competitive O
antagonism O
at O
a O
single O
population O
of O
receptors O
. O
5 O
. O
Functional O
affinities O
for O
compounds O
determined O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
correlated O
well O
with O
binding O
affinities O
at O
cloned O
alpha O
1D-adrenoceptors O
(r O
= O
0.96) O
, O
but O
not O
with O
alpha O
1A O
(r O
= O
0.61) O
or O
alpha O
1B O
(r O
= O
0.46) O
subtypes O
. O
6 O
. O
Noradrenaline-mediated O
contractions O
of O
rat O
aorta O
were O
sensitive O
to O
the O
alkylating O
effects O
of O
chlorethylclonidine O
(CEC) O
. O
CEC O
(10 O
microM) O
caused O
a O
small O
rightward O
shift O
in O
the O
noradrenaline O
concentration-response O
curve O
. O
CEC O
at O
100 O
microM O
caused O
a O
further O
shift O
and O
suppression O
of O
the O
maximum O
response O
to O
noradrenaline.7 O
. O
The O
results O
of O
this O
study O
suggest O
that O
noradrenaline O
predominantly O
, O
but O
not O
exclusively O
, O
mediates O
contraction O
of O
rat O
aorta O
through O
the O
activation O
of O
an O
alphalD-adrenoceptor O
. O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O
in O
a O
randomised O
, O
crossover O
study O
in O
rats O
(P<0.01) O
. O
The O
change O
in O
the O
AUC O
of O
DXM O
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A B
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

Naloxone O
acts O
as O
NOT O
for O
what O
entity O
? O
Changes O
of O
phosphorylation O
of O
cAMP O
response O
element O
binding O
protein O
in O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
: O
naloxone O
reversal.AIM O
: O
To O
study O
the O
changes O
in O
the O
expression O
and O
phosphorylation O
of O
cAMP O
response O
element O
binding O
protein O
(CREB) O
in O
the O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol O
intake O
and O
its O
withdrawal O
. O
METHODS O
: O
Ethanol O
was O
given O
in O
drinking O
water O
at O
the O
concentration O
of O
6 O
% O
(v/v) O
, O
for O
one O
month O
. O
Changes O
in O
the O
levels O
of O
CREB O
and O
phospho-CREB O
(p-CREB) O
protein O
in O
the O
nucleus O
accumbens O
were O
measured O
by O
immunohistochemistry O
methods O
. O
RESULTS O
: O
Ethanol O
given O
to O
rats O
in O
drinking O
water O
decreased O
the O
level O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
(-75 O
%) O
at O
the O
time O
of O
exposure O
to O
ethanol O
. O
The O
decrement O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
remained O
at O
24 O
h O
(-35 O
%) O
and O
72 O
h O
(-28 O
%) O
of O
ethanol O
withdrawal O
, O
which O
recovered O
toward O
control O
level O
after O
7 O
d O
of O
ethanol O
withdrawal O
. O
However O
, O
chronic O
ethanol O
, O
as O
well O
as O
ethanol O
withdrawal O
failed O
to O
produce O
any O
significant O
alteration O
in O
the O
level O
of O
CREB O
protein O
in O
the O
nucleus O
accumbens O
. O
Naloxone O
(alone) O
treatment O
of O
rats O
had O
no O
effect O
on O
the O
levels O
of O
CREB O
and O
p-CREB B
protein O
in O
the O
nucleus O
accumbens O
. O
However O
, O
when O
naloxone O
was O
administered O
concurrently O
with O
ethanol O
treatment O
, O
it O
antagonized O
the O
down-regulation O
of O
p-CREB O
protein O
in O
the O
nucleus O
accumbens O
(142 O
%) O
of O
rats O
exposed O
to O
ethanol O
. O
CONCLUSION O
: O
A O
long-term O
intake O
of O
ethanol O
solution O
down-regulates O
the O
phosphorylation O
of O
CREB O
in O
the O
nucleus O
accumbens O
, O
and O
those O
changes O
can O
be O
reversed O
by O
naloxone O
, O
which O
may O
be O
one O
kind O
of O
the O
molecular O
mechanisms O
associated O
with O
ethanol O
dependence O
. O

α-MeDA O
acts O
as O
NOT O
for O
what O
entity O
? O
Neurotoxicity O
of O
"ecstasy" O
and O
its O
metabolites O
in O
human O
dopaminergic O
differentiated O
SH-SY5Y O
cells.Ecstasy O
(3,4-methylenedioxymethamphetamine O
or O
MDMA) O
is O
a O
widely O
abused O
recreational O
drug O
, O
reported O
to O
produce O
neurotoxic O
effects O
, O
both O
in O
laboratory O
animals O
and O
in O
humans O
. O
MDMA O
metabolites O
can O
be O
major O
contributors O
for O
MDMA O
neurotoxicity O
. O
This O
work O
studied O
the O
neurotoxicity O
of O
MDMA O
and O
its O
catechol O
metabolites O
, O
α-methyldopamine O
(α-MeDA) O
and O
N-methyl-α-methyldopamine O
(N-Me-α-MeDA) O
in O
human O
dopaminergic O
SH-SY5Y O
cells O
differentiated O
with O
retinoic O
acid O
and O
12-O-tetradecanoyl-phorbol-13-acetate O
. O
Differentiation O
led O
to O
SH-SY5Y O
neurons O
with O
higher O
ability O
to O
accumulate O
dopamine O
and O
higher O
resistance O
towards O
dopamine O
neurotoxicity O
. O
MDMA O
catechol O
metabolites O
were O
neurotoxic O
to O
SH-SY5Y O
neurons O
, O
leading O
to O
caspase O
3-independent O
cell O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ- O
glutamylcysteine B
synthetase I
(γ I
-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O
not O
augment O
this O
metabolite O
cytotoxicity O
. O
Even O
so O
, O
BSO O
pre-treatment O
abolished O
NAC O
protective O
effects O
against O
α-MeDA O
neurotoxicity O
, O
which O
were O
, O
at O
least O
partially O
, O
due O
to O
GSH O
de O
novo O
synthesis O
. O
Inversely O
, O
pre-treatment O
of O
cells O
with O
BSO O
augmented O
N-Me-α-MeDA-induced O
neurotoxicity O
, O
but O
only O
slightly O
affected O
NAC O
neuroprotection O
. O
In O
conclusion O
, O
MDMA O
catechol O
metabolites O
promote O
differential O
toxic O
effects O
to O
differentiated O
dopaminergic O
human O
SH-SY5Y O
cells O
. O

adenosine O
acts O
as O
NOT O
for O
what O
entity O
? O
Impaired O
function O
of O
prejunctional O
adenosine O
A1 O
receptors O
expressed O
by O
perivascular O
sympathetic O
nerves O
in O
DOCA-salt O
hypertensive O
rats.Increased O
sympathetic O
nervous O
system O
activity O
contributes O
to O
deoxycorticosterone O
acetate O
(DOCA)-salt O
hypertension O
in O
rats O
. O
ATP O
and O
norepinephrine O
(NE) O
are O
coreleased O
from O
perivascular O
sympathetic O
nerves O
. O
NE O
acts O
at O
prejunctional O
α2-adrenergic O
receptors O
(α2ARs) O
to O
inhibit O
NE O
release O
, O
and O
α2AR O
function O
is O
impaired O
in O
DOCA-salt O
rats O
. O
Adenosine O
, O
an O
enzymatic O
ATP O
degradation O
product O
, O
acts O
at O
prejunctional O
A1 O
adenosine O
receptors O
(A1Rs) O
to O
inhibit O
NE O
release O
. O
We O
tested O
the O
hypothesis O
that O
prejunctional O
A1R O
function O
is O
impaired O
in O
sympathetic O
nerves O
supplying O
mesenteric O
arteries O
(MAs) O
and O
veins O
(MVs) O
of O
DOCA-salt O
rats O
. O
Electrically O
evoked O
NE O
release O
and O
constrictions O
of O
blood O
vessels O
were O
studied O
in O
vitro O
with O
use O
of O
amperometry O
to O
measure O
NE O
oxidation O
currents O
and O
video O
microscopy O
, O
respectively O
. O
Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine O
hydroxylase O
(TH) O
and O
A1Rs O
in O
perivascular O
sympathetic O
nerves O
. O
TH O
and O
A1Rs O
colocalized O
to O
perivascular O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
(CPA O
, O
A1R O
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O
currents O
. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs B
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs O
in O
veins; O
thus O
, O
adenosine O
selectively O
constricts O
the O
veins O
. O
Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA-salt O
rats O
. O
Sympathetic O
autoreceptor O
dysfunction O
is O
not O
specific O
to O
α2ARs O
, O
but O
there O
is O
a O
more O
general O
disruption O
of O
prejunctional O
mechanisms O
controlling O
sympathetic O
neurotransmitter O
release O
in O
DOCA-salt O
hypertension O
. O

Crocin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Protective O
effect O
of O
crocin O
on O
diazinon O
induced O
cardiotoxicity O
in O
rats O
in O
subchronic O
exposure.This O
study O
was O
designed O
to O
evaluate O
the O
effectiveness O
of O
crocin O
, O
main O
component O
of O
Crocus O
sativus O
L O
. O
(Saffron) O
against O
subchronic O
diazinon O
(DZN) O
induced O
cardiotoxicity O
in O
rats O
. O
METHODS O
: O
Rats O
were O
divided O
into O
7 O
groups; O
control O
(corn O
oil O
, O
gavage) O
, O
DZN O
(15mg/kg/day O
, O
gavage,) O
, O
crocin O
(12.5 O
, O
25 O
or O
50mg/kg/day O
, O
i.p) O
plus O
DZN O
, O
vitamin O
E O
(200IU/kg O
, O
i.p O
, O
three O
times O
per O
week) O
plus O
DZN O
and O
crocin O
(50mg/kg/day O
, O
i.p) O
groups O
. O
Treatments O
were O
continued O
for O
4weeks O
. O
Creatine O
phosphokinase O
MB O
(CK-MB) O
, O
malondealdehyde O
(MDA) O
and O
glutathione O
(GSH) O
levels O
were O
evaluated O
in O
heart O
tissue O
at O
the O
end O
of O
treatments O
. O
Levels O
of O
apoptotic O
proteins O
(Bax O
, O
Bcl2 O
, O
caspase O
3) O
and O
cytosolic O
cytochrome O
c O
were O
analyzed O
by O
Western O
blotting O
. O
Transcript O
levels O
of O
Bax O
and O
Bcl2 O
were O
also O
determined O
using O
qRT O
PCR O
. O
RESULTS O
: O
DZN O
induced O
histophatological O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB B
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis O
. O

2,6-dimethyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 O
by O
lumiracoxib.Lumiracoxib O
is O
the O
first O
example O
of O
a O
marketed O
COX-2 O
inhibitor O
of O
the O
arylacetic O
acid O
class O
, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O
COXIB O
in O
vivo O
. O
However O
, O
the O
molecular O
basis O
of O
its O
COX-2 O
inhibition O
has O
not O
been O
completely O
defined O
. O
Using O
standard O
assays O
, O
lumiracoxib O
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine O
COX-1 O
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human O
COX-2 O
. O
The O
extent O
of O
COX-2 O
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme O
. O
Kinetic O
studies O
with O
lumiracoxib O
demonstrated O
that O
it O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human O
COX-2 O
that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition O
. O
Derivatives O
of O
lumiracoxib O
were O
synthesized O
with O
or O
without O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline O
ring O
. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl O
group O
on O
the O
phenylacetic O
acid O
ring O
is O
required O
for O
COX-2 O
selectivity O
. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline O
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX O
inhibition O
as O
well O
as O
COX-2 O
selectivity O
. O
Mutation O
of O
Ser-530 O
to O
Ala O
or O
Val-349 O
to O
Ala O
or O
Leu O
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human O
COX-2 O
and O
key O
lumiracoxib O
analogs O
. O
Interestingly O
, O
a O
Val-349 B
to I
Ile I
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human O
COX-2 O
with O
2,6-dichloro- O
, O
2,6-dimethyl- O
, O
or O
2-chloro-6-methyl-substituted O
inhibitors O
and O
, O
in O
the O
case O
of O
lumiracoxib O
, O
actually O
showed O
an O
increase O
in O
potency O
. O
Taken O
together O
with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 O
complex O
, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s O
by O
lumiracoxib O
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 O
inhibition O
. O

kurarinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
vitro O
inhibition O
of O
diacylglycerol O
acyltransferase O
by O
prenylflavonoids O
from O
Sophora O
flavescens.Four O
prenylflavonoids O
, O
kurarinone O
( O
1) O
, O
a O
chalcone O
of O
1 O
, O
kuraridin O
( O
2) O
, O
kurarinol O
( O
3) O
, O
kushenol O
H O
( O
4) O
and O
kushenol O
K O
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol B
acyltransferase I
(DGAT) O
. O
The O
flavonoids O
inhibited O
DGAT O
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1) O
, O
9.8 O
microM O
( O
2) O
, O
8.6 O
microM O
( O
3) O
, O
142.0 O
microM O
( O
4) O
and O
250 O
microM O
( O
5) O
. O
The O
prenylflavonoids O
without O
C3-OH O
( O
1 O
, O
2 O
, O
3) O
showed O
stronger O
inhibition O
than O
those O
with O
C3-OH O
( O
4 O
, O
5) O
. O
On O
the O
other O
hand O
, O
flavonoids O
without O
side O
chains O
(hesperetin O
, O
naringenin O
, O
quercetin O
and O
kaempferol) O
did O
not O
inhibit O
the O
enzyme O
activity O
at O
a O
final O
concentration O
of O
800 O
microM O
. O
These O
data O
suggest O
that O
the O
lavandulyl O
side O
chain O
and O
the O
position O
of O
the O
hydroxy O
group O
are O
important O
for O
high O
DGAT O
inhibitory O
activity O
. O
Compound O
1 O
also O
inhibited O
de O
novo O
synthesis O
of O
triacylglycerol O
(TG) O
in O
Raji O
cells O
. O

aniracetam O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Lithium O
modulates O
desensitization O
of O
the O
glutamate O
receptor O
subtype O
gluR3 O
in O
Xenopus O
oocytes.Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA O
receptor O
GluR3 O
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium O
produces O
a O
large O
potentiation O
of O
the O
GluR3 O
flop O
splice O
variant O
and O
suggested O
that O
lithium O
might O
inhibit O
rapid O
desensitization O
, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias O
, O
N O
. O
and O
Papke O
, O
R. O
, O
Subtype-specific O
effects O
of O
lithium O
on O
glutamate O
receptor O
function O
. O
J O
. O
Neurophysiol. O
, O
81 O
(1999) O
1506-1512) O
. O
We O
now O
show O
that O
mutation O
of O
the O
769R O
/ O
G O
desensitization O
site O
(Lomeli O
, O
H.M.J. O
, O
Melcher O
, O
T. O
, O
Hoger O
, O
T. O
, O
Geiger O
, O
J.R. O
, O
Kuner O
, O
T. O
, O
Monyer O
, O
H. O
, O
Higuchi O
, O
M.B.A O
. O
and O
Seeburg O
, O
P.H O
, O
Control O
of O
kinetic O
properties O
of O
AMPA O
receptor O
channels O
by O
nuclear O
RNA O
editing O
. O
Science O
, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced O
potentiation O
of O
GluR3 O
. O
Additionally O
, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O
GluR3(L507Y) O
(Stern-Bach O
, O
Y. O
, O
Russo O
, O
S. O
, O
Neuman O
, O
M O
. O
and O
Rosenmund O
, O
C. O
, O
A O
point O
mutation O
in O
the O
glutamate O
binding O
site O
blocks O
desensitization O
of O
AMPA O
receptors O
. O
Neuron O
, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium O
enhances O
GluR3 O
responses O
by O
reducing O
desensitization O
, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant O
. O
Lithium's O
effects O
on O
GluR3 B
desensitization O
are O
distinct O
from O
the O
effects O
of O
aniracetam O
on O
desensitization O
. O
Specifically O
, O
aniracetam O
, O
which O
potentiates O
wild-type O
AMPA O
receptors O
, O
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) O
mutant O
, O
but O
has O
synergistic O
effects O
with O
lithium O
on O
wild-type O
receptors O
. O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 B
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

acyl-CoAs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Redesign O
of O
carnitine O
acetyltransferase O
specificity O
by O
protein O
engineering.In O
eukaryotes O
, O
L-carnitine O
is O
involved O
in O
energy O
metabolism O
by O
facilitating O
beta-oxidation O
of O
fatty O
acids O
. O
Carnitine O
acetyltransferases O
(CrAT) O
catalyze O
the O
reversible O
conversion O
of O
acetyl-CoA O
and O
carnitine O
to O
acetylcarnitine O
and O
free O
CoA O
. O
To O
redesign O
the O
specificity O
of O
rat O
CrAT O
toward O
its O
substrates O
, O
we O
mutated O
Met564 O
. O
The O
M564G O
mutated O
CrAT O
showed O
higher O
activity O
toward O
longer O
chain O
acyl-CoAs O
: O
activity O
toward O
myristoyl-CoA O
was O
1250-fold O
higher O
than O
that O
of O
the O
wild-type O
CrAT O
, O
and O
lower O
activity O
toward O
its O
natural O
substrate O
, O
acetyl-CoA O
. O
Kinetic O
constants O
of O
the O
mutant O
CrAT O
showed O
modification O
in O
favor O
of O
longer O
acyl-CoAs O
as O
substrates O
. O
In O
the O
reverse O
case O
, O
mutation O
of O
the O
orthologous O
glycine O
(Gly553) O
to O
methionine O
in O
carnitine O
octanoyltransferase O
( O
COT) B
decreased O
activity O
toward O
its O
natural O
substrates O
, O
medium- O
and O
long-chain O
acyl-CoAs O
, O
and O
increased O
activity O
toward O
short-chain O
acyl-CoAs O
. O
Another O
CrAT O
mutant O
, O
M564A O
, O
was O
prepared O
and O
tested O
in O
the O
same O
way O
, O
with O
similar O
results O
. O
We O
conclude O
that O
Met564 O
blocks O
the O
entry O
of O
medium- O
and O
long-chain O
acyl-CoAs O
to O
the O
catalytic O
site O
of O
CrAT O
. O
Three-dimensional O
models O
of O
wild-type O
and O
mutated O
CrAT O
and O
COT O
support O
this O
hypothesis O
. O
We O
show O
for O
the O
first O
time O
that O
a O
single O
amino O
acid O
is O
able O
to O
determine O
the O
substrate O
specificity O
of O
CrAT O
and O
COT O
. O

nicardipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
of O
inhibition O
of O
calmodulin-stimulated O
cyclic O
nucleotide O
phosphodiesterase O
by O
dihydropyridine O
calcium O
antagonists.Calmodulin-dependent O
cyclic O
nucleotide O
phosphodiesterase O
(CaMPDE) O
is O
one O
of O
the O
key O
enzymes O
involved O
in O
the O
complex O
interaction O
between O
the O
cyclic O
nucleotide O
and O
Ca2+ O
second-messenger O
systems O
. O
CaMPDE O
exists O
as O
tissue-specific O
isozymes O
, O
and O
initially O
these O
isozymes O
were O
designated O
according O
to O
their O
respective O
subunit O
molecular O
mass O
. O
A O
variety O
of O
pharmacological O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
( O
PDE B
1B1) I
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE O
isozymes O
but O
bring O
about O
different O
levels O
of O
enzyme O
inhibition O
, O
suggesting O
the O
possibility O
of O
designing O
specific O
drugs O
that O
can O
protect O
the O
enzyme O
from O
inhibition O
by O
dihydropyridine O
Ca2+-channel O
blockers O
. O

ORF O
17583 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Effects O
of O
ORF O
17583 O
, O
other O
histamine O
H2-receptor O
antagonists O
and O
omeprazole O
on O
gastric O
acid O
secretory O
states O
in O
rats O
and O
dogs.ORF O
17583 O
, O
a O
histamine B
H2-receptor I
antagonist O
, O
inhibited O
gastric O
acid O
secretion O
in O
pylorus-ligated O
rats O
(ED50 O
= O
4.9 O
mg/kg O
intraduodenal; O
3.4 O
mg/kg O
p.o.; O
and O
0.21 O
mg/kg O
i.p.) O
and O
in O
total O
gastric O
fistula O
or O
Heidenhain O
pouch O
dogs O
stimulated O
by O
betazole O
(ED50 O
= O
0.12 O
mg/kg O
p.o O
. O
and O
0.08 O
mg/kg O
i.v.) O
, O
histamine O
, O
tetragastrin O
, O
bethanechol O
, O
2-deoxy-D-glucose O
or O
a O
meal O
(ED50 O
values O
ranged O
from O
0.11-0.26 O
mg/kg O
p.o.) O
. O
The O
nonspecific O
inhibition O
of O
gastric O
acid O
by O
ORF O
17583 O
supports O
the O
existence O
of O
interdependence O
between O
histamine O
and O
the O
gastrin O
and O
cholinergic O
receptors O
on O
the O
parietal O
cell O
surface O
. O
Antisecretory O
potency O
of O
ORF O
17583 O
after O
intraduodenal O
administration O
in O
pylorus-ligated O
rats O
was O
6.4 O
times O
greater O
than O
cimetidine O
, O
1.8 O
times O
greater O
than O
ranitidine O
, O
equal O
to O
that O
of O
omeprazole O
and O
8 O
times O
less O
than O
that O
of O
famotidine O
. O
Oral O
antisecretory O
potency O
of O
ORF O
17583 O
in O
gastric O
fistula O
dogs O
was O
31 O
times O
greater O
than O
cimetidine O
, O
3.7 O
times O
greater O
than O
ranitidine O
and O
equal O
to O
that O
of O
omeprazole O
and O
famotidine O
. O
Studies O
using O
equieffective O
antisecretory O
doses O
of O
ORF O
17583 O
and O
ranitidine O
in O
dogs O
suggested O
that O
ORF O
17583 O
has O
a O
short O
duration O
of O
antisecretory O
activity O
similar O
to O
that O
of O
ranitidine O
. O

eicosapentaenoic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Lutein O
and O
eicosapentaenoic O
acid O
interact O
to O
modify O
iNOS B
mRNA O
levels O
through O
the O
PPARgamma/RXR O
pathway O
in O
chickens O
and O
HD11 O
cell O
lines.Two O
experiments O
were O
conducted O
to O
investigate O
the O
effect O
of O
lutein O
and O
fat O
or O
eicosapentaenoic O
acid O
(EPA) O
interaction O
on O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
PPARs O
alpha O
, O
beta O
, O
and O
gamma O
, O
and O
retinoic O
acid O
X O
receptor O
(RXR) O
alpha O
and O
gamma O
mRNA O
levels O
. O
In O
Expt O
. O
1 O
, O
macrophages O
were O
collected O
from O
broiler O
chicks O
fed O
3 O
or O
6% O
dietary O
fat O
(g/100 O
g) O
with O
0 O
, O
25 O
, O
and O
50 O
mg O
lutein/kg O
feed O
for O
23 O
d O
. O
In O
Expt O
. O
2 O
, O
using O
a O
3 O
x O
3 O
factorial O
, O
eicosapentaenoic O
acid O
(EPA) O
at O
0 O
, O
15 O
and O
50 O
micromol/L O
and O
lutein O
at O
0 O
, O
10 O
and O
100 O
micromol/L O
were O
applied O
to O
HD11 O
cell O
culture O
for O
24 O
h O
. O
In O
both O
experiments O
, O
cells O
were O
stimulated O
with O
lipopolysaccharide O
before O
RNA O
isolation O
. O
Lutein O
interacted O
with O
fat O
in O
Expt O
. O
1 O
and O
with O
EPA O
in O
Expt O
. O
2 O
to O
affect O
mRNA O
levels O
of O
iNOS O
, O
PPARgamma O
, O
and O
RXRalpha O
in O
chicken O
macrophages O
and O
HD11 O
cells O
, O
respectively O
(P O
< O
0.05) O
. O
At O
3% O
dietary O
fat O
or O
up O
to O
15 O
micromol/L O
EPA O
in O
the O
medium O
, O
increasing O
lutein O
increased O
the O
iNOS O
mRNA O
. O
However O
, O
at O
6% O
dietary O
fat O
or O
50 O
micromol/L O
EPA O
, O
lutein O
did O
not O
cause O
a O
rise O
in O
iNOS O
mRNA O
. O
Increasing O
lutein O
in O
the O
medium O
from O
0 O
to O
100 O
micromol/L O
decreased O
iNOS O
mRNA O
. O
Increasing O
lutein O
with O
high O
fat O
(6%) O
or O
EPA O
(15 O
micromol/L O
EPA) O
increased O
PPARgamma O
and O
RXRalpha O
mRNA O
levels O
. O
Lutein O
increased O
PPARalpha O
mRNA O
levels O
in O
both O
macrophages O
(P O
< O
0.01) O
and O
HD11 O
(P O
= O
0.01) O
cells O
and O
RXRgamma O
(P O
< O
0.01) O
mRNA O
levels O
in O
macrophages O
. O
GW9662 O
, O
a O
PPARgamma O
antagonist O
, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS O
mRNA O
downregulation O
in O
HD11 O
cells O
. O
LG101208 O
, O
a O
RXR O
antagonist O
, O
prevented O
(P O
< O
0.01) O
iNOS O
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS O
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein O
. O
We O
conclude O
that O
lutein O
and O
EPA O
interact O
through O
the O
PPARgamma O
and O
RXR O
pathways O
to O
modulate O
iNOS O
mRNA O
. O

NO O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Anti-inflammatory O
effect O
of O
essential O
oil O
and O
its O
constituents O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
through O
blocking O
JNK O
, O
ERK O
and O
NF-κB O
signaling O
pathways O
in O
LPS-activated O
RAW O
264.7 O
cells.We O
investigated O
the O
composition O
of O
essential O
oil O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
(NO) O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible B
nitric I
oxide I
synthase I
(iNOS) O
and O
cyclooxygenase O
(COX)-2 O
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O
blocked O
activation O
of O
c-Jun O
N-terminal O
kinase O
(JNK) O
and O
extracellular O
signal-regulated O
kinase O
(ERK) O
but O
not O
that O
of O
p38 O
mitogen-activated O
protein O
kinase O
. O
These O
results O
indicate O
that O
FCEO O
inhibits O
LPS-stimulated O
inflammation O
by O
blocking O
the O
NF-κB O
, O
JNK O
, O
and O
ERK O
pathways O
in O
macrophages O
, O
and O
demonstrate O
that O
FCEO O
possesses O
anti-inflammatory O
properties O
. O

oxymetazoline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
(+/-)-tamsulosin O
, O
an O
alpha O
1A-adrenoceptor O
antagonist O
, O
inhibits O
the O
positive O
inotropic O
effect O
but O
not O
the O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
, O
a O
selective O
alpha O
1A-adrenoceptor O
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha O
1-adrenoceptors O
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O
in O
the O
presence O
of O
either O
(+/-)-bupranolol O
or O
S(-)-timolol O
. O
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin O
on O
the O
effect O
of O
phenylephrine O
was O
dependent O
or O
the O
concentration O
applied O
: O
(+/-)-tamsulosin O
at O
1 O
and O
3 O
nM O
acted O
in O
a O
competitive O
manner O
, O
the O
slope O
of O
the O
regression O
line O
of O
the O
Schild O
plot O
being O
unity O
and O
the O
pA2 O
value O
being O
9.12; O
at O
10 O
nM O
, O
it O
shifted O
further O
the O
concentration-response O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha O
1B-adrenoceptors O
by O
treatment O
with O
chlorethylclonidine O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol O
phosphates O
that O
was O
induced O
by O
10 O
microM O
phenylephrine O
. O
Oxymetazoline O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O
inositol O
monophosphate O
induced O
by O
phenylephrine O
. O
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect O
, O
mediated O
via O
(+/-)-tamsulosin- O
and O
oxymetazoline-sensitive O
subtype O
of O
alpha B
1-adrenoceptors I
, O
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol O
phosphates O
. O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase O
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O
high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O
whereas O
only O
ambenonium O
and O
tacrine O
displaced O
[3H]-quinuclinidyl O
benzilate O
binding O
. O
Inhibitors O
such O
as O
desoxypeganine O
, O
parathion O
and O
gramine O
demonstrated O
negligible O
inhibition O
of O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase O
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic B
receptors I
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

putrescine O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Polyamine O
depletion O
delays O
apoptosis O
of O
rat O
intestinal O
epithelial O
cells.The O
polyamines O
spermidine O
, O
spermine O
, O
and O
their O
precursor O
putrescine O
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle O
. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines O
favors O
either O
malignant O
transformation O
or O
apoptosis O
, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus O
. O
This O
study O
examines O
the O
involvement O
of O
polyamines O
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA O
topoisomerase O
I O
inhibitor O
, O
camptothecin O
. O
In O
IEC-6 O
cells O
, O
camptothecin O
induced O
apoptosis O
within O
6 O
h O
, O
accompanied O
by O
detachment O
of O
cells O
. O
Detached O
cells O
showed O
DNA O
laddering O
and O
caspase O
3 O
induction O
, O
characteristic O
features O
of O
apoptosis O
. O
Depletion O
of O
putrescine O
, O
spermidine O
, O
and O
spermine O
by O
DL-alpha-difluoromethylornithine O
(DFMO) O
, O
a O
specific O
inhibitor O
of O
ornithine O
decarboxylase O
(ODC) O
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine O
biosynthesis O
, O
decreased O
the O
apoptotic O
index O
. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase O
3 O
activity O
in O
polyamine-depleted O
cells O
. O
Addition O
of O
putrescine O
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase B
3 I
activity O
. O
Polyamine O
depletion O
did O
not O
change O
the O
level O
of O
caspase O
3 O
protein O
. O
Inhibition O
of O
S-adenosylmethionine O
decarboxylase O
by O
a O
specific O
inhibitor O
[diethylglyoxal O
bis-(guanylhydrazone); O
DEGBG] O
led O
to O
depletion O
of O
spermidine O
and O
spermine O
with O
a O
significant O
accumulation O
of O
putrescine O
and O
induction O
of O
ODC O
. O
The O
DEGBG-treated O
cells O
showed O
an O
increase O
in O
apoptosis O
, O
suggesting O
the O
importance O
of O
putrescine O
in O
the O
apoptotic O
process O
. O
Addition O
of O
putrescine O
to O
DFMO-treated O
cell O
extracts O
did O
not O
increase O
caspase O
3 O
activity O
. O
The O
above O
results O
indicate O
that O
polyamine O
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents O
, O
suggesting O
that O
polyamines O
might O
be O
involved O
in O
the O
caspase O
activating O
signal O
cascade O
. O

[3H]-clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Atypical O
neuroleptics O
have O
low O
affinity O
for O
dopamine O
D2 O
receptors O
or O
are O
selective O
for O
D4 O
receptors.This O
review O
examines O
the O
possible O
receptor O
basis O
of O
the O
atypical O
action O
of O
those O
atypical O
antipsychotic O
drugs O
that O
elicit O
low O
levels O
of O
Parkinsonism O
. O
Such O
an O
examination O
requires O
consistent O
and O
accurate O
dissociation O
constants O
for O
the O
antipsychotic O
drugs O
at O
the O
relevant O
dopamine O
and O
serotonin O
receptors O
. O
It O
has O
long O
been O
known O
, O
however O
, O
that O
the O
dissociation O
constant O
of O
a O
given O
antipsychotic O
drug O
at O
the O
dopamine O
D2 O
receptor O
varies O
between O
laboratories O
. O
Although O
such O
variation O
depends O
on O
several O
factors O
, O
it O
has O
recently O
been O
recognized O
that O
the O
radioligand O
used O
to O
measure O
the O
competition O
between O
the O
antipsychotic O
drug O
and O
the O
radioligand O
is O
an O
important O
variable O
. O
The O
present O
review O
summarizes O
information O
on O
this O
radioligand O
dependence O
. O
In O
general O
, O
a O
radioligand O
of O
low O
solubility O
in O
the O
membrane O
(i.e. O
, O
low O
tissue:buffer O
partition) O
results O
in O
a O
low O
value O
for O
the O
antipsychotic O
dissociation O
constant O
when O
the O
drug O
competes O
with O
the O
radioligand O
. O
Hence O
, O
by O
first O
obtaining O
the O
antipsychotic O
dissociation O
constants O
using O
different O
radioligands O
of O
different O
solubility O
in O
the O
membrane O
, O
one O
can O
then O
extrapolate O
the O
data O
to O
low O
or O
"zero" O
ligand O
solubility O
. O
The O
extrapolated O
value O
represents O
the O
radioligand-independent O
dissociation O
constant O
of O
the O
antipsychotic O
. O
These O
values O
are O
here O
given O
for O
dopamine O
D2 O
and O
D4 O
receptors O
, O
as O
well O
as O
for O
serotonin O
5-HT2A O
receptors O
. O
These O
values O
, O
moreover O
, O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 B
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O
seroquel O
, O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 O
receptor O
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O
to O
5 O
nM O
at O
dopamine O
D2 O
receptors O
, O
making O
them O
more O
resistant O
to O
displacement O
by O
endogenous O
dopamine O
. O
Finally O
, O
a O
relation O
was O
found O
between O
the O
neuroleptic O
doses O
for O
rat O
catalepsy O
and O
the O
D2:D4 O
ratio O
of O
the O
radioligand-independent O
K O
values O
for O
these O
two O
receptors O
. O
Thus O
, O
the O
atypical O
neuroleptics O
appear O
to O
fall O
into O
two O
groups O
, O
those O
that O
have O
a O
low O
affinity O
for O
dopamine O
D2 O
receptors O
and O
those O
that O
are O
selective O
for O
dopamine O
D4 O
receptors O
. O

Leu O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
of O
the O
mammalian O
type O
I O
and O
type O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
determine O
differential O
ligand O
selectivity O
to O
GnRH-I O
and O
GnRH-II.Mammalian O
type O
I O
and O
II O
gonadotropin-releasing O
hormone O
(GnRH) O
receptors O
(GnRHRs) O
show O
differential O
ligand O
preference O
for O
GnRH-I O
and O
GnRH-II O
, O
respectively O
. O
Using O
a O
variety O
of O
chimeric O
receptors O
based O
on O
green O
monkey O
GnRHR-2 O
(gmGnRHR-2) O
, O
a O
representative O
type O
II O
GnRHR O
, O
and O
rat O
GnRHR O
, O
a O
representative O
type O
I O
GnRHR O
, O
this O
study O
elucidated O
specific O
domains O
responsible O
for O
this O
ligand O
selectivity O
. O
A O
chimeric O
gmGnRHR-2 O
with O
the O
extracellular O
loop O
3 O
(EL3) O
and O
EL3-proximal O
transmembrane O
helix O
7 O
(TMH7) O
of O
rat O
GnRHR O
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I O
but O
not O
to O
GnRH-II O
. O
Point-mutation O
studies O
indicate O
that O
four O
amino O
acids O
, O
Leu/Phe(7.38) O
, O
Leu/Phe(7.43) O
, O
Ala/Pro(7.46) O
, O
and O
Pro/Cys(7.47) O
in O
TMH7 O
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation O
. O
Furthermore O
, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) O
motif O
to O
Ser-Glu-Pro O
in O
EL3 O
and O
Leu(7.38) O
, O
Leu(7.43) O
, O
Ala(7.46) O
, O
and O
Pro(7.47) O
to O
those O
of O
rat B
GnRHR) I
in O
gmGnRH-2 O
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I O
, O
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II O
from O
GnRH-I O
. O
[Trp(7)]GnRH-I O
and O
[Trp(8)]GnRH-I O
but O
not O
[His(5)]GnRH-I O
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O
gmGnRHR-2 O
than O
native O
GnRH-I O
, O
indicating O
that O
amino O
acids O
at O
positions O
7 O
and O
8 O
of O
GnRHs O
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type O
I O
and O
type O
II O
GnRHRs O
. O
As O
a O
whole O
, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O
the O
molecular O
interaction O
between O
GnRHs O
and O
their O
cognate O
receptors O
. O

sulfates O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Differential O
binding O
of O
fibroblast O
growth O
factor-2 O
and O
-7 O
to O
basement O
membrane O
heparan O
sulfate O
: O
comparison O
of O
normal O
and O
abnormal O
human O
tissues.Fibroblast O
growth O
factors O
(FGFs) O
play O
multiple O
roles O
during O
development O
and O
in O
adult O
tissues O
as O
paracrine O
regulators O
of O
growth O
and O
differentiation O
. O
FGFs O
signal O
through O
transmembrane O
receptor O
tyrosine O
kinases O
, O
but O
heparan O
sulfate O
is O
also O
required O
for O
signaling O
by O
members O
of O
the O
FGF O
family O
. O
In O
addition O
, O
heparan O
sulfate O
may O
be O
involved O
in O
determining O
tissue O
distribution O
of O
FGFs O
. O
Using O
biotinylated O
FGF-2 O
and O
FGF-7 O
(KGF) O
as O
probes O
, O
we O
have O
identified O
specific O
interactions O
between O
FGFs B
and O
heparan O
sulfates O
in O
human O
tissues O
. O
Both O
FGF O
species O
bind O
to O
tissue O
mast O
cells O
and O
to O
epithelial O
cell O
membranes O
. O
Binding O
to O
basement O
membrane O
heparan O
sulfate O
is O
tissue O
source O
dependent O
and O
specific O
. O
Although O
FGF-2 O
strongly O
binds O
to O
basement O
membrane O
heparan O
sulfate O
in O
skin O
and O
most O
other O
tissue O
sites O
examined O
, O
FGF-7 O
fails O
to O
bind O
to O
basement O
membrane O
heparan O
sulfate O
in O
most O
locations O
. O
However O
, O
in O
subendothelial O
matrix O
in O
blood O
vessels O
and O
in O
the O
basement O
membrane O
of O
a O
papillary O
renal O
cell O
carcinoma O
, O
strong O
FGF-7 O
binding O
is O
seen O
. O
In O
summary O
, O
distinct O
and O
specific O
affinities O
of O
heparan O
sulfates O
for O
different O
FGFs O
were O
identified O
that O
may O
affect O
growth O
factor O
activation O
and O
local O
distribution O
. O
Heparan O
sulfate O
may O
have O
a O
gatekeeper O
function O
to O
either O
restrict O
or O
permit O
diffusion O
of O
heparin-binding O
growth O
factors O
across O
the O
basement O
membrane O
. O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 B
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 O
by O
production O
of O
3H-GABA O
from O
3H-glutamate O
, O
enzyme O
kinetics O
, O
binding O
to O
the O
enzyme O
cofactor O
pyridoxal O
phosphate O
(PLP) O
, O
stability O
according O
to O
differences O
in O
pH O
, O
temperature O
and O
duration O
of O
storage O
, O
and O
antigenic O
reactivity O
with O
various O
GAD-specific O
antisera O
. O
RESULTS O
: O
The O
properties O
of O
rGAD67/65 O
were O
compared O
with O
published O
data O
for O
mammalian O
brain O
GAD O
(brackets) O
. O
These O
included O
a O
specific O
enzyme O
activity O
of O
22.7 O
(16.7) O
nKat O
, O
optimal O
pH O
for O
enzymatic O
activity O
7.4 O
(6.8) O
, O
K(m) O
of O
1.3 O
(1.3) O
mM O
, O
efficient O
non-covalent O
binding O
to O
the O
cofactor O
PLP O
, O
and O
high O
autoantigenic O
potency O
. O
The O
stability O
of O
rGAD67/65 O
was O
optimal O
over O
3 O
months O
at O
-80 O
degrees O
C O
, O
or O
in O
lyophilized O
form O
at O
-20 O
degrees O
C O
. O
CONCLUSIONS O
: O
Hybrid O
rGAD67/65 O
has O
enzymatic O
and O
other O
properties O
similar O
to O
those O
of O
the O
mixed O
isoforms O
of O
GAD O
in O
preparations O
from O
mammalian O
brain O
as O
described O
elsewhere O
, O
in O
addition O
to O
its O
previously O
described O
similar O
immunoreactivity O
. O

15d-PGJ2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cyclopentenone O
prostaglandins O
suppress O
activation O
of O
microglia O
: O
down-regulation O
of O
inducible O
nitric-oxide O
synthase O
by O
15-deoxy-Delta12,14-prostaglandin O
J2.Mechanisms O
leading O
to O
down-regulation O
of O
activated O
microglia O
and O
astrocytes O
are O
poorly O
understood O
, O
in O
spite O
of O
the O
potentially O
detrimental O
role O
of O
activated O
glia O
in O
neurodegeneration O
. O
Prostaglandins O
, O
produced O
both O
by O
neurons O
and O
glia O
, O
may O
serve O
as O
mediators O
of O
glial O
and O
neuronal O
functions O
. O
We O
examined O
the O
influence O
of O
cyclopentenone O
prostaglandins O
and O
their O
precursors O
on O
activated O
glia O
. O
As O
models O
of O
glial O
activation O
, O
production O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
was O
studied O
in O
lipopolysaccharide-stimulated O
rat O
microglia O
, O
a O
murine O
microglial O
cell O
line O
BV-2 O
, O
and O
IL-1beta-stimulated O
rat O
astrocytes O
. O
Cyclopentenone O
prostaglandins O
were O
potent O
inhibitors O
of O
iNOS O
induction O
and O
were O
more O
effective O
than O
their O
precursors O
, O
prostaglandins O
E2 O
and O
D2 O
. O
15-Deoxy-Delta12,14-prostaglandin O
J2 O
(15d-PGJ2) O
was O
the O
most O
potent O
prostaglandin O
among O
those O
tested O
. O
In O
activated O
microglia O
, O
15d-PGJ2 O
suppressed O
iNOS O
promoter O
activity O
, O
iNOS O
mRNA O
, O
and O
protein O
levels O
. O
The O
action O
of O
15d-PGJ2 O
does O
not O
appear O
to O
involve O
its O
nuclear O
receptor O
peroxisome O
proliferator-activated O
receptor O
gamma O
(PPARgamma) O
because O
troglitazone O
, O
a O
specific O
ligand O
of O
PPARgamma O
, O
was O
unable O
to O
inhibit O
iNOS O
induction O
, O
and O
neither O
troglitazone O
nor O
15d-PGJ2 O
could O
stimulate O
the O
activity O
of O
a O
PPAR-dependent O
promoter O
in O
the O
absence O
of O
cotransfected O
PPARgamma O
. O
15d-PGJ2 O
did O
not O
block O
nuclear O
translocation O
or O
DNA-binding O
activity O
of O
the O
transcription O
factor O
NFkappaB O
, O
but O
it O
did O
inhibit O
the O
activity O
of O
an O
NFkappaB B
reporter O
construct O
, O
suggesting O
that O
the O
mechanism O
of O
suppression O
of O
microglial O
iNOS O
by O
15d-PGJ2 O
may O
involve O
interference O
with O
NFkappaB O
transcriptional O
activity O
in O
the O
nucleus O
. O
Thus O
, O
our O
data O
suggest O
the O
existence O
of O
a O
novel O
pathway O
mediated O
by O
cyclopentenone O
prostaglandins O
, O
which O
may O
represent O
part O
of O
a O
feedback O
mechanism O
leading O
to O
the O
cessation O
of O
inflammatory O
glial O
responses O
in O
the O
brain O
. O

BRL-50481 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Characterization O
of O
renal O
ecto-phosphodiesterase.In O
kidneys O
, O
stimulation O
of O
adenylyl O
cyclase O
causes O
egress O
of O
cAMP O
, O
conversion O
of O
cAMP O
to O
AMP O
by O
ecto-phosphodiesterase O
, O
and O
metabolism O
of O
AMP O
to O
adenosine O
by O
ecto-5'-nucleotidase O
. O
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase O
, O
the O
renal O
ecto-phosphodiesterase O
remains O
uncharacterized O
. O
We O
administered O
cAMP O
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys O
. O
AMP O
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry O
. O
In O
control O
kidneys O
(n=19) O
, O
basal O
renal O
secretion O
rate O
of O
AMP O
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g O
kidney O
weight/min O
during O
administration O
of O
cAMP O
. O
A O
broad-spectrum O
phosphodiesterase O
(PDE) O
inhibitor O
(1,3-isobutyl-1-methylxanthine O
, O
300 O
microM O
, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine O
, O
1 O
mM O
, O
n=6) O
significantly O
attenuated O
cAMP-induced O
AMP O
secretion O
by O
60 O
and O
74% O
, O
respectively O
. O
Blockade O
of O
PDE1 O
(8-methoxymethyl-3-isobutyl-1-methylxanthine O
, O
100 O
microM) O
, O
PDE2 O
[erythro-9-(2-hydroxy-3-nonyl)adenine O
, O
30 O
microM] O
, O
PDE3 O
(milrinone O
, O
10 O
microM; O
cGMP O
, O
10 O
microM) O
, O
PDE4 O
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one] O
, O
100 O
microM) O
, O
PDE5 O
and O
PDE6 O
(zaprinast O
, O
30 O
microM) O
, O
and O
PDE7 B
[BRL-50481 O
(5-nitro-2,N,N-trimethylbenzenesulfonamide) O
, O
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase O
activity O
. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole O
that O
blocks O
PDE8 O
inhibited O
ecto-phosphodiesterase O
activity O
(by O
44%) O
. O
However O
, O
a O
lower O
concentration O
of O
dipyridamole O
(3 O
microM) O
that O
blocks O
PDE9 O
, O
PDE10 O
, O
and O
PDE11 O
, O
but O
not O
PDE8 O
, O
did O
not O
inhibit O
ecto-phosphodiesterase O
activity O
. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase O
activity O
is O
not O
mediated O
by O
PDE1 O
, O
PDE2 O
, O
PDE3 O
, O
PDE4 O
, O
PDE5 O
, O
PDE6 O
, O
PDE7 O
, O
PDE9 O
, O
PDE10 O
, O
or O
PDE11 O
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole O
. O
Ecto-phosphodiesterase O
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8 O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Identification O
of O
a O
new O
interaction O
mode O
between O
the O
Src O
homology O
2 O
(SH2) O
domain O
of O
C-terminal O
Src O
kinase O
(Csk) O
and O
Csk-binding O
protein O
(Cbp)/phosphoprotein O
associated O
with O
glycosphingolipid O
microdomains O
(PAG).Proteins O
with O
Src O
homology O
2 O
(SH2) O
domains O
play O
major O
roles O
in O
tyrosine O
kinase O
signaling O
. O
Structures O
of O
many O
SH2 O
domains O
have O
been O
studied O
, O
and O
the O
regions O
involved O
in O
their O
interactions O
with O
ligands O
have O
been O
elucidated O
. O
However O
, O
these O
analyses O
have O
been O
performed O
using O
short O
peptides O
comprising O
phosphotyrosine O
followed O
by O
a O
few O
amino O
acids O
, O
which O
are O
described O
as O
the O
canonical O
recognition O
sites O
. O
Here O
we O
report O
the O
solution O
structure O
of O
the O
SH2 O
domain O
of O
C-terminal B
Src I
kinase I
(Csk) O
in O
complex O
with O
a O
longer O
phosphopeptide O
from O
Csk-binding O
protein O
(Cbp) O
. O
This O
structure O
, O
together O
with O
biochemical O
experiments O
, O
revealed O
the O
existence O
of O
a O
novel O
binding O
region O
in O
addition O
to O
the O
canonical O
phosphotyrosine-314 O
binding O
site O
of O
Cbp O
. O
Mutational O
analysis O
of O
this O
second O
region O
in O
cells O
showed O
that O
both O
canonical O
and O
novel O
binding O
sites O
are O
required O
for O
tumor O
suppression O
through O
the O
Cbp-Csk O
interaction O
. O
Furthermore O
, O
the O
data O
indicate O
an O
allosteric O
connection O
between O
Cbp O
binding O
and O
Csk O
activation O
that O
arises O
from O
residues O
in O
the O
βB/βC O
loop O
of O
the O
SH2 O
domain O
. O

sulfonylureas O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2 B
/ O
SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

phthalide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine B
oxidase I
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO O
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O
the O
nineteen O
homologues O
evaluated O
, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O
MAO-A O
and O
-B O
were O
0.096 O
and O
0.0014 O
μM O
, O
respectively O
. O
In O
most O
instances O
, O
C6-substituted O
phthalides O
exhibit O
MAO-B O
specific O
inhibition O
. O
Among O
a O
series O
of O
6-benzyloxyphthalides O
bearing O
substituents O
on O
the O
para O
position O
of O
the O
phenyl O
ring O
the O
general O
order O
of O
potency O
was O
CF(3) O
> O
I O
> O
Br O
> O
Cl O
> O
F O
> O
CH(3) O
> O
H O
. O
The O
results O
also O
show O
that O
the O
binding O
modes O
of O
representative O
phthalides O
are O
reversible O
and O
competitive O
at O
both O
MAO O
isoforms O
. O
Based O
on O
these O
data O
, O
C6-substituted O
phthalides O
may O
serve O
as O
leads O
for O
the O
development O
of O
therapies O
for O
neurodegenerative O
disorders O
such O
as O
Parkinson's O
disease O
. O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Pterostilbene O
exerts O
antitumor O
activity O
against O
human O
osteosarcoma O
cells O
by O
inhibiting O
the O
JAK2/STAT3 O
signaling O
pathway.Osteosarcoma O
is O
a O
high-grade O
malignant O
bone O
tumor O
. O
Pterostilbene O
(PTE) O
is O
a O
natural O
, O
dimethylated O
analog O
of O
resveratrol O
with O
higher O
bioavailability O
. O
While O
PTE O
has O
been O
shown O
to O
have O
potent O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL B
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

aldosterone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain B
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ursolic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 B
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin B
light I
chain I
kinase I
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

trifluoperazine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phenothiazines O
inhibit O
S100A4 O
function O
by O
inducing O
protein O
oligomerization.S100A4 O
, O
a O
member O
of O
the O
S100 O
family O
of O
Ca(2+)-binding O
proteins O
, O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA O
. O
Numerous O
studies O
indicate O
that O
S100A4 O
is O
not O
simply O
a O
marker O
for O
metastatic O
disease O
, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression O
. O
These O
observations O
suggest O
that O
S100A4 O
is O
an O
excellent O
target O
for O
therapeutic O
intervention O
. O
Using O
a O
unique O
biosensor-based O
assay O
, O
trifluoperazine O
(TFP) O
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4 O
/ O
myosin-IIA B
interaction O
. O
To O
examine O
the O
interaction O
of O
S100A4 O
with O
TFP O
, O
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 O
bound O
to O
TFP O
. O
Two O
TFP O
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 O
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation O
. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O
the O
crystal O
structure O
and O
demonstrate O
that O
TFP O
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 O
in O
solution O
. O
Remarkably O
, O
TFP O
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP O
dimers O
into O
a O
tightly O
packed O
pentameric O
ring O
. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 O
dimers O
occurs O
through O
the O
TFP O
moieties O
. O
The O
Ca(2+)-S100A4/prochlorperazine O
(PCP) O
complex O
exhibits O
a O
similar O
pentameric O
assembly O
. O
Equilibrium O
sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP O
oligomer O
in O
solution O
. O
Assays O
examining O
the O
ability O
of O
TFP O
to O
block O
S100A4-mediated O
disassembly O
of O
myosin-IIA O
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 O
function O
occurs O
only O
at O
TFP O
concentrations O
that O
promote O
S100A4 O
oligomerization O
. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines O
disrupt O
the O
S100A4/myosin-IIA O
interaction O
by O
sequestering O
S100A4 O
via O
small O
molecule-induced O
oligomerization O
. O

Benzodiazepines O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Inhibition O
of O
recombinant O
L-type O
voltage-gated O
calcium O
channels O
by O
positive O
allosteric O
modulators O
of O
GABAA O
receptors.Benzodiazepines O
(BDZs) O
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) O
receptors O
( O
GABA(A)R) B
 O
. O
BDZs O
and O
other O
positive O
GABA(A)R O
modulators O
, O
including O
barbiturates O
, O
ethanol O
, O
and O
neurosteroids O
, O
can O
also O
inhibit O
L-type O
voltage-gated O
calcium O
channels O
(L-VGCCs) O
, O
which O
could O
contribute O
to O
reduced O
neuronal O
excitability O
. O
Because O
neuronal O
L-VGCC O
function O
is O
up-regulated O
after O
long-term O
GABA(A)R O
modulator O
exposure O
, O
an O
interaction O
with O
L-VGCCs O
may O
also O
play O
a O
role O
in O
physical O
dependence O
. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs O
(diazepam O
, O
flurazepam O
, O
and O
desalkylflurazepam) O
, O
allopregnanolone O
, O
pentobarbital O
, O
and O
ethanol O
on O
whole-cell O
Ba(2+) O
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 O
and O
Ca(v)1.3 O
L-VGCCs O
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells O
. O
Allopregnanolone O
was O
the O
most O
potent O
inhibitor O
(IC(50) O
, O
approximately O
10 O
muM) O
, O
followed O
by O
BDZs O
(IC(50) O
, O
approximately O
50 O
muM) O
, O
pentobarbital O
(IC(50) O
, O
0.3-1 O
mM) O
, O
and O
ethanol O
(IC(50) O
, O
approximately O
300 O
mM) O
. O
Ca(v)1.3 O
channels O
were O
less O
sensitive O
to O
pentobarbital O
inhibition O
than O
Ca(v)1.2 O
channels O
, O
similar O
to O
dihydropyridine O
(DHP) O
L-VGCC O
antagonists O
. O
All O
GABA(A)R O
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O
inactivation O
curve O
of O
Ca(v)1.3 O
channels O
, O
but O
only O
BDZs O
and O
pentobarbital O
induced O
a O
negative O
shift O
in O
Ca(v)1.2 O
channel O
inactivation O
. O
Mutation O
of O
the O
high-affinity O
DHP O
binding O
site O
(T1039Y O
and O
Q1043M) O
in O
Ca(v)1.2 O
channels O
reduced O
pentobarbital O
potency O
. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines O
and O
BDZs O
, O
mutation O
of O
an O
amino O
acid O
important O
for O
diltiazem O
potency O
(I1150A) O
did O
not O
affect O
diazepam O
potency O
. O
Although O
L-VGCC O
inhibition O
by O
BDZs O
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs O
during O
long-term O
treatment O
, O
pentobarbital O
and O
ethanol O
inhibited O
L-VGCCs O
at O
clinically O
relevant O
concentrations O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Acid O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells O
. O
Ursolic O
acid O
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK B
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

7βOHC O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Absence O
of O
correlation O
between O
oxysterol O
accumulation O
in O
lipid O
raft O
microdomains O
, O
calcium O
increase O
, O
and O
apoptosis O
induction O
on O
158N O
murine O
oligodendrocytes.There O
is O
some O
evidence O
that O
oxidized O
derivatives O
of O
cholesterol O
, O
7-ketocholesterol O
(7KC) O
and O
7β-hydroxycholesterol O
(7βOHC) O
, O
are O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 B
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O
rise O
was O
found O
with O
the O
different O
oxysterols O
, O
whereas O
strong O
signals O
were O
detected O
with O
ionomycin O
used O
as O
positive O
control O
. O
At O
concentrations O
which O
induced O
apoptosis O
, O
7KC O
but O
not O
7βOHC O
accumulated O
in O
lipid O
rafts O
. O
Although O
not O
cytotoxic O
, O
27OHC O
was O
mainly O
detected O
in O
lipid O
rafts O
. O
It O
is O
noteworthy O
that O
α-tocopherol O
(but O
not O
ellagic O
acid O
and O
resveratrol) O
was O
able O
to O
counteract O
7KC- O
and O
7βOHC-induced O
apoptosis O
and O
to O
decrease O
the O
accumulation O
of O
7KC O
and O
27OHC O
in O
lipid O
rafts O
. O
Thus O
, O
in O
158N O
cells O
, O
the O
ability O
of O
oxysterols O
to O
trigger O
a O
mode O
of O
cell O
death O
by O
apoptosis O
involving O
GSK-3 O
and O
caspase-3 O
activation O
is O
independent O
of O
the O
increase O
in O
the O
Ca(2+) O
level O
and O
of O
their O
accumulation O
in O
lipid O
raft O
microdomains O
. O

Amprenavir O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Pregnane O
X O
Receptor O
Mediates O
Dyslipidemia O
Induced O
by O
the O
HIV O
Protease O
Inhibitor O
Amprenavir O
in O
Mice.HIV O
protease O
inhibitors O
(PIs) O
have O
been O
used O
successfully O
in O
extending O
the O
lifespan O
of O
people O
infected O
with O
HIV O
. O
The O
use O
of O
PIs O
has O
also O
been O
associated O
with O
dyslipidemia O
and O
an O
increased O
risk O
of O
cardiovascular O
disease O
but O
the O
underlying O
mechanisms O
remain O
elusive O
. O
Several O
PIs O
have O
been O
implicated O
to O
activate O
the O
nuclear O
receptor O
pregnane O
X O
receptor O
(PXR) O
, O
which O
acts O
as O
a O
xenobiotic O
sensor O
to O
regulate O
xenobiotic O
metabolism O
in O
the O
liver O
and O
intestine O
. O
Recent O
studies O
indicate O
that O
PXR O
may O
also O
play O
an O
important O
role O
in O
the O
regulation O
of O
lipid O
homeostasis O
. O
In O
the O
present O
study O
, O
we O
identified O
amprenavir O
, O
a O
widely O
used O
HIV O
PI O
, O
as O
a O
potent O
PXR-selective O
agonist O
. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR O
that O
constitute O
points O
of O
interaction O
with O
amprenavir O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O
Short-term O
exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low-density O
lipoprotein O
cholesterol O
levels O
in O
wild-type O
mice O
, O
but O
not O
in O
PXR-deficient O
mice O
. O
Amprenavir-mediated O
PXR B
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O
involved O
in O
lipid O
homeostasis O
. O
These O
findings O
provide O
critical O
mechanistic O
insight O
for O
understanding O
the O
impact O
of O
PIs O
on O
cardiovascular O
disease O
and O
demonstrate O
a O
potential O
role O
of O
PXR O
in O
mediating O
adverse O
effects O
of O
HIV O
PIs O
in O
humans O
. O

Adrenaline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Involvement O
of O
pertussis O
toxin-sensitive O
G-proteins O
in O
the O
hormonal O
inhibition O
of O
dihydropyridine-sensitive O
Ca2+ O
currents O
in O
an O
insulin-secreting O
cell O
line O
(RINm5F).Adrenaline O
inhibits O
insulin B
secretion O
via O
pertussis O
toxin-sensitive O
mechanisms O
. O
Since O
voltage-dependent O
Ca2+ O
currents O
play O
a O
key O
role O
in O
insulin O
secretion O
, O
we O
examined O
whether O
adrenaline O
modulates O
voltage-dependent O
Ca2+ O
currents O
of O
the O
rat O
insulinoma O
cell O
line O
, O
RINm5F O
. O
In O
the O
whole-cell O
configuration O
of O
the O
patch-clamp O
technique O
, O
dihydropyridine- O
but O
not O
omega-conotoxin-sensitive O
Ca2+ O
currents O
were O
identified O
. O
Adrenaline O
via O
alpha O
2-adrenoceptors O
inhibited O
the O
Ca2+ O
currents O
by O
about O
50% O
. O
Somatostatin O
which O
also O
inhibits O
insulin O
secretion O
was O
less O
efficient O
(inhibition O
by O
20%) O
. O
The O
hormonal O
inhibition O
of O
Ca2+ O
currents O
was O
not O
affected O
by O
intracellularly O
applied O
cAMP O
but O
blocked O
by O
the O
intracellularly O
applied O
GDP O
analog O
guanosine O
5'-O-(2-thiodiphosphate) O
and O
by O
pretreatment O
of O
cells O
with O
pertussis O
toxin O
. O
In O
contrast O
to O
adrenaline O
and O
somatostatin O
, O
galanin O
, O
another O
inhibitor O
of O
insulin O
secretion O
, O
reduced O
Ca2+ O
currents O
by O
about O
40% O
in O
a O
pertussis O
toxin-insensitive O
manner O
. O
Immunoblot O
experiments O
performed O
with O
antibodies O
generated O
against O
synthetic O
peptides O
revealed O
that O
membranes O
of O
RINm5F O
cells O
possess O
four O
pertussis O
toxin-sensitive O
G-proteins O
including O
Gi1 O
, O
Gi2 O
, O
Go2 O
, O
and O
another O
Go O
subtype O
, O
most O
likely O
representing O
Go1 O
. O
In O
membranes O
of O
control O
but O
not O
of O
pertussis O
toxin-treated O
cells O
, O
adrenaline O
via O
alpha O
2-adrenoceptors O
stimulated O
incorporation O
of O
the O
photo-reactive O
GTP O
analog O
[alpha-32P]GTP O
azidoanilide O
into O
pertussis O
toxin O
substrates O
comigrating O
with O
the O
alpha-subunits O
of O
Gi2 O
, O
Go2 O
, O
and O
the O
not O
further O
identified O
Go O
subtype O
. O
The O
present O
findings O
indicate O
that O
activated O
alpha O
2-adrenoceptors O
of O
RINm5F O
cells O
interact O
with O
multiple O
G-proteins O
, O
i.e O
. O
two O
forms O
of O
Go O
and O
with O
Gi2 O
. O
These O
G-proteins O
are O
likely O
to O
be O
involved O
in O
the O
adrenaline-induced O
inhibition O
of O
dihydropyridine-sensitive O
Ca2+ O
currents O
and O
in O
other O
signal O
transduction O
pathways O
contributing O
to O
the O
adrenaline-induced O
inhibition O
of O
insulin O
secretion O
. O

Ser40 O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Tyrosine O
hydroxylase O
binds O
tetrahydrobiopterin O
cofactor O
with O
negative O
cooperativity O
, O
as O
shown O
by O
kinetic O
analyses O
and O
surface O
plasmon O
resonance O
detection.Kinetic O
studies O
of O
tetrameric O
recombinant O
human O
tyrosine O
hydroxylase O
isoform O
1 O
(hTH1) O
have O
revealed O
properties O
so O
far O
not O
reported O
for O
this O
enzyme O
. O
Firstly O
, O
with O
the O
natural O
cofactor O
(6R)-Lerythro-5,6,7 O
, O
8-tetrahydrobiopterin O
(H4biopterin) O
a O
time-dependent O
change O
(burst) O
in O
enzyme O
activity O
was O
observed O
, O
with O
a O
half-time O
of O
about O
20 O
s O
for O
the O
kinetic O
transient O
. O
Secondly O
, O
nonhyperbolic O
saturation O
behaviour O
was O
found O
for O
H4biopterin O
with O
a O
pronounced O
negative O
cooperativity O
(0.39 O
< O
h O
< O
0.58; O
[S]0.5 O
= O
24 O
+/- O
4 O
microM) O
. O
On O
phosphorylation O
of O
Ser40 O
by O
protein B
kinase I
A I
, O
the O
affinity O
for O
H4biopterin O
increased O
([S]0.5 O
= O
11 O
+/- O
2 O
microM) O
and O
the O
negative O
cooperativity O
was O
amplified O
(h O
= O
0.27 O
+/- O
0.03) O
. O
The O
dimeric O
C-terminal O
deletion O
mutant O
(Delta473-528) O
of O
hTH1 O
also O
showed O
negative O
cooperativity O
of O
H4biopterin O
binding O
(h O
= O
0.4) O
. O
Cooperativity O
was O
not O
observed O
with O
the O
cofactor O
analogues O
6-methyl-5,6,7,8-tetrahydropterin O
(h O
= O
0.9 O
+/- O
0.1; O
Km O
= O
62.7 O
+/- O
5.7 O
microM) O
and O
3-methyl-5,6,7 O
, O
8-tetrahydropterin O
(H43-methyl-pterin)(h O
= O
1.0 O
+/- O
0.1; O
Km O
= O
687 O
+/- O
50 O
microM) O
. O
In O
the O
presence O
of O
1 O
mM O
H43-methyl-pterin O
, O
used O
as O
a O
competitive O
cofactor O
analogue O
to O
BH4 O
, O
hyperbolic O
saturation O
curves O
were O
also O
found O
for O
H4biopterin O
(h O
= O
1.0) O
, O
thus O
confirming O
the O
genuine O
nature O
of O
the O
kinetic O
negative O
cooperativity O
. O
This O
cooperativity O
was O
confirmed O
by O
real-time O
biospecific O
interaction O
analysis O
by O
surface O
plasmon O
resonance O
detection O
. O
The O
equilibrium O
binding O
of O
H4biopterin O
to O
the O
immobilized O
iron-free O
apoenzyme O
results O
in O
a O
saturable O
positive O
resonance O
unit O
(DeltaRU) O
response O
with O
negative O
cooperativity O
(h O
= O
0.52-0.56) O
. O
Infrared O
spectroscopic O
studies O
revealed O
a O
reduced O
thermal O
stability O
both O
of O
the O
apo-and O
the O
holo-hTH1 O
on O
binding O
of O
H4biopterin O
and O
Lerythro-dihydrobiopterin O
(H2biopterin) O
. O
Moreover O
, O
the O
ligand-bound O
forms O
of O
the O
enzyme O
also O
showed O
a O
decreased O
resistance O
to O
limited O
tryptic O
proteolysis O
. O
These O
findings O
indicate O
that O
the O
binding O
of O
H4biopterin O
at O
the O
active O
site O
induces O
a O
destabilizing O
conformational O
change O
in O
the O
enzyme O
which O
could O
be O
related O
to O
the O
observed O
negative O
cooperativity O
. O
Thus O
, O
our O
studies O
provide O
new O
insight O
into O
the O
regulation O
of O
TH O
by O
the O
concentration O
of O
H4biopterin O
which O
may O
have O
significant O
implications O
for O
the O
physiological O
regulation O
of O
catecholamine O
biosynthesis O
in O
neuroendocrine O
cells O
. O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O
R-modafinil O
displays O
an O
in O
vitro O
profile O
different O
from O
cocaine O
. O
Future O
trials O
with O
R-modafinil O
as O
a O
substitute O
therapy O
with O
the O
potential O
benefit O
of O
cognitive O
enhancement O
for O
psychostimulant O
addiction O
are O
warranted O
. O

311C90 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pre-clinical O
pharmacology O
of O
zolmitriptan O
(Zomig; O
formerly O
311C90) O
, O
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D O
agonist O
for O
migraine.Zolmitriptan O
(Zomig; O
formerly O
311C90) O
is O
a O
novel O
5-hydroxytryptamine B
(5HT)1B/1D I
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O
it O
combines O
5HT1B/1D O
receptor O
partial O
agonist O
activity O
with O
robust O
oral O
pharmacokinetics O
and O
an O
ability O
to O
inhibit O
trigeminovascular O
activation O
centrally O
as O
well O
as O
peripherally O
in O
preclinical O
studies O
. O
Consistent O
with O
its O
selectivity O
for O
5HT1B/1D O
receptors O
, O
zolmitriptan O
produces O
constriction O
of O
various O
isolated O
blood O
vessels O
, O
most O
notably O
cranial O
arteries O
. O
In O
anaesthetized O
animals O
, O
these O
vascular O
effects O
manifest O
as O
a O
selective O
constriction O
of O
cranial O
arterio-venous O
anastomoses O
resulting O
in O
a O
redistribution O
of O
carotid O
arterial O
blood O
flow O
. O
This O
effect O
is O
produced O
without O
significant O
effects O
on O
heart O
rate O
, O
blood O
pressure O
or O
blood O
flow O
to O
the O
brain O
, O
heart O
or O
lungs O
. O
Zolmitriptan O
also O
inhibits O
trigeminal-evoked O
increases O
in O
cerebral O
blood O
flow O
in O
anaesthetized O
cats O
and O
blocks O
trigeminal-evoked O
plasma O
protein O
extravasation O
in O
the O
dura O
of O
guinea-pigs O
. O
These O
actions O
are O
consistent O
with O
a O
pre-junctional O
inhibition O
of O
neuropeptide O
release O
from O
perivascular O
afferents O
of O
the O
trigeminal O
nerve O
, O
as O
confirmed O
by O
independent O
studies O
showing O
that O
zolmitriptan O
blocks O
elevations O
of O
calcitonin-gene-related O
peptide O
in O
jugular O
venous O
blood O
during O
electrical O
stimulation O
of O
the O
trigeminal O
ganglion O
. O
In O
all O
of O
these O
effects O
, O
zolmitriptan O
is O
three O
to O
four O
times O
more O
potent O
than O
sumatriptan O
, O
but O
produces O
the O
same O
maximum O
response O
. O
Zolmitriptan O
crosses O
the O
intact O
blood-brain O
barrier O
to O
inhibit O
trigeminovascular O
activation O
in O
the O
brainstem O
. O
This O
was O
shown O
initially O
by O
the O
ability O
of O
the O
drug O
to O
block O
a O
brainstem O
reflex O
provoking O
vasoactive O
intestinal O
peptide O
release O
from O
the O
VIIth O
cranial O
(facial) O
nerve O
during O
trigeminal O
stimulation O
. O
Subsequent O
ex O
vivo O
autoradiography O
confirmed O
that O
intravenously O
injected O
[3H]zolmitriptan O
labels O
a O
discrete O
population O
of O
cells O
in O
the O
trigeminal O
nucleus O
caudalis O
(TNC) O
and O
nucleus O
tractus O
solitarius O
. O
Direct O
evidence O
for O
a O
central O
neuromodulatory O
effect O
of O
zolmitriptan O
was O
provided O
by O
electrophysiological O
experiments O
which O
clearly O
demonstrated O
that O
the O
drug O
inhibits O
the O
excitability O
of O
cells O
in O
the O
TNC O
after O
systemic O
administration O
. O
This O
novel O
pre-clinical O
profile O
not O
only O
distinguishes O
zolmitriptan O
from O
sumatriptan O
, O
but O
raises O
intriguing O
questions O
about O
the O
clinical O
relevance O
of O
a O
dual O
action O
. O
Studies O
to O
date O
show O
that O
zolmitriptan O
indeed O
modulates O
cranial O
sensory O
processing O
in O
humans O
, O
yet O
central O
side-effects O
are O
no O
different O
from O
sumatriptan O
. O
This O
property O
may O
account O
for O
the O
remarkable O
consistency O
in O
clinical O
efficacy O
observed O
in O
clinical O
trials O
. O

RS-17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Analysis O
of O
alpha O
1L-adrenoceptor O
pharmacology O
in O
rat O
small O
mesenteric O
artery.1 O
. O
To O
illuminate O
the O
controversy O
on O
alpha O
1A- O
or O
alpha O
1L-adrenoceptor O
involvement O
in O
noradrenaline-mediated O
contractions O
of O
rat O
small O
mesenteric O
artery O
(SMA) O
, O
we O
have O
studied O
the O
effects O
of O
subtype-selective O
alpha O
1-adrenoceptor O
agonists O
and O
antagonists O
under O
different O
experimental O
conditions O
. O
2 O
. O
The O
agonist O
potency O
order O
in O
rat O
SMA O
was O
: O
A61603 O
>> O
SKF89748-A O
> O
cirazoline O
> O
noradrenaline O
> O
ST-587 O
> O
methoxamine O
. O
Prazosin O
antagonized O
all O
agonists O
with O
a O
low O
potency O
(pA2 O
: O
8.29-8.80) O
indicating O
the O
involvement O
of O
alpha O
1L-rather O
than O
alpha O
1A-adrenoceptors O
. O
3 O
. O
The O
putative O
alpha O
1L-adrenoceptor O
antagonist O
JTH-601 O
, O
but O
not O
the O
alpha O
1B-adrenoceptor O
antagonist O
chloroethylclonidine O
(10 O
microM) O
antagonized O
noradrenaline-induced O
contractions O
of O
SMA O
. O
The O
potency O
of O
the O
selective O
alpha O
1D-adrenoceptor O
antagonist O
BMY O
7378 O
against O
noradrenaline O
(pA2 O
= O
6.16 O
+/- O
0.13) O
and O
of O
the O
selective O
alpha O
1A-adrenoceptor O
antagonist O
RS-17053 O
against O
noradrenaline O
(pKB O
= O
8.35 O
+/- O
0.10) O
and O
against O
the O
selective O
alpha O
1A-adrenoceptor O
agonist O
A-61603 O
(pKB O
= O
8.40 O
+/- O
0.09) O
were O
too O
low O
to O
account O
for O
alpha O
1D- O
and O
alpha O
1A-adrenoceptor O
involvement O
. O
4 O
. O
The O
potency O
of O
RS-17053 O
(pKB/pA2's O
= O
7.72-8.46) O
was O
not O
affected O
by O
lowering O
temperature O
, O
changing O
experimental O
protocol O
or O
inducing O
myogenic O
tone O
via O
KCl O
or O
U46619 O
. O
5 O
. O
Selective O
protection O
of O
a O
putative O
alpha O
1A-adrenoceptor O
population O
against O
the O
irreversible O
action O
of O
phenoxybenzamine O
also O
failed O
to O
increase O
the O
potency O
of O
RS-17053 O
(pA2 O
= O
8.25 O
+/- O
0.06 O
against O
A61603) O
. O
6 O
. O
Combined O
concentration-ratio O
analysis O
demonstrated O
that O
tamsulosin O
, O
which O
does O
not O
discriminate O
between O
alpha O
1A- O
and O
alpha B
1L-adrenoceptors I
, O
and O
RS-17053 O
competed O
for O
binding O
at O
the O
same O
site O
in O
the O
SMA O
. O
7 O
. O
In O
summary O
, O
data O
obtained O
in O
our O
experiments O
in O
rat O
SMA O
indicate O
that O
the O
alpha O
1-adrenoceptor O
mediating O
noradrenaline-induced O
contraction O
displays O
a O
distinct O
alpha O
1L-adrenoceptor O
pharmacology O
. O
This O
study O
does O
not O
provide O
evidence O
for O
the O
hypothesis O
that O
alpha O
1L-adrenoceptors O
represent O
an O
affinity O
state O
of O
the O
alpha O
1A-adrenoceptor O
in O
functional O
assays O
. O
Furthermore O
, O
there O
is O
no O
co-existing O
alpha O
1A-adrenoceptor O
in O
the O
SMA O
. O

Bambuterol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effects O
of O
bambuterol O
and O
terbutaline O
on O
isolated O
rat's O
tracheal O
smooth O
muscle.Terbutaline O
(Bricanyl) O
and O
its O
prodrug O
Bambuterol O
(Bambec) O
are O
highly O
potent O
beta(2)-adrenoceptor B
agonists O
often O
used O
in O
asthma O
patients O
. O
Terbutaline O
in O
the O
form O
of O
inhaled O
short-acting O
bronchodilator O
relieves O
asthmatic O
symptoms O
. O
However O
, O
the O
effects O
of O
bambuterol O
given O
intratracheally O
have O
rarely O
been O
explored O
. O
To O
verify O
the O
effect O
of O
bambuterol O
and O
terbutaline O
, O
which O
act O
on O
the O
tracheal O
smooth O
muscle O
directly O
in O
vitro O
, O
we O
used O
our O
preparation O
to O
test O
the O
effects O
of O
bambuterol O
on O
isolated O
rat's O
tracheal O
smooth O
muscle O
compared O
with O
terbutaline O
. O
The O
following O
assessments O
of O
bambuterol O
and O
terbutaline O
were O
performed O
: O
(1) O
effect O
on O
tracheal O
smooth O
muscle O
resting O
tension; O
(2) O
effect O
on O
contraction O
caused O
by O
10(-6) O
M O
methacholine O
as O
a O
parasympathetic O
mimetic; O
(3) O
effect O
of O
the O
drugs O
on O
electrically O
induced O
tracheal O
smooth O
muscle O
contractions O
. O
The O
results O
indicated O
that O
adding O
bambuterol O
induced O
a O
significant O
further O
contraction O
to O
10(-6) O
M O
methacholine-induced O
contraction O
when O
the O
preparation O
was O
increased O
to O
10(-4) O
M O
. O
But O
terbutaline O
elicited O
a O
relaxation O
response O
at O
a O
dose O
of O
10(-6) O
M O
or O
more O
. O
Both O
bambuterol O
and O
terbutaline O
could O
inhibit O
electrical O
field O
stimulation O
(EFS) O
induced O
spike O
contraction O
. O
Terbutaline O
had O
an O
anti-cholinergic O
effect O
that O
could O
relieve O
asthmatic O
symptoms O
. O
But O
the O
effect O
of O
bambuterol O
acting O
on O
tracheal O
smooth O
muscle O
directly O
was O
controversial O
. O

naltrindole O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
vivo O
and O
in O
vitro O
characterization O
of O
naltrindole-derived O
ligands O
at O
the O
κ-opioid B
receptor I
.Accumulating O
evidence O
supports O
a O
role O
for O
κ-opioid O
receptor O
antagonists O
in O
the O
treatment O
of O
mood O
disorders O
. O
Standard O
κ-antagonists O
have O
an O
unusual O
pharmacodynamic O
action O
, O
with O
a O
single O
injection O
blocking O
receptor O
signaling O
for O
several O
weeks O
. O
Here O
, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands O
, O
5'-(2-aminomethyl) O
naltrindole O
(5'-AMN) O
and O
N-((Naltrindol-5-yl) O
methyl) O
pentanimidamide O
(5'-MABN) O
, O
to O
identify O
whether O
modifications O
of O
the O
naltrindole O
side O
chain O
produces O
short-acting O
κ-antagonists O
. O
Opioid O
receptor O
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O
0.08 O
, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18 O
, O
respectively) O
and O
μ-receptor O
antagonists O
(pA(2) O
7.62 O
and O
7.85 O
, O
respectively) O
in O
the O
ileum O
. O
Contrary O
to O
our O
hypothesis O
, O
in O
vivo O
, O
5'-AMN O
and O
5'-MABN O
displayed O
long-lasting O
antagonist O
effects O
in O
mice O
, O
reducing O
the O
antinociceptive O
actions O
of O
U50,488 O
(10 O
mg/kg) O
at O
28 O
and O
21 O
days O
post-injection O
, O
respectively O
. O
Interestingly O
, O
while O
5'-AMN O
and O
5'-MABN O
were O
not O
κ-selective O
, O
both O
compounds O
did O
show O
significant O
antidepressant- O
and O
anxiolytic-like O
effects O
at O
7-14 O
days O
post-injection O
in O
mice O
. O

t-butyl O
acts O
as O
NOT O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP B
phosphodiesterase I
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

SC-236 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon.To O
determine O
the O
role O
of O
14-3-3 O
in O
colorectal O
cancer O
apoptosis O
induced O
by O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
we O
evaluated O
the O
effects O
of O
sulindac O
on O
14-3-3epsilon O
protein O
expression O
in O
colorectal O
cancer O
cells O
. O
Sulindac O
sulfide O
inhibited O
14-3-3epsilon O
proteins O
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
Sulindac O
sulfone O
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29 O
. O
Indomethacin O
and O
SC-236 O
, O
a O
selective O
cyclooxygenase-2 B
(COX-2) O
inhibitor O
, O
exerted O
a O
similar O
effect O
as O
sulindac O
. O
Sulindac O
suppressed O
14-3-3epsilon O
promoter O
activity O
. O
As O
14-3-3epsilon O
promoter O
activation O
is O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
delta O
(PPARdelta) O
, O
we O
determined O
the O
correlation O
between O
14-3-3epsilon O
inhibition O
and O
PPARdelta O
suppression O
by O
NSAIDs O
. O
Sulindac O
sulfide O
inhibited O
PPARdelta O
protein O
expression O
and O
PPARdelta O
transcriptional O
activity O
. O
Overexpression O
of O
PPARdelta O
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon O
proteins O
from O
elimination O
by O
sulindac O
or O
indomethacin O
. O
NSAID-induced O
14-3-3epsilon O
suppression O
was O
associated O
with O
reduced O
cytosolic O
Bad O
with O
elevation O
of O
mitochondrial O
Bad O
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta O
transduction O
. O
Stable O
expression O
of O
14-3-3epsilon O
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis O
. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O
colorectal O
cancer O
apoptosis O
via O
the O
PPARdelta/14-3-3epsilon O
transcriptional O
pathway O
. O
These O
results O
suggest O
that O
14-3-3epsilon O
is O
a O
target O
for O
the O
prevention O
and O
therapy O
of O
colorectal O
cancer O
. O

milrinone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Modulation O
of O
TNF O
and O
GM-CSF O
release O
from O
dispersed O
human O
nasal O
polyp O
cells O
and O
human O
whole O
blood O
by O
inhibitors O
of O
different O
PDE O
isoenzymes O
and O
glucocorticoids.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
role O
of O
the O
inhibitors O
of O
different O
PDE O
isoenzymes O
(PDE O
1-5) O
on O
the O
production O
of O
two O
pro-inflammatory O
cytokines O
- O
tumor O
necrosis O
factor O
alpha O
(TNF) O
and O
granulocyte-macrophage O
colony-stimulating O
factor O
(GM-CSF) O
. O
Two O
in O
vitro O
models O
were O
used O
to O
compare O
the O
antiinflammatory O
properties O
of O
PDE O
inhibitors O
with O
that O
of O
glucocorticoids O
. O
The O
effect O
on O
TNF O
release O
from O
diluted O
human O
blood O
following O
lipopolysaccharide O
(LPS O
from O
Salmonella O
abortus O
equi) O
stimulation O
as O
well O
as O
the O
GM-CSF O
and O
TNF O
release O
from O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF B
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE O
4 O
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

metformin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
AMP-activated O
protein O
kinase-dependent O
and O
-independent O
mechanisms O
underlying O
in O
vitro O
antiglioma O
action O
of O
compound O
C.We O
investigated O
the O
effect O
of O
compound O
C O
, O
a O
well-known O
inhibitor O
of O
the O
intracellular O
energy O
sensor O
AMP-activated O
protein O
kinase O
(AMPK) O
, O
on O
proliferation O
and O
viability O
of O
human O
U251 O
and O
rat O
C6 O
glioma O
cell O
lines O
. O
Compound O
C O
caused O
G(2)/M O
cell O
cycle O
block O
, O
accompanied O
by O
apoptotic O
glioma O
cell O
death O
characterized O
by O
caspase O
activation O
, O
phosphatidylserine O
exposure O
and O
DNA O
fragmentation O
. O
The O
mechanisms O
underlying O
the O
pro-apoptotic O
action O
of O
compound O
C O
involved O
induction O
of O
oxidative O
stress O
and O
downregulation O
of O
antiapoptotic O
molecule O
Bcl-2 O
, O
while O
no O
alteration O
of O
pro-apoptotic O
Bax O
was O
observed O
. O
Compound O
C O
diminished O
AMPK O
phosphorylation O
and O
enzymatic O
activity O
, O
resulting O
in O
reduced O
phosphorylation O
of O
its O
target O
acetyl O
CoA O
carboxylase O
. O
AMPK B
activators O
metformin O
and O
AICAR O
partly O
prevented O
the O
cell O
cycle O
block O
, O
oxidative O
stress O
and O
apoptosis O
induced O
by O
compound O
C O
. O
The O
small O
interfering O
RNA O
(siRNA) O
targeting O
of O
human O
AMPK O
mimicked O
compound O
C-induced O
G(2)/M O
cell O
cycle O
arrest O
, O
but O
failed O
to O
induce O
oxidative O
stress O
and O
apoptosis O
in O
U251 O
glioma O
cells O
. O
In O
conclusion O
, O
our O
data O
indicate O
that O
AMPK O
inhibition O
is O
required O
, O
but O
not O
sufficient O
for O
compound O
C-mediated O
apoptotic O
death O
of O
glioma O
cells O
. O

Terbutaline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Effects O
of O
bambuterol O
and O
terbutaline O
on O
isolated O
rat's O
tracheal O
smooth O
muscle.Terbutaline O
(Bricanyl) O
and O
its O
prodrug O
Bambuterol O
(Bambec) O
are O
highly O
potent O
beta(2)-adrenoceptor B
agonists O
often O
used O
in O
asthma O
patients O
. O
Terbutaline O
in O
the O
form O
of O
inhaled O
short-acting O
bronchodilator O
relieves O
asthmatic O
symptoms O
. O
However O
, O
the O
effects O
of O
bambuterol O
given O
intratracheally O
have O
rarely O
been O
explored O
. O
To O
verify O
the O
effect O
of O
bambuterol O
and O
terbutaline O
, O
which O
act O
on O
the O
tracheal O
smooth O
muscle O
directly O
in O
vitro O
, O
we O
used O
our O
preparation O
to O
test O
the O
effects O
of O
bambuterol O
on O
isolated O
rat's O
tracheal O
smooth O
muscle O
compared O
with O
terbutaline O
. O
The O
following O
assessments O
of O
bambuterol O
and O
terbutaline O
were O
performed O
: O
(1) O
effect O
on O
tracheal O
smooth O
muscle O
resting O
tension; O
(2) O
effect O
on O
contraction O
caused O
by O
10(-6) O
M O
methacholine O
as O
a O
parasympathetic O
mimetic; O
(3) O
effect O
of O
the O
drugs O
on O
electrically O
induced O
tracheal O
smooth O
muscle O
contractions O
. O
The O
results O
indicated O
that O
adding O
bambuterol O
induced O
a O
significant O
further O
contraction O
to O
10(-6) O
M O
methacholine-induced O
contraction O
when O
the O
preparation O
was O
increased O
to O
10(-4) O
M O
. O
But O
terbutaline O
elicited O
a O
relaxation O
response O
at O
a O
dose O
of O
10(-6) O
M O
or O
more O
. O
Both O
bambuterol O
and O
terbutaline O
could O
inhibit O
electrical O
field O
stimulation O
(EFS) O
induced O
spike O
contraction O
. O
Terbutaline O
had O
an O
anti-cholinergic O
effect O
that O
could O
relieve O
asthmatic O
symptoms O
. O
But O
the O
effect O
of O
bambuterol O
acting O
on O
tracheal O
smooth O
muscle O
directly O
was O
controversial O
. O

[1,8]naphthyridines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase O
inhibitors.The O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase O
( O
BuChE) B
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines O
(2 O
, O
3) O
, O
[1,8]naphthyridines O
(5 O
, O
6) O
, O
4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines O
(11-13) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine O
(14) O
, O
4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline O
(15) O
/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine O
(16) O
are O
described O
. O
These O
compounds O
are O
tacrine O
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl O
[6-amino-5-cyano-4H-pyran]-3-carboxylates O
(9 O
, O
10) O
, O
ethyl O
[6-amino-5-cyanopyridine]-3-carboxylates O
(7 O
, O
8) O
, O
2-amino-3-cyano-4,5-diarylfurans O
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene O
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones O
. O
These O
compounds O
are O
competitive O
and O
, O
in O
a O
few O
cases O
, O
non-competitive O
inhibitors O
for O
AChE O
, O
the O
most O
potent O
being O
compound O
(14) O
, O
though O
three-fold O
less O
active O
than O
tacrine O
. O
The O
BuChE O
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14 O
, O
ten-fold O
less O
active O
than O
tacrine O
. O
Furthermore O
, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE O
inhibitors O
. O

N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
A O
novel O
metabotropic O
glutamate O
receptor O
5 O
positive O
allosteric O
modulator O
acts O
at O
a O
unique O
site O
and O
confers O
stimulus O
bias O
to O
mGlu5 O
signaling.Metabotropic O
glutamate O
receptor O
5 O
(mGlu5) O
is O
a O
target O
for O
the O
treatment O
of O
central O
nervous O
system O
(CNS) O
disorders O
, O
such O
as O
schizophrenia O
and O
Alzheimer's O
disease O
. O
Furthermore O
, O
mGlu5 O
has O
been O
shown O
to O
play O
an O
important O
role O
in O
hippocampal O
synaptic O
plasticity O
, O
specifically O
in O
long-term O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 O
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 B
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
(LTD/LTP) O
, O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP O
site O
PAMs O
. O
This O
suggests O
that O
although O
mGlu5 O
PAMs O
may O
have O
similar O
responses O
in O
some O
systems O
, O
they O
can O
induce O
differential O
effects O
on O
mGlu5-mediated O
physiologic O
responses O
in O
the O
CNS O
. O
Such O
stimulus O
bias O
by O
mGlu5 O
PAMs O
may O
complicate O
drug O
discovery O
efforts O
but O
would O
also O
allow O
for O
specifically O
tailored O
therapies O
, O
if O
pharmacological O
biases O
can O
be O
attributed O
to O
different O
therapeutic O
outcomes O
. O

Ca(2+) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Predicting O
cardiomyopathic O
phenotypes O
by O
altering O
Ca2+ O
affinity O
of O
cardiac O
troponin O
C.Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin O
subunits O
include O
hypertrophic O
cardiomyopathy O
(HCM) O
, O
dilated O
cardiomyopathy O
(DCM) O
, O
and O
restrictive O
cardiomyopathy O
(RCM) O
. O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) O
sensitivity O
of O
contraction O
. O
Mutations O
in O
the O
Ca(2+) O
sensor O
, O
troponin O
C O
(TnC) O
, O
were O
generated O
to O
increase/decrease O
the O
Ca(2+) O
sensitivity O
of O
cardiac O
skinned O
fibers O
to O
create O
the O
characteristic O
effects O
of O
DCM O
, O
HCM O
, O
and O
RCM O
. O
We O
also O
used O
a O
reconstituted O
assay O
to O
determine O
the O
mutation O
effects O
on O
ATPase O
activation O
and O
inhibition O
. O
One O
mutant O
(A23Q) O
was O
found O
with O
HCM-like O
properties O
(increased O
Ca(2+) O
sensitivity O
of O
force O
and O
normal O
levels O
of O
ATPase O
inhibition) O
. O
Three O
mutants O
(S37G O
, O
V44Q O
, O
and O
L48Q) O
were O
identified O
with O
RCM-like O
properties O
(a O
large O
increase O
in O
Ca(2+) O
sensitivity O
, O
partial O
loss O
of O
ATPase O
inhibition O
, O
and O
increased O
basal O
force) O
. O
Two O
mutations O
were O
identified O
(E40A O
and O
I61Q) O
with O
DCM O
properties O
(decreased O
Ca(2+) O
sensitivity O
, O
maximal O
force O
recovery O
, O
and O
activation O
of O
the O
ATPase O
at O
high O
[Ca(2+)]) O
. O
Steady-state O
fluorescence O
was O
utilized O
to O
assess O
Ca(2+) O
affinity O
in O
isolated O
cardiac O
(c)TnCs O
containing O
F27W O
and O
did O
not O
necessarily O
mirror O
the O
fiber O
Ca(2+) O
sensitivity O
. O
Circular O
dichroism O
of O
mutant O
cTnCs B
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa O
. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows O
: O
1) O
cTnC O
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM O
, O
RCM O
, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC O
associated O
with O
increased O
Ca(2+) O
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W O
reporter O
mutation O
affected O
Ca(2+) O
sensitivity O
, O
maximal O
force O
, O
and O
ATPase O
activation O
of O
some O
mutants O
. O

streptozotocin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Clock O
Gene O
Expression O
in O
the O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-controlled O
genes O
( O
CCGs) B
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
(STZ)-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs O
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O
followed O
by O
real-time O
polymerase O
chain O
reaction O
. O
Diabetic O
STZ O
and O
Iddm O
rats O
, O
as O
well O
as O
insulin-substituted O
Iddm O
rats O
, O
exhibited O
a O
significant O
diurnal O
expression O
pattern O
of O
clock O
genes O
as O
determined O
by O
Cosinor O
analysis; O
however O
, O
the O
MESOR O
(midline O
estimating O
statistic O
of O
rhythm) O
of O
Bmal1 O
, O
Per2 O
, O
and O
Clock O
transcript O
expression O
was O
altered O
in O
Iddm O
and O
insulin-substituted O
Iddm O
rats O
. O
The O
hepatic O
expression O
of O
the O
CCGs O
Dbp O
and O
RevErbα O
revealed O
a O
diurnal O
rhythm O
in O
all O
investigated O
groups O
. O
Insulin O
administration O
to O
Iddm O
rats O
normalized O
the O
enhanced O
MESOR O
in O
the O
expression O
of O
Dbp O
, O
RevErbα O
, O
and O
E4bp4 O
to O
the O
levels O
of O
normoglycemic O
controls O
. O
Cosinor O
analysis O
indicated O
no O
diurnal O
rhythm O
of O
Pparγ O
expression O
in O
the O
livers O
of O
diabetic O
STZ O
or O
Iddm O
rats O
or O
in O
those O
of O
insulin-substituted O
Iddm O
rats O
. O
Also O
, O
insulin O
substitution O
could O
not O
reverse O
the O
decreased O
MESOR O
of O
Pparγ O
expression O
in O
Iddm O
rats O
. O
In O
consequence O
of O
the O
diabetic O
disease O
, O
changes O
in O
the O
expression O
of O
clock O
genes O
and O
CCGs O
suggest O
alterations O
in O
the O
hepatic O
peripheral O
clock O
mechanism O
. O

Prazosin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Analysis O
of O
alpha O
1L-adrenoceptor O
pharmacology O
in O
rat O
small O
mesenteric O
artery.1 O
. O
To O
illuminate O
the O
controversy O
on O
alpha O
1A- O
or O
alpha O
1L-adrenoceptor O
involvement O
in O
noradrenaline-mediated O
contractions O
of O
rat O
small O
mesenteric O
artery O
(SMA) O
, O
we O
have O
studied O
the O
effects O
of O
subtype-selective O
alpha O
1-adrenoceptor O
agonists O
and O
antagonists O
under O
different O
experimental O
conditions O
. O
2 O
. O
The O
agonist O
potency O
order O
in O
rat O
SMA O
was O
: O
A61603 O
>> O
SKF89748-A O
> O
cirazoline O
> O
noradrenaline O
> O
ST-587 O
> O
methoxamine O
. O
Prazosin O
antagonized O
all O
agonists O
with O
a O
low O
potency O
(pA2 O
: O
8.29-8.80) O
indicating O
the O
involvement O
of O
alpha B
1L- I
rather O
than O
alpha O
1A-adrenoceptors O
. O
3 O
. O
The O
putative O
alpha O
1L-adrenoceptor O
antagonist O
JTH-601 O
, O
but O
not O
the O
alpha O
1B-adrenoceptor O
antagonist O
chloroethylclonidine O
(10 O
microM) O
antagonized O
noradrenaline-induced O
contractions O
of O
SMA O
. O
The O
potency O
of O
the O
selective O
alpha O
1D-adrenoceptor O
antagonist O
BMY O
7378 O
against O
noradrenaline O
(pA2 O
= O
6.16 O
+/- O
0.13) O
and O
of O
the O
selective O
alpha O
1A-adrenoceptor O
antagonist O
RS-17053 O
against O
noradrenaline O
(pKB O
= O
8.35 O
+/- O
0.10) O
and O
against O
the O
selective O
alpha O
1A-adrenoceptor O
agonist O
A-61603 O
(pKB O
= O
8.40 O
+/- O
0.09) O
were O
too O
low O
to O
account O
for O
alpha O
1D- O
and O
alpha O
1A-adrenoceptor O
involvement O
. O
4 O
. O
The O
potency O
of O
RS-17053 O
(pKB/pA2's O
= O
7.72-8.46) O
was O
not O
affected O
by O
lowering O
temperature O
, O
changing O
experimental O
protocol O
or O
inducing O
myogenic O
tone O
via O
KCl O
or O
U46619 O
. O
5 O
. O
Selective O
protection O
of O
a O
putative O
alpha O
1A-adrenoceptor O
population O
against O
the O
irreversible O
action O
of O
phenoxybenzamine O
also O
failed O
to O
increase O
the O
potency O
of O
RS-17053 O
(pA2 O
= O
8.25 O
+/- O
0.06 O
against O
A61603) O
. O
6 O
. O
Combined O
concentration-ratio O
analysis O
demonstrated O
that O
tamsulosin O
, O
which O
does O
not O
discriminate O
between O
alpha O
1A- O
and O
alpha O
1L-adrenoceptors O
, O
and O
RS-17053 O
competed O
for O
binding O
at O
the O
same O
site O
in O
the O
SMA O
. O
7 O
. O
In O
summary O
, O
data O
obtained O
in O
our O
experiments O
in O
rat O
SMA O
indicate O
that O
the O
alpha O
1-adrenoceptor O
mediating O
noradrenaline-induced O
contraction O
displays O
a O
distinct O
alpha O
1L-adrenoceptor O
pharmacology O
. O
This O
study O
does O
not O
provide O
evidence O
for O
the O
hypothesis O
that O
alpha O
1L-adrenoceptors O
represent O
an O
affinity O
state O
of O
the O
alpha O
1A-adrenoceptor O
in O
functional O
assays O
. O
Furthermore O
, O
there O
is O
no O
co-existing O
alpha O
1A-adrenoceptor O
in O
the O
SMA O
. O

MPH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Methylphenidate O
administration O
to O
juvenile O
rats O
alters O
brain O
areas O
involved O
in O
cognition O
, O
motivated O
behaviors O
, O
appetite O
, O
and O
stress.Thousands O
of O
children O
receive O
methylphenidate O
(MPH; O
Ritalin) O
for O
attention O
deficit/hyperactivity O
disorder O
(ADHD) O
, O
yet O
the O
long-term O
neurochemical O
consequences O
of O
MPH O
treatment O
are O
unknown O
. O
To O
mimic O
clinical O
Ritalin O
treatment O
in O
children O
, O
male O
rats O
were O
injected O
with O
MPH O
(5 O
mg/kg) O
or O
vehicle O
twice O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35 O
. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135) O
, O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH O
effects O
and/or O
ADHD O
etiology O
. O
At O
PND35 O
, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH O
showed O
55% O
greater O
immunoreactivity O
(-ir) O
for O
the O
catecholamine O
marker O
tyrosine B
hydroxylase I
(TH) O
, O
60% O
more O
Nissl-stained O
cells O
, O
and O
40% O
less O
norepinephrine O
transporter O
(NET)-ir O
density O
. O
In O
hippocampal O
dentate O
gyrus O
, O
MPH-receiving O
rats O
showed O
a O
51% O
decrease O
in O
NET-ir O
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM O
(polysialylated O
form O
of O
neural O
cell O
adhesion O
molecule) O
. O
In O
medial O
striatum O
, O
TH-ir O
decreased O
by O
21% O
, O
and O
in O
hypothalamus O
neuropeptide O
Y-ir O
increased O
by O
10% O
in O
MPH-exposed O
rats O
. O
At O
PND135 O
, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir O
in O
the O
mPFC O
. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH O
exposure O
. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH O
has O
short-term O
effects O
on O
select O
neurotransmitters O
in O
brain O
regions O
involved O
in O
motivated O
behaviors O
, O
cognition O
, O
appetite O
, O
and O
stress O
. O
Although O
the O
observed O
neuroanatomical O
changes O
largely O
resolve O
with O
time O
, O
chronic O
modulation O
of O
young O
brains O
with O
MPH O
may O
exert O
effects O
on O
brain O
neurochemistry O
that O
modify O
some O
behaviors O
even O
in O
adulthood O
. O

DEX O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Low-Dose O
Dexamethasone O
Treatment O
Promotes O
Pro-Survival O
Signalling O
Pathway O
In O
Adult O
Rat O
Prefrontal O
Cortex.Synthetic O
glucocorticoid O
dexamethasone O
(DEX) O
, O
a O
highly O
potent O
anti-inflammatory O
and O
immunosuppressive O
agent O
, O
is O
widely O
used O
in O
treatments O
of O
brain O
cancer O
, O
inflammatory O
and O
autoimmune O
diseases O
. O
The O
objective O
of O
the O
current O
study O
was O
to O
determine O
whether O
a O
low-dose O
subchronic O
DEX O
treatment O
(100 O
μg/kg O
for O
8 O
consecutive O
days) O
exerts O
long-term O
effects O
on O
apoptosis O
in O
the O
adult O
rat O
prefrontal O
cortex O
(PFC) O
by O
examining O
the O
expression O
of O
cell O
death-promoting O
molecules O
(poly O
(ADP-ribose) O
polymerase O
(PARP) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax) O
and O
cell-survival O
molecules O
(AKT O
, O
Bcl-2) O
. O
Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone O
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX O
injection O
. O
In O
PFC O
, O
DEX O
caused O
activation O
of O
AKT B
, O
augmentation O
of O
pro-survival O
Bcl-2 O
protein O
and O
enhanced O
Bcl-2/Bax O
protein O
ratio O
, O
as O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 O
and O
Bax O
mRNA O
expressions O
in O
DEX-treated O
rats O
. O
Finally O
, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O
staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O
PFC O
. O
Our O
findings O
support O
the O
concept O
that O
a O
low-dose O
DEX O
creates O
the O
hypocorticoid O
state O
in O
the O
brain O
and O
indicate O
that O
subchronic O
DEX O
treatment O
activates O
pro-survival O
signalling O
pathway O
but O
does O
not O
change O
apoptotic O
markers O
in O
rat O
PFC O
. O
This O
mechanism O
might O
be O
relevant O
for O
DEX-induced O
apoptosis O
resistance O
observed O
during O
and O
after O
chemotherapy O
of O
patients O
with O
brain O
tumours O
. O
© O
2013 O
British O
Society O
for O
Neuroendocrinology O
. O

xanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
xanthine O
derivatives O
on O
dipeptidyl O
peptidase O
4.A O
series O
of O
xanthine O
derivatives O
in O
which O
a O
methylene O
was O
inserted O
at O
position O
8 O
of O
xanthine O
scaffold O
was O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
dipeptidyl B
peptidase I
4 I
(DPP-4) O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O
As O
the O
results O
of O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
series O
, O
the O
compounds O
with O
4-methyl-quinazoline-2-yl-methyl O
group O
at O
N-1 O
position O
and O
2-aminoethylaminomethyl O
group O
gave O
better O
activities O
. O
Compounds O
H4 O
and O
H9 O
showed O
good O
DPP-4 O
inhibition O
and O
more O
than O
100-fold O
selectivity O
over O
DPP-7 O
and O
DPP-8 O
. O

brexpiprazole O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin O
(5-HT) O
receptor O
subtypes O
5-HT1A O
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A O
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O
wide O
clinical O
use O
. O
In O
the O
DRN O
, O
brexpiprazole O
completely O
inhibited O
the O
firing O
of O
5-HT O
neurons O
via O
5-HT1A O
agonism O
and O
was O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A O
receptor O
agonist O
DOI O
(2,5-dimethoxy-4-iodoamphetamine) O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 B
receptors I
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O
full O
agonist O
at O
5-HT1A O
receptors O
on O
pyramidal O
neurons O
. O
Furthermore O
, O
it O
increased O
5-HT O
release O
by O
terminal O
alpha2-adrenergic O
heteroceptor O
but O
not O
5-HT1B O
autoreceptor O
antagonism O
. O
In O
the O
lateral O
geniculate O
nucleus O
, O
brexpiprazole O
displayed O
alpha1B-adrenoceptor O
antagonistic O
action O
. O
Taken O
together O
, O
these O
results O
provide O
insight O
into O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
monoamine O
targets O
relevant O
in O
the O
treatment O
of O
depression O
and O
schizophrenia O
. O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Swim O
training O
of O
monosodium O
L-glutamate-obese O
mice O
improves O
the O
impaired O
insulin O
receptor O
tyrosine O
phosphorylation O
in O
pancreatic O
islets.The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose O
homoeostasis O
and O
of O
the O
insulin O
receptor O
(IR) O
and O
insulin O
receptor O
substrate-1 O
(IRS-1) O
signalling O
in O
pancreatic O
islets O
from O
MSG-obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

C2-ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Exogenous O
C2-ceramide O
activates O
c-fos O
serum O
response O
element O
via O
Rac-dependent O
signalling O
pathway.Ceramide O
is O
an O
important O
regulatory O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines O
. O
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide O
to O
the O
nucleus O
, O
in O
the O
present O
study O
, O
we O
examined O
whether O
C2-ceramide O
, O
a O
cell O
permeable O
ceramide O
, O
activates O
c-fos O
serum O
response O
element O
(SRE) O
. O
Treatment O
of O
Rat-2 O
fibroblast O
cells O
with O
C2-ceramide O
caused O
the O
stimulation O
of O
c-fos O
SRE-dependent O
reporter O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O
transfection O
analysis O
. O
Next O
, O
we O
examined O
the O
role O
of O
Rho O
family O
GTPases O
in O
the O
ceramide-induced O
signalling O
to O
SRE O
activation O
. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42 O
, O
Rac1 O
or O
RhoA O
, O
C2-ceramide-induced O
SRE O
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1 O
, O
suggesting O
that O
Rac O
activity O
is O
essential O
for O
the O
signalling O
cascade O
of O
ceramide O
to O
the O
nucleus O
. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine O
, O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE B
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 O
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide-signalling O
to O
nucleus O
. O

Pranlukast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotriene O
receptor O
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene B
receptor I
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O
pranlukast O
in O
mild-to-moderate O
asthma O
. O
METHODOLOGY O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea O
. O
Mild-to-moderate O
asthma O
patients O
who O
had O
been O
treated O
with O
beta2-agonists O
and/or O
inhaled O
corticosteroids O
were O
studied O
. O
The O
patients' O
symptoms O
were O
evaluated O
by O
asthma O
diary O
and O
twice-daily O
peak O
flow O
monitoring O
. O
RESULTS O
: O
Of O
the O
206 O
patients O
enrolled O
, O
197 O
were O
eligible O
for O
analysis O
. O
The O
pranlukast O
group O
(n O
= O
98) O
showed O
statistically O
significant O
improvement O
in O
asthma O
symptoms O
, O
including O
asthma O
attack O
rate O
, O
daily O
living O
score O
, O
and O
morning O
and O
evening O
asthma O
scores O
. O
Pranlukast O
significantly O
reduced O
the O
consumption O
of O
beta2-agonist O
. O
Compared O
with O
the O
placebo O
group O
, O
forced O
vital O
capacity O
(FVC) O
and O
forced O
expiratory O
volume O
in O
1 O
s O
(FEV1) O
were O
not O
significantly O
higher O
in O
the O
pranlukast O
group O
. O
Morning O
and O
evening O
peak O
expiratory O
flow O
(PEF) O
were O
significantly O
increased O
after O
pranlukast O
treatment O
at O
weeks O
2 O
and O
4 O
(380.8 O
+/- O
10.1 O
L/min O
at O
baseline O
, O
394.5 O
+/- O
10.1 O
at O
week O
2 O
, O
396.3 O
+/- O
10.4 O
at O
week O
4) O
. O
There O
were O
no O
serious O
adverse O
reactions O
. O
CONCLUSION O
: O
Pranlukast O
, O
an O
oral O
leukotriene O
antagonist O
, O
was O
well O
tolerated O
and O
was O
effective O
for O
the O
management O
of O
mild-to-moderate O
asthma O
. O

5-FU O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
mechanisms O
of O
acquired O
resistance O
to O
fluorinated O
pyrimidines O
in O
human O
colorectal O
cancer O
cells.5-Fluorouracil O
(5-FU) O
, O
5-fluoro-2'-deoxyuridine O
(FdUrd) O
and O
5-trifluorothymidine O
(F3(d)Thd) O
are O
antimetabolites O
which O
are O
metabolized O
to O
their O
corresponding O
active O
forms O
which O
inhibit O
DNA O
synthesis O
via O
inhibition O
of O
thymidylate O
synthase O
( O
TS) B
 O
. O
To O
investigate O
ways O
of O
overcoming O
5-FU-resistance O
, O
we O
established O
acquired-resistant O
colorectal O
cancer O
cell O
lines O
against O
these O
three O
drugs O
by O
continuous O
and O
step-wise O
escalation O
of O
drugs O
, O
and O
analyzed O
the O
cytotoxicity O
and O
the O
mechanism O
of O
resistance O
to O
the O
drugs O
. O
When O
cells O
were O
incubated O
with O
the O
3 O
drugs O
for O
72 O
h O
, O
the O
resistance O
ratio O
to O
parental O
DLD-1 O
human O
colorectal O
tumor O
cells O
was O
65.2 O
for O
DLD-1/5-FU O
, O
9.7 O
for O
DLD-1/FdUrd O
and O
448.6 O
for O
DLD-1/F3(d)Thd O
cells O
. O
DLD-1/5-FU O
cells O
did O
not O
show O
any O
cross-resistance O
against O
FdUrd O
and O
F(3)dThd O
. O
However O
, O
DLD-1/FdUrd O
cells O
showed O
3- O
and O
9-fold O
increased O
resistance O
to O
5-FU O
and O
F3(d)Thd O
, O
respectively O
, O
and O
DLD-1/F3(d)Thd O
cells O
also O
showed O
about O
90-fold O
resistance O
to O
FdUrd O
. O
Analysis O
of O
enzyme O
activities O
and O
gene O
expression O
associated O
with O
pyrimidine O
metabolism O
indicated O
that O
a O
significant O
decrease O
in O
orotate O
phosphoribosyltransferase O
activity O
in O
DLD-1/5-FU O
cells O
, O
a O
7-fold O
increase O
of O
TS O
mRNA O
in O
DLD-1/FdUrd O
cells O
, O
and O
a O
37-fold O
decrease O
in O
thymidine O
kinase O
activity O
of O
DLD-1/F3(d)Thd O
cells O
were O
the O
major O
mechanisms O
of O
drug O
resistance O
. O
These O
findings O
were O
closely O
associated O
with O
the O
cytotoxicity O
of O
5-FU O
, O
FdUrd O
and O
F3(d)Thd O
against O
the O
established O
5-FU- O
, O
FdUrd- O
or O
F3(d)Thd-resistant O
cells O
. O
When O
DLD-1/FdUrd O
cells O
expressing O
increased O
TS O
mRNA O
were O
treated O
with O
FdUrd O
and O
F3(d)Thd O
for O
only O
4 O
h O
, O
the O
resistance O
ratios O
of O
DLD-1/FdUrd O
cells O
to O
parental O
DLD-1 O
cells O
were O
markedly O
different O
for O
FdUrd O
and O
F3(d)Thd O
, O
suggesting O
that O
the O
cytotoxicity O
with O
short-time O
exposure O
to O
F3(d)Thd O
is O
due O
to O
a O
mechanism O
other O
than O
TS O
inhibition O
, O
although O
the O
cytotoxicity O
of O
F3(d)Thd O
in O
the O
short-time O
is O
low O
compared O
to O
that O
of O
long-time O
exposure O
. O
In O
conclusion O
, O
F3(d)Thd O
, O
an O
antimetabolite O
that O
inhibits O
TS O
activity O
, O
may O
be O
effective O
against O
5-FU O
and/or O
FdUrd-resistance O
in O
colorectal O
cancer O
cells O
caused O
by O
amplification O
of O
TS O
and/or O
deletion O
of O
orotate O
phosphoribosyltransferase O
. O

Ifenprodil O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating.Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1/GluN2B O
N-methyl-D-aspartate B
receptors I
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O
interface O
of O
the O
GluN1/GluN2B O
amino O
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism O
. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B O
receptor O
gating O
, O
we O
recorded O
steady-state O
currents O
from O
cell-attached O
and O
outside-out O
patches O
. O
At O
pH O
7.9 O
in O
cell-attached O
patches O
, O
ifenprodil O
increased O
the O
occupancy O
of O
the O
long-lived O
shut O
conformations O
, O
thereby O
reducing O
the O
open O
probability O
of O
the O
receptor O
with O
no O
change O
in O
the O
mean O
open O
time O
. O
In O
addition O
, O
ifenprodil O
selectively O
affected O
the O
area O
of O
shut O
time O
constants O
, O
but O
not O
the O
time O
constants O
themselves O
. O
Kinetic O
analyses O
suggested O
that O
ifenprodil O
prevents O
the O
transition O
of O
the O
receptor O
to O
an O
open O
state O
and O
increases O
its O
dwell O
time O
in O
an O
intrinsically O
occurring O
closed O
conformation O
or O
desensitized O
state O
. O
We O
found O
distinct O
differences O
in O
the O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O
mean O
open O
time O
of O
GluN1/GluN2B O
receptors O
, O
which O
may O
be O
responsible O
for O
its O
usefulness O
as O
a O
context-dependent O
inhibitor O
in O
conditions O
like O
ischemia O
and O
stroke O
, O
when O
the O
pH O
of O
the O
extracellular O
milieu O
becomes O
acidic O
. O

methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Methylenedioxymethamphetamine O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
( O
DAT) B
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT O
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O
DAT O
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O
may O
underlie O
the O
dissimilar O
neurotoxic O
profile O
of O
these O
agents O
. O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Cucurbitacin O
I O
inhibits O
rac1 O
activation O
in O
breast O
cancer O
cells O
by O
a O
reactive O
oxygen O
species-mediated O
mechanism O
and O
independently O
of O
janus O
tyrosine O
kinase O
2 O
and O
p-rex1.The O
small O
GTPase O
Rac1 O
has O
been O
widely O
implicated O
in O
mammary O
tumorigenesis O
and O
metastasis O
. O
Previous O
studies O
established O
that O
stimulation O
of O
ErbB O
receptors O
in O
breast O
cancer O
cells O
activates O
Rac1 O
and O
enhances O
motility O
via O
the O
Rac-guanine O
nucleotide O
exchange O
factor O
P-Rex1 O
. O
As O
the O
Janus O
tyrosine O
kinase O
2 O
(Jak2)/signal O
transducer O
and O
activator O
of O
transcription O
3 O
(Stat3) O
pathway O
has O
been O
shown O
to O
be O
functionally O
associated O
with O
ErbB O
receptors O
, O
we O
asked O
if O
this O
pathway O
could O
mediate O
P-Rex1/Rac1 O
activation O
in O
response O
to O
ErbB O
ligands O
. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin O
I O
, O
a O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O
mediated O
by O
reactive O
oxygen O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O
activation O
in O
breast O
cancer O
cells O
proceeds O
independently O
of O
the O
Jak2 O
pathway O
. O
Moreover O
, O
they O
established O
that O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 B
activity O
involves O
the O
alteration O
of O
the O
balance O
between O
Rho O
and O
Rac O
. O

Pranlukast O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pranlukast O
, O
a O
leukotriene O
receptor O
antagonist O
, O
inhibits O
interleukin-5 O
production O
via O
a O
mechanism O
distinct O
from O
leukotriene O
receptor O
antagonism.BACKGROUND O
: O
Pranlukast O
, O
a O
cysteinyl O
leukotriene O
receptor O
1 O
( O
CysLTR1) B
antagonist O
, O
inhibits O
not O
only O
airway O
smooth O
muscle O
contraction O
, O
but O
also O
allergic O
inflammation O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
mechanism O
of O
pranlukast-induced O
interleukin-5 O
(IL-5) O
inhibition O
in O
allergic O
inflammation O
. O
METHODS O
: O
Surgically O
resected O
human O
lung O
tissue O
was O
passively O
sensitized O
in O
vitro O
with O
mite-allergen-sensitized O
sera O
, O
followed O
by O
stimulation O
with O
mite O
allergen O
after O
pretreatment O
of O
the O
tissue O
with O
pranlukast O
, O
dexamethasone O
, O
or O
both O
. O
The O
IL-5 O
protein O
level O
in O
the O
culture O
medium O
was O
measured O
, O
and O
in O
situ O
hybridization O
of O
IL-5 O
and O
CysLTR1 O
mRNA O
was O
performed O
using O
lung O
tissues O
. O
RESULTS O
: O
Pretreatment O
of O
lung O
tissues O
with O
pranlukast O
alone O
significantly O
decreased O
the O
amount O
of O
IL-5 O
protein O
in O
the O
culture O
medium O
by O
40% O
. O
The O
combination O
of O
pranlukast O
and O
dexamethasone O
synergistically O
enhanced O
this O
effect O
. O
Quantitative O
in O
situ O
hybridization O
with O
image O
analysis O
revealed O
abundant O
expression O
of O
IL-5 O
mRNA O
in O
eosinophils O
, O
lymphocytes O
, O
and O
mast O
cells O
in O
sensitized O
and O
allergen-stimulated O
lung O
tissues O
. O
CysLTR1 O
mRNA O
was O
detected O
in O
macrophages O
, O
smooth O
muscle O
cells O
, O
eosinophils O
, O
and O
mast O
cells O
, O
but O
was O
less O
expressed O
in O
lymphocytes O
. O
Pranlukast-induced O
inhibition O
of O
IL-5 O
mRNA O
expression O
was O
noted O
in O
various O
cells O
, O
irrespective O
of O
their O
CysLTR1 O
mRNA O
expression O
status O
. O
In O
addition O
, O
cysteinyl O
leukotrienes O
per O
se O
failed O
to O
upregulate O
the O
IL-5 O
production O
. O
CONCLUSION O
: O
Our O
results O
indicate O
that O
pranlukast O
inhibits O
IL-5 O
synthesis O
via O
a O
mechanism O
distinct O
from O
CysLTR1 O
antagonism O
. O

